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  Abstract 
Background:  
Pulmonary hypertension (PH) is defined as a rise in the pressure in the pulmonary arteries 
resulting from a variety of diseases including chronic infectious diseases, lung diseases and 
left heart diseases (LHD). It is a global health problem and accounts for a substantial portion 
of cardiovascular disease. PH due to LHD (PH-LHD) is credited to be the most common form 
of PH worldwide and is associated with adverse outcomes. Considering the suggestions of 
high prevalence and potential adverse outcomes of PH in sub-Saharan Africa (SSA), the 
investigation of the etiologies, clinical profile, correlates, and outcomes of PH-LHD in this 
region is a medical priority. 
Methods: 
Through a systematic review, we assessed existing evidence on the predictors of PH-LHD 
outcomes. Then, through two prospective multinational cohort registries, we investigated 1) 
the spectrum of PH in SSA; 2) the clinical profile and 6 months outcome of PH-LHD; 3) the role 
of electrocardiogram for diagnosing PH and 4) its prognostic role in heart failure (HF). PH was 
diagnosed by echocardiography in the context of clinical suspicion.  
Results: 
In high income countries, PH-LHD is almost invariably associated with increased mortality risk, 
but the effects on hospitalization are yet to be fully characterized. All groups of PH are found 
in SSA with LHD being the major cause. PH-LHD affects young people and is predominantly 
due to HF and rheumatic valvular heart disease. In these patients, left atrium size and 
tricuspid annular plan excursion are predictors of pulmonary pressures, and PH-LHD predicts 
short term hospitalization but not mortality. A normal electrocardiogram is very rare in 
patients with PH, but electrocardiogram criteria of right ventricular strain are rather rare and 
non-specific. Similarly, electrocardiogram abnormalities are frequent among Africans with HF, 
some have prognostic value for mortality risk.  
Conclusion: PH-LHD is the most common form of PH in SSA, with affected patients presenting 
with advanced disease, and it is associated with adverse outcomes. ECG abnormalities are 
prevalent in both PH and HF, but few of these abnormalities have prognostic value for 
mortality risk. Evaluating the efficacy and safety of low-cost and available drugs in reducing 
HF hospitalizations in PH-LHD is a key future priority. Improving early diagnosis of PH should 
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Summary of Chapters 
Chapter 1 of this PhD thesis is an overview of the literature reviewing the current knowledge 
and concepts on the definition, diagnostic strategy of pulmonary hypertension (PH), 
prevalence and correlates of PH due to left heart disease (PH-LHD). In a published systematic 
review, we also investigate the predictors of hospitalizations for heart failure and mortality in 
patients with PH-LHD. The chapter ends with a description of the gaps in the knowledge that 
subsequent chapters will attempt to address.  
Chapter 2 describes the hypothesis, aim and specific questions investigated in this doctoral 
research.  
Chapter 3 is a description of the two major prospective multicentric cohort studies that form 
the basis of the analyses presented in this thesis, including the sub Saharan Africa survey of 
heart failure (THESUS-HF) and the Pan African pulmonary hypertension cohort (PAPUCO) 
study. This chapter also contains a second publication on the rationale and design of the 
PAPCUCO registry. In the PAPUCO registry, PH was diagnosed using Echocardiography, 
defined as a right ventricular systolic pressure (RVSP)>35 mmHg in the absence of pulmonary 
stenosis and acute right heart failure, and in a patient with clinical suspicion of the disease, 
with electrocardiogram (ECG) and chest x-ray changes in keeping with PH. 
Chapter 4 to 7 present the results of this thesis in terms of condensed publications including 
notations as to if the manuscripts are still under review or, in terms of full publications, when 
they were accepted and published in peer-reviewed journals.  
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 In Chapter 4 (under review), we present the baseline characteristics, clinical profile, 
etiological types and outcome of patients with PH in sub Saharan Africa. PH generally 
affects women who are poorly or uneducated and exposed to indoor fumes, from 
cooking. All groups of PH are found in SSA with left heart disease being the dominant 
etiology. PH is associated with a high 6-month mortality rate and right heart failure is 
a predictor of death in these patients. 
 Chapter 5 (under review) focuses on PH due to left heart disease (PH-LHD). We 
describe the clinical profile and predictors of PH-LHD, and the 6-month outcomes with 
their corresponding predictors. PH-LHD in our cohort was predominantly due to heart 
failure and its etiologies, and rheumatic valvular heart disease. Left atrium size and 
tricuspid annular plan excursion (TAPSE) were predictors of RVSP in patients with PH-
LHD, and RVSP predicted short term hospitalizations, but not mortality.  
 In Chapter 6 (under review), we investigated the diagnostic utility of 
electrocardiogram (ECG) in patients with PH. Our findings demonstrated that a normal 
ECG is very rare among patients with PH. Furthermore, most of these abnormalities 
are non-specific and ECG abnormalities relating to right heart strain are less frequent. 
ECG patterns focusing on the R and S amplitude have the best negative predictive 
values.  
 Chapter 7 (full publication) investigated the predictive value of ECG for mortality risk 
in patients with heart failure. The study showed that ECG abnormalities are almost 
universal among Africans with acute heart failure, and some of these ECG findings 
have prognostic value for risk of death, but most of the abnormalities add little to the 
risk stratification. 
 
Chapter 8 summarizes the major findings of this thesis and discusses the implications for 





Appendix is a compendium of documents that were mandatory for the conduct of this 
doctoral research including the list of contributors to the two multinational cohort registries, 
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Chapter 1. Background of the Thesis  
1.1. Conceptual definition and historical perspectives on 
pulmonary hypertension  
Pulmonary hypertension (PH) is an elevation of the pressure in the lungs’ arteries, resulting 
from a variable combination of increases in pulmonary vascular resistance (PVR), pulmonary 
blood flow and pulmonary venous pressure (PVP) (1). This definition applies irrespective of 
the underlying etiology of PH which includes a range of conditions such as obstructive sleep 
apnea, lung diseases and left heart diseases. Pulmonary arterial hypertension (PAH), a specific 
type of PH, is a disease of the blood vessels of the lungs causing elevation in pressure. This 
section provides a historical perspective on PH. 
Over the last century, significant progresses in the diagnosis and management of PH have 
gradually moved this condition from an orphan disease to a multidisciplinary and now 
acknowledged major global public health problem which affected more than 25 million 
individuals worldwide in 2010 (2, 3). The first clinical case reports on PH are attributed to the 
German physicians Klob in 1865 (4) and Romberg in 1891 (5) who both described a clinical-
pathological syndrome characterized by the obstruction of the small pulmonary arteries and 
right ventricular hypertrophy in patients presenting with severe dyspnea and cyanosis. Nearly 
nine decades later, in the 1960s, several authors reported on an epidemic of PH cases in 
Europe due to appetite-suppressants (6-8). Almost concomitantly, with the development of 
right heart catheterization in the second half of the 20th century (9), it was found that many 
diseases could cause PH and the distinction between pre and post capillary PH was made. 
Nevertheless, it remains widely believed that PH is a rare fatal disease. Although true for 
idiopathic pulmonary arterial hypertension (PAH) or the formerly known primary PH, a 
condition which affects around six to ten individuals per million population in high income 
countries, the true burden of PH at large is currently unknown and largely underestimated 
(10). Interest has previously focused on studying the disease and this has led to increased 
recognition and development of new therapies. Pre-capillary PH now describes a group of 
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noninfectious, nonmalignant respiratory diseases causing breathlessness, loss of exercise 
capacity and leading, in the advanced form, to irreversible right heart failure (HF), a decreased 
quality of life and premature mortality (11). PH is largely recognized simply as high blood 
pressure in the pulmonary circulation. 
Mitral valve stenosis due to rheumatic heart disease was the most common cause of PH 
before the 1950s (4, 12). However, this has greatly changed with the enormous and growing 
global burden of heart failure (HF) over the last 50 years. Left heart disease (LHD) in general 
(valvular heart disease or HF due to hypertension, ischemic heart disease, peripartum 
cardiomyopathy etc.) has progressively been credited to be the most common cause of PH in 
contemporary clinical settings (13, 14). Furthermore, among patients with LHD, some will 
develop a pre capillary component with pulmonary arterial disease, compounding the effects 
of the initial increase of pulmonary pressures(15). However, a great contrast still persist 
between the abundant literature on PAH and the paucity of data on PH due to LHD (PH-LHD). 
An operational definition better highlights the relevant distinction between PH at large and 
PAH and has been of major focus at all previous world meetings on PH. The next section is on 
the main operational definitions of PH.   
1.2. Operational definitions of pulmonary hypertension 
Pulmonary hypertension (PH) is currently defined as a pathological condition with an increase 
in mean pulmonary arterial pressure (PAP) beyond 25 mmHg at rest as assessed by right heart 
catheterization (16, 17). This hemodynamic definition of PH is not evidence-based. According 
to the 4th World Symposium on PH held in Dana Point in 2008 (18), a mean pulmonary artery 
pressure (mPAP) <21 mmHg was defined as normal, from 21 to 25 mmHg as borderline, and 
mPAP >25 mmHg was considered as overt PH. Correspondingly, echocardiographic systolic 
tricuspid regurgitant velocity thresholds <2.5 m/s were defined as normal, 2.5 to 2.8 m/s as 
borderline, and >2.8 m/s as highly suggestive of an overt PH. A more pragmatic definition by 
echocardiography uses right ventricular systolic pressure, commonly estimated from the 
velocity of tricuspid regurgitation. PH is then defined as an elevation of RVSP above 35 mmHg 
(19). Table 1 summarizes these definitions.  As shown on Table 2, the 2015 joint European 
Society of Cardiology (ESC) – European Respiratory Society (ERS) further defines and 
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distinguishes pre- and post-capillary PH, Isolated post-capillary PH and combined post-
capillary and pre-capillary PH using diastolic pressure gradient, mPAP and pulmonary arterial 
wedge pressure. 
Table 1: Thresholds of pulmonary hypertension determined at the 4th World 
Symposium held in Dana Point 2008 (20). 
Definitions of pulmonary hypertension   
 
Invasive (mean Pulmonary artery pressure) 
Normal < 21 mmHg 
Borderline 21 – 25 mmHg 
Manifest >25 mmHg 
 
Noninvasive (systolic tricuspid regurgitant velocity 
threshold) 
Normal <2.5 m/s 
Borderline 2.5 – 2.8 m/s 
Manifest >2.8 m/s 
Table 2: Operational (or hemodynamic) definitions of pulmonary hypertension 
according to European Society of Cardiology/European Respiratory Society (21) 
Definitions  Characteristicsa Typical clinical groupsb 
PH Mean PAP > 25 mmHg All 
 
Pre-capillary PH 
Mean PAP > 25 mmHg 
Pulmonary wedge 
pressure ≤ 15 mmHg 
1. Pulmonary arterial hypertension 
3. PH due to lung diseases 
4. Chronic thromboembolic PH 
5. PH with unclear and/or multifactorial 
mechanisms 
Post-capillary PH (pc-PH) Mean PAP > 25 mmHg  
PAP > 15 mmHg 
2. PH due to left heart disease 
5. PH with unclear and/or multifactorial 
mechanisms Isolated pc-PH DPG <7 mmHg and/or 
PVR ≤3 WU 
Combined post-capillary 
and pre-capillary PH 
DPG≥7 mm Hg and/or  
PVR >3 WUc 
CO ¼ cardiac output; DPG ¼ diastolic pressure gradient (diastolic PAP – mean PAWP); mPAP ¼ mean pulmonary 
arterial pressure; PAWP ¼ pulmonary arterial wedge pressure; PH ¼ pulmonary hypertension; PVR ¼ pulmonary 
vascular resistance; WU ¼ Wood units. 
a All values measured at rest; b See also section 1.3.3. c Wood Units are preferred to dynes.s.cm-5. 
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The term pulmonary arterial hypertension (PAH) defines a subpopulation of patients with PH 
hemodynamically characterized by the presence of pre-capillary PH comprising an end-
expiratory pulmonary artery wedge pressure ≤ 15 mmHg and a pulmonary vascular resistance 
(PVR) >3 Woods units. As a subtype of PH, PAH is a group of diseases characterized by a 
progressive increase in PVR leading to right ventricular (RV) failure and death (23).  
1.3. Diagnostic strategy and clinical classification of pulmonary 
hypertension 
The diagnostic approach for a patient with suspected PH requires a clinical evaluation and a 
number of investigations to confirm the diagnosis and subsequent classification of the disease 
within the specific etiologic PH groups and deciding on the appropriate therapy. The 
diagnostic strategy for PH is summarised hereafter in four steps: 1) detection of a 
predisposing condition in which the likelihood of PH may be high; 2) uncovering of the 
presence of PH; 3) classification of the type of PH; and 4) confirmation of the presence of 
suspected PH. 
1.3.1. Detection of a predisposing condition 
A number of conditions summarized in Table 3 are recognized from a European perspective 
as predisposing factors to the development of PH. African data are lacking and may differ, we 
described      
below three conditions that are relevant to sub-Saharan Africa (SSA).  
1.3.1.1. Human immunodeficiency virus (HIV) infection 
HIV-infected patients have a 2500-fold increased risk of developing PAH (22). Though the 
pathogenesis is yet to be fully understood, it has been postulated that during the course of 
HIV infection, secretion of inflammatory and immune response mediators such as endothelin-
1 may contribute directly to endothelial damage (23). 
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1.3.1.2. Sickle cell disease 
In sickle cell disease patients, persistent intravascular haemolysis for decades can lead to 
haemolysis-mediated endothelial dysfunction and chronic vasculopathy, with approximately 
10% of patients developing PAH (24).  
1.3.1.3. Schistosomiasis 
In people infected with schistosomiasis, chronic infection in particular from Schistosoma 
mansoni, causes PH. The mechanisms seem to involve: parasite egg–induced pulmonary 
vascular granulomas; antigen or interleukin-13 associated vasculopathy and ensuing cascade; 
underlying liver disease and ensuing portal hypertension emulating portopulmonary 
hypertension pathophysiology; or a combination of these mechanisms (25, 26).  
1.3.2. Uncovering the presence of PH  
When PH is suspected, the patient shall undergo a clinical evaluation and a battery of 
investigations to confirm the diagnosis, clarify the clinical group of PH and the precise etiology 
within the PH group, and evaluate the functional and haemodynamic impairment.  
1.3.2.1. Clinical evaluation 
Pulmonary hypertension should be suspected in any patient with otherwise unexplained 
shortness of breath or fatigue upon exertion, dizziness, coughing and wheezing, cyanosis, 
syncope and/or signs of right ventricular dysfunction. At the early stages of the disease, the 
signs and symptoms of PH are subtle and may not be apparent for months or even years as 
well as generally non-specific (27-29). 
Clinical examination may reveal the following (30): a left parasternal lift, an accentuated 
pulmonary component of second heart sound, a pansystolic murmur of tricuspid 
regurgitation, a diastolic murmur of pulmonary insufficiency, a right ventricular (RV) third 
sound, a jugular vein distension, hepatomegaly, peripheral oedema and ascites and cool 
extremities. Presence of some physical signs might suggest severe PH including an 
accentuated pulmonary component of S2 (audible at apex in over 90%), an early systolic click, 
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a midsystolic ejection murmur, a left parasternal lift, a right ventricular S4 and an increased 
jugular “a” wave. In Table 4, we summarize the most common signs on physical examination 
that are suggestive of possible underlying causes or associated PH. 
When the clinical evaluation is suggestive of PH, the patient should initially undergo non-
invasive investigations which should where possible include as initial tests a chest X-ray, 
electrocardiogram (ECG) and echocardiography. The utilization of other investigations will 
depend on both the results of the above initial tests and the clinical context.
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Table 3: Approach to predisposing conditions of pulmonary hypertension (31) 
Substrate Further assessment Rationale 
BMPR2 mutation Echocardiogram  yearly;  RHC if echocardiogram demonstrates evidence of PAH (high 
right ventricular systolic pressure or right heart chamber enlargement) 
Early detection of PAH; 20% chance of developing  
PAH 
1st degree relative of patient with BMPR2 
mutation or within pedigree of 2 or more 
patients with a diagnosis of PAH 
Genetic counselling and recommendation  for BMPR2 genotyping; proceed as above 
if positive 
Autosomal dominant transmission 
Systemic sclerosis Echocardiogram  yearly; RHC if echocardiogram demonstrates evidence of PAH (high 
right ventricular systolic pressure or right heart chamber enlargement) 
About 8% (by RHC) and 27% (by echocardiogram 
screening) prevalence of PAH in systemic sclerosis 
Human immunodeficiency  virus infection Echocardiogram if symptoms or signs suggestive of PAH; RHC if echo demonstrates 
evidence of PAH (high  right ventricular systolic pressure or right heart chamber 
enlargement) 
0.5% prevalence of PAH 
Portal hypertension Echocardiogram if OLT considered;   RHC if echocardiogram demonstrates evidence 
of PAH (high right  ventricular systolic pressure or right heart chamber enlargement) 
4% prevalence of PAH in candidates for OLT; PAH 
is predictive of poor OLT outcome 
Prior appetite suppressant use (fenfluramine) Echocardiogram only if symptomatic Incidence of PAH is approximately 0.005% if agent 
used > 3 months 
Congenital heart disease with shunt Echocardiogram  and RHC at time of diagnosis; consider repair of defect if significant 
left to right shunt present 
High probability of PAH developing  in unrepaired 
shunt (Eisenmenger syndrome) 
Recent acute pulmonary embolism Ventilation-perfusion  (V/Q) scintigraphy  3 months after event if symptomatic; 
pulmonary angiogram if positive 
3% risk of chronic thromboembolic PH; negative  
VQ scan excludes chronic thromboembolism 
Sickle cell disease Echocardiogram  yearly; RHC if echocardiogram demonstrates evidence of PAH (high 
right ventricular systolic pressure or right heart chamber enlargement) 
30% develop PH, about 10% develop PAH, 
Increased mortality if PH present. 
Schistosomiasis - 10.7% to 18.5% prevalence in patients with 
hepatoesplenic schistosomiasis 
BMPR2 indicates bone morphogenetic protein receptor 2; OLT, orthotopic liver transplantation; PAH, pulmonary arterial hypertension; and RHC, right heart catheterization 
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Table 4: Features of the Physical Examination suggesting underlying cause or 
associated pulmonary hypertension (32) 
Physical Signs suggesting Possible Underlying Cause or Associations of pulmonary hypertension 
Central cyanosis  Abnormal V/Q, intra-pulmonary shunt, 
hypoxemia, pulmonary-to-systemic shunt 
Clubbing Congenital heart disease, pulmonary venopathy 
Cardiac auscultatory findings, including systolic 
murmurs, diastolic murmurs, opening snap, and gallop 
Congenital or acquired heart or valvular disease 
Rales, dullness, or decreased breath sounds  Pulmonary congestion or effusion or both 
Fine rales, accessory muscle use, wheezing, protracted 
expiration, productive cough 
Pulmonary parenchymal disease 
Obesity, kyphoscoliosis, enlarged tonsils Possible substrate for disordered ventilation 
Sclerodactyly, arthritis, telangiectasia, Raynaud 
phenomenon, rash 
Connective tissue disorder 
Peripheral venous insufficiency or obstruction  Possible venous thrombosis 
Venous stasis ulcers  Possible sickle cell disease 
Pulmonary vascular bruits Chronic thromboembolic pulmonary 
hypertension 
Splenomegaly, spider angiomata, palmary erythema, 
icterus, caput medusa, ascites 
Portal hypertension 
1.3.2.2. The role of electrocardiogram 
Our knowledge of the contribution of ECG in the management of PH is limited and originates 
primarily from studies either on heart failure or pulmonary arterial hypertension. Guidelines 
from the European Society of Cardiology (33) and the National Institute for Clinical Excellence 
(34, 35) recommend that patients with suspected HF should have an ECG done in the 
diagnostic process. A normal ECG is very rare in the presence of heart disease. Of the 5934 
patients who had an ECG done in the Euroheart survey (36), only 75 ECGs were normal. An 
abnormal ECG may show elements suggestive of heart disease and/or may provide more 
suggestive or supportive evidence for PH by demonstrating some signs that are common in 
patients with PAH. This include RV hypertrophy and strain, and right atrial dilatation as shown 
in Figure 1. The ECG has low sensitivity (55%) and specificity (70%) to be used as a screening 
tool for detecting significant PAH (37). ECG abnormalities have been associated with a short 
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survival in patients with primary PH (38), but the diagnostic and prognostic utility for other 
PH groups has yet to be explored. 
1.3.2.3. Chest radiograph 
The chest radiograph allows associated moderate-to-severe lung diseases to be reasonably 
excluded but also, abnormalities on chest radiograph are frequent in PH-LHD. Findings may 
reflect the underlying cardiac disease and include left heart or combined heart enlargement, 
left atrial enlargement, mild to moderate pleural effusion, cephalization or may reflect PH 
such as central pulmonary arterial dilatation, which contrasts with ‘pruning’ (loss) of the 
peripheral blood vessels (Figure 1). Right atrium and RV enlargement may be seen in more 
advanced cases. Overall, the degree of PH in any given patient does not correlate with the 







Figure 1: Chest X-ray and electrocardiogram in Pulmonary Arterial Hypertension 
(PAH)  
A postero-anterior and lateral chest X-ray (upper panel) showing decreased peripheral lung 
vascular markings, hilar pulmonary artery prominence, and right ventricular enlargement of 
a patient with idiopathic PAH. An ECG (lower panel) of the same patient showing right atrial 
enlargement, right ventricular hypertrophy and strain, and right axis deviation of the QRS 
complex. Adapted with permission from McLaughlin et al (31). 
 
1.3.2.4. The key role of transthoracic Doppler echocardiography 
After a clinical evaluation of the patient with suspicion of PH, with or without presence of ECG 
or chest X-ray features, a transthoracic Doppler echocardiography (DE) examination is the 
next and most appropriate course of study. DE provides several variables which correlate with 
right heart hemodynamics including an estimate of RV systolic pressure (RVSP), and can 
simultaneously uncover functional and morphologic cardiac sequelae of PH, and assist in the 
identification of possible cardiac causes of PH. 
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1.3.2.4.1. Estimation of right ventricular systolic pressure and function 
As shown in Figure 2, the Doppler echocardiographic (DE) estimation of PAP is based on the 
peak velocity of the jet of tricuspid regurgitation (TR). TR velocity can be obtained by either a 
duplex imaging from the right ventricular inflow view, parasternal short axis view at the basal 
level, para-apical four chamber view, apical four chamber view, or even the subcostal view. 
The TR maximal instantaneous gradient (TR MIG) is frequently automatically calculated and 
displayed on the screen (Figure 2) when the maximal TR velocity is measured. Else, it is easily 
calculated using the simplified Bernoulli equation (39): TR MIG = 4(TR velocity) ². The 
Bernoulli’s equation then allows for the estimation of the right ventricular systolic pressure 
(RVSP) (39) taking into account right atrial pressure (RAP): RVSP = TR MIG + RAP. In this 
equation, RAP stands for right atrial pressure and is estimated as explained in Table 5. 
Table 5: Estimation of right arterial pressure using the diameter of the inferior vena 




Inferior vena cava 
diameter (cm) 
Inferior vena cava collapse with 
inspiration (sniff) 
0-5 <2.1 >50%
5-10 <2.1 <50% 
10-20 ≥2.1 <50% 
In patients with PH, DE also contributes in the evaluation of the RV systolic function through measurement of 
the tricuspid annular plan systolic excursion movement (TAPSE). TAPSE represents the distance of systolic 
excursion of the RV annular plane towards the apex. As shown in Figure 2, it is obtained using an M-mode cursor 
passed through the tricuspid lateral annulus in a four-chamber view and measuring the amount of longitudinal 
displacement of the annulus at peak-systole. While it is an easy and simple parameter to use in patients with 
PH, it is necessary to emphasise that TAPSE measurement is an angle dependent parameter and it is influenced 





Figure 2: Diagnosing pulmonary hypertension using transthoracic two-dimensional Doppler 
echocardiography  
(A) Four-chamber view showing grossly enlarged right ventricle (RV) and right atrium (RA); 
with right ventricularisation of the left ventricle (LV), and bulging of the RA into the left atrium 
(LA); (B) Color-wave and continuous-wave Doppler across the tricuspid valve in the four-
chamber view showing severe tricuspid regurgitation (TR), despite the deceivingly less 
impressive color-flow jet seen across the valve; TR maximal velocity (TR Vmax) is indicated by 
the yellow solid line, the yellow dotted line indicates an over gained which can lead to an 
overestimation of the TR Vmax;  (C) M-mode measurement of tricuspid annular plan 
excursion (TAPSE) depicting right ventricular systolic dysfunction; (D) Long-axis view of right 
ventricular apical thrombus. TR MIG, TR maximal instantaneous gradient. Adapted and 
modified from Thienneman F, Dzudie A, Mocumbi AO et al (41). 
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Right atrial pressure (RAP) is estimated based on the measured diameter and respiratory 
variation of the inferior vena cava (IVC) with the patient lying supine and the IVC brought into 
view in the long axis (Figure 3).  RAP is then estimated as indicated in Table 5 above. 
 
Figure 3: Echocardiographic evaluation of RAP using IVC dimension and collapsibility.  
Subcostal 2DE during expiration (A) and inspiration (B) and M-mode echocardiography (C) 
demonstrating good inspiratory collapse (asterisk) of the inferior vena cava (IVC) (arrow) in a 
patient with normal RAP and 2DE during expiration (D) and inspiration (E) and M-mode 
echocardiography (F) demonstrating no inspiratory collapse of the IVC in a patient with 
elevated right atrial pressure. Adapted (with permission) from Beigel et al (40). 
In the absence of pulmonary stenosis, the estimated RVSP is assumed to equal the pulmonary 
artery systolic pressure. To avoid errors in the measurement of RVSP, it is mandatory to 
observe the following conditions: 
1) Measurement of the IVC diameter should be made just proximal to the junction of the 
hepatic veins that lies approximately 0.5-3.0 cm proximal to the ostium of the right 
atrium.  
2) Avoid measuring over-gained (shaggy) signals (see the doted horizontal line in Figure 
2 above) which results in an overestimation of the RVSP. The correct maximal TR 
velocity shall be measured in the shaggy, very faint portion of the Doppler signal as 
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indicated by the dense, sharply outlined Doppler signal. The horizontal line on this 
image indicates the true maximal TR velocity.  
3) If the heart rhythm is irregular, it is recommended that 3-5 consecutive cycles be 
measured and the mean of these cycles be recorded. 
4) The maximal TR velocity may be misleadingly low when severe TR is present due to 
severely increased RAP.  In this case, other parameters must be used to assess 
whether or not pulmonary hypertension is present. 
An estimated RV systolic pressure greater than 35 mmHg generally warrants further 
evaluation in a patient with unexplained dyspnea (19). Furthermore, other 
echocardiographic findings as an estimated RA or RV enlargement or intraventricular 
septal flattening, may also motivate further evaluation. 
1.3.2.4.2. Echocardiographic functional and morphologic cardiac sequelae of 
pulmonary hypertension 
Other echocardiographic findings that are consistent with PH include RA or RV enlargement 
(Figure 2) or RV systolic dysfunction as assessed by measuring a tricuspid annular plan 
excursion (TAPSE) (42). Furthermore, DE can also identify coexistent abnormalities which are 




Table 6: Possible causes of pulmonary hypertension identified by Echocardiography 
[(adapted from McLaughlin et al (32)] 
Predisposing conditions to Pulmonary Hypertension 
 Valvular disease (Mitral (Aortic) stenosis/regurgitation, prosthetic valve 
dysfunction) 
 Left ventricular systolic dysfunction (including hypertensive heart failure, dilated 
cardiomyopathy, peripartum cardiomyopathy, myocardial infarction etc.) 
 Left ventricular diastolic function (including ischemic heart disease, hypertensive 
heart disease, hypertrophic cardiomyopathy, Fabry’s disease, infiltrative 
cardiomyopathies) 
 Other obstructive lesions (coarctation, supravalvular Aortic stenosis, subaortic 
membrane, cor triatriatum) 
 Congenital disease with shunt (Atrial (ventricular) septal defect, coronary fistula, 
patent ductus) 
arteriosus, anomalous pulmonary venous return) 
 Pulmonary embolus (thrombus in inferior vena cava, right-sided cardiac chamber, 
or pulmonary artery; 
tricuspid or pulmonic valve vegetation) 
 Pulmonary vein thrombosis/stenosis 
Findings That Suggest Specific Disease Entity 
 Left-sided valve changes (Systemic lupus erythematous, anorexigen use) 
 Intra-pulmonary shunts (hereditary hemorrhagic telangiectasia) 
 Pericardial effusion (Idiopathic pulmonary arterial hypertension, Systemic lupus 
erythematous, systemic sclerosis) 
 
1.3.2.5. The role of other tests 
A range of other tests can contribute to establishing a diagnosis of PH (30). These include: 
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 The 6-minute walk test (6MWT) which has been reported to have both a diagnostic 
and prognostic value in patients with PAH (38, 43, 44). 
 A transoesophagal echocardiography might be necessary to better study congenital 
or acquired valvular heart disease.   
 Arterial blood gases, cardiopulmonary exercise test, pulmonary function tests and 
computerized tomography of the chest which can show abnormal findings suggestive 
of a chronic obstructive pulmonary disease as a cause of PH. 
 Ventilation-perfusion scintigram and/or pulmonary angiogram which can show 
arguments in favour of chronic thromboembolic PH (CETPH). A normal or very low 
probability essentially excludes CTEPH, and a high probability scan warrants further 
evaluation with a pulmonary angiogram.  
 Antinuclear antibody serology, rheumatoid factor, C-reactive protein which patient 
should undergo if suspicion of connective tissue disease is warranted.  
 The human immunodeficiency virus screening in case HIV infection is suspected as a 
contributing etiology of PH. 
Once a definitive diagnosis of PH and been reached and potential underlying comorbidities or 
causes identified, classification in an appropriate etiologic group must be considered before 
discussing appropriate treatment. The paragraph below summarises the historical aspects of 
the clinical classification and describes the most current classification. 
1.3.3. Classification of the type of Pulmonary Hypertension 
With the first descriptions of the epidemic of drug induced PH caused by appetite 
suppressants in the 1960’s (45, 46), a systematic collection of data on PH was initiated. This 
led to the first international classification conference on PH, endorsed by the World Health 
Organization in 1973 (47, 48). Since 1973, the clinical classification of PH has undergone a 
series of changes. The   Evian classification was proposed in 1998 (49). This classification was 
based on similar pathophysiological mechanism, clinical presentation and therapeutic 
options, and was modified further in Venice in 2003 (50), where two relevant changes 
occurred. Firstly, the term idiopathic PAH (IPAH) was replaced by the term primary pulmonary 
hypertension (51). Secondly, pulmonary veno-occlusive disease (PVOD) and pulmonary 
capillary haemangiomatosis (PCH) were merged into a single subcategory of PAH. During the 
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fourth World Symposium on PH held in 2008 in Dana Point, California (20), consensus was 
achieved to maintain the general philosophy and organization of the Evian-Venice 
classifications and to amend some specific points that would improve clarity and take into 
account new information. The most updated clinical classification which derives from the 5th 
world symposium on pulmonary hypertension held in Nice in 2013 (Table 7). 
With regard to the pathophysiology of elevated pulmonary artery pressures as well as to 
therapeutic concepts, PH-LHD has been further sub-classified according to the suspected 
underlying etiology (52), with a particular interest to provide a detailed differentiation 
between heart failure with reduced left ventricular ejection fraction (HFrEF; “systolic heart 
failure”), heart failure with preserved ejection fraction (HFpEF; “diastolic heart failure”), left-
sided valvular heart disease, and other causes (52). 
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Table 7: Updated clinical classification of pulmonary hypertension from the 5th 
World Symposium on Pulmonary hypertension, Nice 2013 (18, 53). 
1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic pulmonary arterial hypertension
1.2. Heritable pulmonary arterial hypertension
  1.2.1. Bone Morphogenetic Protein Receptor 2 
  1.2.2. Activin receptor-like kinase-1, Endoglin, Mothers against decapentaplegic homolog 9, Caveolin-1, 
Potassium channel subfamily K member 3 
  1.2.3. Unknown 
1.3. Drug- and toxin-induced 
1.4. Associated with 
  1.4.1. Connective tissue diseases 
  1.4.2. human immunodeficiency virus Infection 
  1.4.3. Portal hypertension 
  1.4.4. Congenital heart diseases 
  1.4.5. Schistosomiasis 
1′. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) 
1” Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary hypertension owing to left heart disease
2.1. Systolic dysfunction 
2.2. Diastolic dysfunction 
2.3. Valvular disease
2.4. 2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental lung diseases
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1. Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary histiocytosis: lymphangioleiomyomatosis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH
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Table 8: Classification of pulmonary hypertension due to left heart diseases (52) 
Heart failure with reduced ejection fraction (HFrEF; EF ≤50%)* 
 Ischemic cardiomyopathy 
 Dilated cardiomyopathy (Hypertensive heart failure, Peripartum cardiomyopathy, 
etc.) 
Heart failure with preserved ejection fraction (HFpEF; EF >50%)* 
 Hypertensive heart disease 
 Coronary heart disease  
 Diabetic cardiomyopathy 
 Hypertrophic cardiomyopathy 
 Restrictive cardiomyopathy 
 Constrictive pericarditis 
Valvular diseases 
• Aortic valve stenosis 
• Aortic valve insufficiency 
• Mitral valve stenosis 
 Mitral valve insufficiency 
 Persistent/residual pulmonary 
hypertension after corrected 
valvular defect 
Other causes 
 Atrial fibrillation 
 Other arrhythmias 
 Triatrial heart  
 Myxoma or left atrial 
thrombus 
*Instead of differentiating between systolic and diastolic heart failure, the differentiation 
between heart failure with reduced versus preserved left ventricular (LV) function (ejection 
fraction) is made in accordance with current recommendations and guidelines (54); in most 
cases, heart failure with reduced LV function is associated with signs of left ventricular 
diastolic dysfunction. 
Because PAH, and particularly IPAH, is a diagnosis of exclusion, an algorithm is very useful as 
a starting point in any case of suspected PH. A diagnostic algorithm adapted to resource-
constrained settings has been proposed in Chapter 3 of this thesis, on Page 129. 
Finally, although the non-invasive estimation of RVSP, introduced to echocardiography 
laboratories in the 1990s by Stephen et al (55) is regarded with great excitement, an invasive 
test is still in principle warranted to confirm the diagnosis. In the next section, we discuss the 
relevance of right heart catheterization (RHC). 
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1.3.4. Confirmation of the presence of pulmonary hypertension 
Cardiac catheterization is the standard test to definitively confirm any form of PH, define the 
hemodynamic profile with accuracy and determine prognosis and response to therapy.  
Using RHC, PH has been defined as an increase in mean pulmonary arterial pressure (PAP) 
equal or above 25 mmHg at rest (53, 56). Available studies have shown that the normal mean 
PAP at rest is 14 ± 3 mmHg, with an upper limit of normal of being 20 mmHg (57, 58). This 
value has been used for selecting patients in most randomized control trials and registries of 
PH. The significance of a mean PAP between 21 and 24 mmHg is unclear (17). By directly 
measuring pressures and indirectly measuring flow, RHC allows the acquisition of prognostic 
markers such as RAP, cardiac output, and mean PAP. Other essential components of invasive 
hemodynamic assessment include oxygen saturations, RV pressure, systolic and diastolic PAP, 
pulmonary capillary wedge pressure, LA pressure or LV end-diastolic pressure, pulmonary 
vascular resistance (PVR), systemic BP, heart rate and response to acute vasodilator. 
1.3.5. Echocardiography versus right heart catheterization in the diagnosis of 
pulmonary hypertension 
While echocardiography has the advantage of being non-invasive and a useful screening tool 
for the presence of PH hypertension as described in section 1.3.1.3, it provides only an 
estimate of RVSP. Thus, confirming PH diagnosis with RHC before any specific therapeutic 
action is required. The inability of echocardiography to measure pulmonary capillary wedge 
pressure also argues for the relevance of RHC. However, RHC needs to be performed in 
specialized centers, remains an invasive procedure and as reported by Hoeper et al (59), even 
in expert’s hands, has a non-negligible procedure-related mortality and serious events risk. 
1.4. The burden of pulmonary hypertension in left heart diseases 
The global epidemiology of PH as a whole is currently unknown, but is estimated to vary 
across regions of the world, socioeconomic and health system related factors. Nevertheless, 
there is a general consensus that LHD is the most common etiology worldwide. This section 
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is on the incidence, prevalence and determinants of PH-LHD as well as outcome and 
determinants of outcome of patients with PH-LHD. 
1.4.1. Incidence of pulmonary hypertension in left heart disease 
Incidence data on PH as a whole is scanty and available incidence studies have focussed on 
very specific groups. In people with systemic sclerosis, Foocharoen et al (27) have reported 
an incidence rate of 0.2 per 100 person-years in Thailand, while Yan et al (54) have found an 
incidence of 23.5% from 2004 to 2011 in patients with pulmonary fibrosis in China.  The 
INCIPIT trial (INCidence of Pulmonary Hypertension in Italian ulTrasonography laboratories) 
is likely the only incidence study of PH as a whole and PH-LHD in particular (60). This study on 
21,483 echocardiograms from 110 Italian centers showed that 1410 (6.6%) exams had a 
systolic regurgitant flow velocity >3 m/s (median value 3.3). The ratio of women/men among 
patients was 734/67. Their mean age was 71.8 years and median body mass index was 25.7 
kg/m2. Overall, 52.6% had left heart disease, 7.5% lung disease, 1.3% chronic thromboembolic 
pulmonary hypertension, while 26.4% had more than one comorbidities, and 10.5% had 
unknown etiology. 
1.4.2. Prevalence and determinants of pulmonary hypertension due to left 
heart disease 
Comparable prevalence data on different groups of PH are not lacking. In the Armadale 
echocardiography cohort (61), the prevalence of PH (defined as RVSP>40 mmHg) among 4579 
patients was 10.5%. Among 936 cases with PH, 636 (67.9%) had PH-LHD, 87 (9.3%) had lung 
disease and hypoxia (group 3), 25(2.7%) had PAH (group 1), 19(2.2%) had chronic 
thromboembolic PH (group 4), 25(2.7%) were in PH group 5 and in 144(15.3%) patients, it was 
not possible to define a diagnosis.  
Pulmonary hypertension occurs commonly in patients with LHD, with a high level of variability 
in its development and severity, and consequently a variability in prevalence due to the 
following reasons: 1) available data are largely derived from heart failure referral centers of 
different health care systems, very few from community-based HF populations (61, 62); 2) the 
diagnostic method and the criteria vary across studies; 3) populations have been 
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heterogeneous, in terms of symptoms, age, and the severity of the LHD; 4) the degree of 
hemodynamic decompensation at the time of echo or RHC assessment influences pressure 
measurement. In the following lines, we discuss and distinguish the prevalence of PH-LHD 
according its etiology (HF or valvular heart disease).  
1.4.2.1. Prevalence and determinants of pulmonary hypertension in people with heart 
failure 
The prevalence of PH-LHD in people with HF ranges from 19% to 83.3% and depends on the 
method and criterion used to define PH as well as the type of HF (Figure 4).  
1.4.2.1.1. PH in heart failure with reduced ejection fraction 
The prevalence of PH in HFrEF varies from 25 to 83.3%. In a tertiary care center of 
Pennsylvania, Abramson et al (63) studied 108 consecutive patients with HFrEF due to dilated 
cardiomyopathy, and reported the lowest echocardiographic prevalence of PH-LHD (25.9%) 
when PH was defined as a tricuspid regurgitation (TR) jet >2.5 m/s (Table 9). A contrario, in a 
retrospective population-based study in Tayside, Scotland, Szwejkowski et al (64)  
investigated 1612 patients with HFrEF and reported that PH (defined as RSVP>33 mmHg) was 
present in up to 83.3% of patients. Variable prevalence has been reported elsewhere (Figure 
4). 
1.4.2.1.2. PH in heart failure with preserved ejection fraction 
Unlike PH in patient with HFrEF, PH in patients with HFpEF has been less documented; 
although there has been recent increasing awareness of the condition (Figure 4 and Table 9). 
In a study on the prognostic value of PH in hospitalized patients with HFpEF, Carrasco-Sanchez 
et al (65) reported a prevalence of 32.2% when PH was defined as a RVSP > 35 mmHg on DE. 
Using the same tool and the same definition, Lam et al (66) reported the highest prevalence 
of 83% in a community-based study of 244 HFpEF patients (Table 9). Another DE study by 
Damy et al in France (67) reported a prevalence of 46% with a definition of PH as a tricuspid 
gradient > 25 mmHg. In a retrospective review of 239 Lebanese patients with HFpEF who 
underwent right-side and left-side cardiac catheterization with ventriculography from 
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October 1996 to September 2007, 52.5% had PH, defined as mean pulmonary artery pressure 
>25 mmHg (68). 
 
Figure 4: Variability of the prevalence of pulmonary hypertension in patients with 
heart failure 
HFp(r)EF, Heart failure with preserved (reduced) ejection fraction. * Studies that used RHC for 
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Table 9: Prevalence of pulmonary hypertension in patients with heart failure [(adapted from Georgiopoulou et al (13)] 
 Study N Population Method Definition Prevalence 
Heart failure with predominantly reduced ejection fraction (Chronic) 
Stewart et al, 2008(69) 844 De novo cases of HF, mean LVEF=45%, 23% 
HFpEF 
DE RVSP>35 mm Hg 22% 
Makubi et al, 2015 (70)  Prevalent cases of HF, mean LVEF=41%, 68% 
with HFrEF 
DE RVSP>35 mm Hg 19% 
Torres-Macho et al, 
2012(71) 
419 Advance HF and left ventricular systolic 
dysfunction 
RHC mPAP>25 mmHg 62.2% 
Abramson et al 1992 (63) 108 Dilated cardiomyopathy; mean LVEF 17.2%                        DE TR jet velocity >2.5  m/s                                25.9% 
Butler et al 1999 (72) 320 Ambulatory patients for therapeutic evaluation; 
LVEF 23±9%            
RHC PVR >1.5 WU 72% 
Ghio et al, 2001 (73) 377 Ambulatory patients for treatment evaluation; 
LVEF 21.8±6.7% 
RHC mPAP>20 mmHg 63.2% 
Cappola et al, 2002 (74) 1134 New-onset cardiomyopathy; LVEF: N/A  PAP ≥25 mmHg 46% 
Grigioni et al, 2006 (75) 196 NYHA class III-IV; LVEF 27±9% RHC mPAP>25 mmHg 40.3% 
Shalaby et al, 2008 (76) 270 Cardiac resynchronization therapy recipients; 
LVEF 22.6±9.7% 
DE RSVP>45 mmHg 34.8% 
Adhypak et al, 2010 (77) 147 Ambulatory patients DE RSVP>45 mmHg 53.7% 
Miller et al, 2011 (78) 1541 HF with LVEF ≤40%; LVEF 30.5±8.3% DE RSVP>45 mmHg 34.6% 
Karaye et al, 2013 (79) 80 HF with LVEF 39.4±19.4 in PH vs. LVEF 
48.5±19.8% in non PH group 
DE mPAP>25 mmHg 66.5% 
44 
Szwejkowski et al, 2012 (64) 1612 LVSD (qualitative), loop diuretics, and measured 
RVSP 
DE RVSP ≥35 mmHg* 83.5% 
Bursi 2012 (62) 1049 Community inpatients and outpatients with HF, 
mean EF=47.6% 
DE RVSP >35 mmHg 79% 
Heart failure with reduced ejection fraction (Acute decompensation) 
Kjaergaard et al,  2007 (80) 388 Admitted for acute HF; LVEF 33 (23–50)% DE RVSP ≥39 mmHg 50% 
Khush et al, 2009 (81) 171 Acute HF, clinical  trial; SBP ≤125 mmHg; LVEF 
≤30% 
RHC Mixed PH: mPAP ≥25 mmHg; PCWP 
>15  mm  Hg; PVR ≥3 WU
47% 
Aronson et al, 2011 (82) 242 Acute  HF, clinical  trial;  LVEF 25±13% RHC mPAP >25  mmHg 76.0% 
Heart failure with preserved ejection fraction 
Lam et al, 2009(83) 244 Community inpatients and outpatients; LVEF 
≥50% 
DE RVSP >35 mmHg 83% 
Leung et al, 2010(68) 455 Cardiac catheterization registry; LVEDP >15 
mmHg; LVEF ≥50% 
RHC mPAP >25  mmHg 52.5% 
Heart failure with mixed populations (reduced or preserved ejection fraction, prevalence of HFrEF vs HFpEF) 
Tatebe 2011(84) 676 HF patients  NYHA II-IV referred  for RHC RHC mPAP ≥25 mmHg 21.1 vs 15.1% 
Damy et al, 2010(67) 270 HFrEF (LVEF ≤45%) vs HFpEF (LVEF>45%), 
measured RVSP 
DE TR gradient >25 mmHg 50% vs 46%  
DE, Doppler echocardiography; EF, ejection fraction; HF, heart failure; HFr(p)EF, HF with reduced(preserved) ejection fraction,  LVEF; left 
ventricular EF, PAP, pulmonary artery pressure; mPAP, mean PAP; PASP, pulmonary artery systolic pressure, PCWP, pulmonary capillary wedge 
pressure; PVR, pulmonary vascular resistance; RHC, right heart catheterization; SBP, systolic blood pressure; RVSP, right ventricular systolic 
pressure. * No   a priori definition of PH.
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1.4.2.1.3. Cardiac structural and functional correlates of PH in patients with heart 
failure 
In normal subjects, pulmonary artery pressure is correlated with age and BMI (85). In patients 
with LHD, the degree of PH is thought to be independently related to a certain number of 
factors among which the LV filling pressure, mitral regurgitation and RV dysfunction, 
regardless of LV systolic function or HF stage.   
1.4.2.1.4. The role of left ventricular filling pressure and mitral regurgitation 
Elevated left-sided filling pressure and functional mitral regurgitation are the two major 
determinants of PH in LHD. In the initial stage of all HF, an elevation of the LV filling pressure 
will consequently via a backward hemodynamic effect lead to an increase in LA pressure and 
LA dilatation. Functional mitral regurgitation (MR) occurring with LV systolic dysfunction 
inevitably leads to increasing LA pressure. In any case, increase LA pressure then causes an 
increase in hydrostatic pressure in pulmonary capillaries and the PH. In 102 consecutive 
patients with primary LV systolic dysfunction, Enriquez-Sarano et al (49), demonstrated that 
the development of PH in patients with systolic HF was strongly associated with restrictive LV 
filling pattern, a marker of increased chamber stiffness. In this study, ejection fraction and 
end-systolic volume were not independent predictors of pulmonary artery pressure. Other 
surrogates of elevated left ventricular filling pressures have also been found to be correlated 
with RVSP including LA volume (86).  
1.4.2.1.5. The RV systolic function 
RV systolic function is directly affected by increased SPAP, and the severity of RV systolic 
dysfunction strongly parallels progression of LV failure in patients with severe systolic HF(13). 
Studies have shown that RV function assessed using TAPSE, is impaired in HF, even when 
accounting for the degree of pulmonary hypertension, and that LV diastolic dysfunction and 




1.4.2.2. Prevalence and determinants of pulmonary hypertension in patients with 
valvular heart disease 
Table 10 depicts the prevalence of PH from selected studies of patients with valvular heart 
disease. Mitral valve disease has been the classical cardiac disease associated with PH (4) and 
the presence of PH plays an important role in the evolution of the primary disease (88). 
Moderate to severe mitral stenosis (MS) is frequently associated with PH and the prevalence 
of PH itself likely vary according to the severity of the disease. In 559 patients with MS 
undergoing MBV, Fawzy et al (89) reported that the prevalence of mild PH in patients with 
severe MS was 62%, while the moderate PH was encountered in 33% and the severe PH in 5% 
of the study population. Hart et al (90) reported that up to 73% of patients with MS 
undergoing percutaneous balloon valvuloplasty have PH. Chronic isolated mitral regurgitation 
with preserved LV function is also frequently associated with PH. When the presence of PH is 
defined as sPAP>40 mmHg by RHC or RVSP>40 mmHg by echo, a prevalence of 53% was 
observed by Ghoreishi et al (91). In patients with degenerative MR, if the definition of 
RVSP>50 mmHg by echo was used, a prevalence of 23% was observed by Barbieri et al (92), 
whereas with a definition of sPAP≥50 mmHg, Magne et al described only 15% prevalence (93). 
A recent study of patients with asymptomatic MR showed that exercise-induced PH (sPAP>60 
mmHg) was more common, with a prevalence of more than 46% compared with 15% 
prevalence of PH at rest (sPAP>50 mmHg) (93). This explains symptom development during 
exercise.  
Aortic stenosis results in PH by inducing LV hypertrophy and subsequent LV diastolic 
dysfunction, which in turn leads to increased pulmonary pressures. Over time, structural 
changes in the pulmonary vasculature occur and PH might become irreversible. Compared 
with mitral stenosis, the prevalence of PH in patients with aortic stenosis tends to be lower, 
with a prevalence of approximately 30% (94). Although less frequently, aortic regurgitation 
(AR) can also lead to PH. The underlying mechanism is also chronic elevation of LVEDP, which 
in turn leads to an increase in left atrial and pulmonary artery pressures. Khandhar et al 
reported 16% of their patients with severe AR had severe PH (95). 
In conclusion, mirroring patients with HF, an elevation in LV filling pressure and the 
occurrence of mitral regurgitation plays a major role in the development and severity of PH 
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in patients with LHD. How PH independently affects hospitalizations or mortality from heart 





Table 10: Prevalence of pulmonary hypertension from selected studies of patients with valvular heart disease 
Study N Population Method Definition Prevalence 
 Zühlke et al 3343 All rheumatic valvular heart disease DE RVSP>35 mm Hg 28.8% 
Ward and Ward (96)  586 Mitral valve disease  RHC SPAP > 80 mmHg and PVR>10 
Wu 
8.2% 
Hart et al (90) 317 Mitral stenosis undergoing percutaneous balloon 
valvuloplasty 
RHC mPAP>25 mmHg 73% 
TPG>15 mmHg 19% 
Magne et a l(93) 78 MR; severe in 60% of the cohort RHC Rest SPAP>50 mmHg 15% 
Barbieri et al (92) 437 MR DE RSVP>50 mmHg 23% 
Nozohor et al (97) 270 MR undergoing mitral valve surgery DE RSVP>50 mmHg 27% 
Ghoreishi et al(91) 873 MR undergoing mitral valve surgery RHC and DE sPAP or RSVP mmHg>40 mmHg 53% 
Johnson et al (98) 92 Severe AS RHC SPAP 31 – 50 mmHg  34% 
    SPAP>50 mmHg  16% 
Ben-Dor et al (99) 509 AS DE RSVP>30 mmHg 68.3 
Silver et al (94)  45 Severe AS RHC SPAP>50 mmHg 29% 
Melby et al (100) 1080 AS undergoing surgery RHC SPAP>35 mmHg 47% 
Khandhar et al (95) 506 Severe AR DE  RSVP>60 mmHg 16% 
AS(R), Aortic stenosis(regurgitation); SPAP, Systolic pulmonary artery pressure; mPAP, mean pulmonary arterial pressure; PVR, Pulmonary 
vascular resistance; RVSP, Right ventricular systolic pressure; TPG, Transpulmonary gradient. 
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1.5. Predictors of hospitalizations for heart failure and mortality in 
patients with pulmonary hypertension due to left heart disease 
This section is available as a research publication in the peer-reviewed journal British Medical 
Journal Open. 
 
Dzudie A, Kengne AP, Thienneman F, et al Predictors of hospitalisations for heart failure and 
mortality in patients with pulmonary hypertension associated with left heart disease: a 
systematic review. BMJ Open 2014;4:e004843. doi:10.1136/bmjopen-2014004843. 
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Objectives: Left heart disease (LHD) is the main 
cause of pulmonary hypertension (PH), but little is 
known regarding the predictors of adverse outcome of 
PH associated with LHD (PH-LHD).  We conducted a 
systematic review to investigate the predictors of 
hospitalisations for heart failure and mortality in 
patients with PH-LHD. 
Design: Systematic review. 
Data sources: PubMed MEDLINE and SCOPUS from 
inception to August 2013 were searched, and citations 
identified via the ISI Web of Science. 
Study selection: Studies that reported on 
hospitalisation and/or mortality in patients with PH- 
LHD were included if the age of participants was 
greater than 18 years and PH was diagnosed using 
Doppler echocardiography and/or right heart 
catheterisation.  Two reviewers independently selected 
studies, assessed their quality and extracted relevant 
data. 
Results: In all, 45 studies (38 from Europe and USA) 
were included among which 71.1% were of high 
quality. 39 studies were published between 2003 and 
2013. The number of participants across studies 
ranged from 46 to 2385; the proportion of men from 
21% to 91%; mean/median age from 63 to 82 years; 
and prevalence of PH from 7% to 83.3%. PH was 
consistently associated with increased mortality risk in 
all forms of LHD, except for aortic valve disease where 
findings were inconsistent. Six of the nine studies with 
data available on hospitalisations reported a significant 
adverse effect of PH on hospitalisation risk. Other 
predictors of adverse outcome were very broad and 
heterogeneous including right ventricular dysfunction, 
functional class, left ventricular function and presence 
of kidney disease. 
Conclusions: PH is almost invariably associated with 
increased mortality risk in patients with LHD. However, 
effects on hospitalisation risk are yet to be fully 
characterised; while available evidence on the adverse 
effects of PH have been derived essentially from 
Caucasians. 
▸ Prepublication  history and 
additional material is
available. To view please visit 




Pulmonary   hypertension  (PH)  describes a Received 12 January 2014 
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group  of disorders  resulting  from an increase 
in pulmonary vascular resistance,  pulmonary 
blood  flow, pulmonary venous pressure  or  a 
combination  of  these   features.1   Based   on 
shared pathological and haemodynamic 
characteristics, and therapeutic approaches, 
five clinical  groups  of PH  have been  distin- 
guished   with PH associated with left heart 
disease (PH-LHD) or PH group  2 credited to 
be the  most frequent form of PH in contem- 
porary clinical  settings.3   Indeed, PH  is 
common  in   patients   with  LHD,   where   it 
often  reflects  the  background LHD,  but  has 
also been  reported to be a maker  of disease 
severity and  unfavourable prognosis.  Patients 
with PH-LHD have more severe symptoms, 
worse tolerance to effort,  experience higher 
hospitalisation  rates  and  are  more  likely to 
receive an indication of the  need  for cardiac 
transplant  with major implications  for the 
quality   of  life  of  patients   and   healthcare 
costs. Several studies  have  reported  PH-LHD 
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Strengths and limitations of this study 
▪  Our search  strategy  was  likely   limited by  its
focus on a full-report article published in English
and French, and traceable via PubMed MEDLINE 
and/or SCOPUS.
▪ Important heterogeneity in the included studies
precluded  the  pooling  of  data  to  perform  a
meta-analysis.
▪ This is the first systematic review on  determi- 
nants of hospitalisations and mortality in patients
with pulmonary hypertension associated with left
heart   disease,   which  presents   the   available




to   be   associated    with   increased   mortality,   both    in 
patients   with  systolic  dysfunction   and   those   with  pre- 
served    left   ventricular    ejection    fraction    (LVEF).3–6 
Furthermore, the  presence of preoperative PH has been 
associated   with  poor   outcomes  in  patients   with  valve 
disease  undergoing valve replacement.7  However,  there 
are  still several gaps in  the  existing  evidence,  including 
the   prevalence  of  PH-LHD  and   measurement  of  the 
true  impact  of PH on symptoms and  outcome of various 
LHDs. Equally, little is known regarding the  effect of the 
severity of PH on  hospitalisations, rehospitalisations and 
death,  and  their  co-factors in patients  with LHD. 
Considering the  number of recent advances  in the  man- 
agement of PH, it is likely that a better  understanding  of 
the  impact  of PH-LHD  on  major  outcomes might  assist 
the clinical management of patients  with PH. 
We performed a systematic review of the existing litera- 
ture  to  determine the  predictors of hospitalisation and 
mortality  in patients  with PH secondary to LHDs includ- 
ing   systolic  dysfunction,   diastolic   dysfunction   and/or 
valve disease.  Additionally,  we aimed  to  assess whether 
the severity of PH affects the risk of the two outcomes. 
The   following   variables   were   extracted  from   each 
study:  publication year,  country of  origin  of  the  study, 
study design, study population’s demographics, the 
mean/median  follow-up  duration,  the   outcome  pre- 
dicted,  the  proportion of measurable RVSP, the  mean/ 
median baseline  RVSP or  mPAP, the  prevalence of PH, 
the  readmission rate,  the  mortality  rate  with odds  ratio 
(OR)  or hazard  ratio  (HR)  for PH where  reported and 
the    predictors   of   outcome   including   the    tricuspid 
annular plan systolic excursion  (TAPSE). One  study8 
reported  the   effect   of  PH   in   relation  with  survival. 
Effects on  mortality  were obtained by taking  the  inverse 
of the HR for survival. 
Quality assessment 
The  methodological quality  of the  selected  studies  was 
assessed using the  Quality In Prognosis  Studies (QUIPS) 
tool, designed  for systematic reviews of prognostic studies 
through an  international expert  consensus  (table 1).52 
The QUIPS contains  six domains  assessing the following: 
(1)  bias due  to patient selection;  (2)  attrition; (3)  meas- 
urement  of  prognostic  factors;  (4)   outcome  measure- 
ment;    (5)    confounding   on    statistical   analysis   and 
reporting results; and  (6)  confounding on presentation. 
predict    a   specific 
of  several  possible 
is   not    an    issue. 
In   prognosis    studies   designed    to 
outcome  based   on  a  combination 
prognostic   factors,    confounding 
METHODS 
We searched MEDLINE via PubMed  and  SCOPUS from 
inception to  August  2013  for  all  published studies  on 
PH-LHD, using a combination of key words described in 
the   online   supplementary  box   1.  All  searches   were 
restricted to studies in humans published in ‘English’ or 
‘French’  languages.  In  addition, we manually  searched 
the   reference  lists  of   eligible   studies   and   relevant 
reviews, and  traced  studies  that  had  cited  them  through 
the  ISI Web of Science  for  any relevant  published and 
unpublished  data.   Two   independent  reviewers   (AD 
and APK) performed the study selection,  data extraction 
and  quality assessment; and  disagreements were resolved 
by consensus  or consulting a third  reviewer (KS). 
Studies  that  reported on  hospitalisation and/or mor- 
tality in patients  with PH-LHD  were included if the  fol- 
lowing criteria  were met:  (1)  age of participants greater 
than   18 years;  (2)   Right   ventricular  systolic  pressure 
(RVSP) measured by transthoracic Doppler echocardiog- 
raphy  (DE)  and  calculated  from the  maximum tricuspid 
regurgitation  jet  velocity  using  the  modified Bernoulli 
equation (4v2) and  adding  right  atrial  pressure  (RAP). 
RAP could  be a fixed  value from  5 to 10 mm Hg, could 
have been  estimated  clinically using  the  jugular  venous 
pressure  ( JVP), or  estimated  by measuring the  inferior 
vena cava size and  change  with spontaneous respiration 
using  echocardiography; and/or  (3)  mean   pulmonary 
artery pressure   (mPAP)  measured by right  heart   cath- 
eterisation  (RHC)   or   by  DE.  We  excluded  narrative 
reviews and  case series. Studies  on  persistent PH follow- 
ing  heart  transplantation were not  included because  of 
Therefore, the  items  on  confounding were  considered 
irrelevant  for our  quality assessment.  The  remaining  17 
items of the five categories  each were scored to assess the 
quality of the  included studies.  For each  study, the  five 
domains   were  scored  separately  as high  (+),  moderate 
(±) or low (−) quality (ie, presenting a low, moderate or 
high risk of bias, respectively). To strengthen the discrim- 
inative capacity of the  QUIPS, we used  the  scoring  algo- 
rithm   developed  by  de   Jonge   et   al,53     as  explained, 
described in detail in the online  supplementary table. 
Data synthesis 
Hospitalisations  or  rehospitalisations  for  heart   failure 
and  mortality  identified by multivariable  analysis in indi- 
vidual  studies  are  presented  (table 2),  including their 
estimated   effect  size  (eg,   OR  or  HR)   and   95%  CI. 
Quantitative  analysis  of  results  was  not   done   due   to 
important heterogeneity in  study  design,  study  popula- 
tion,  PH  definition and  measurement, outcome defini- 
tions  in  the  studies  and  confounding or  other  types of 
prognostic factors. We have therefore presented a narra- 
tive summary of the available evidence  (table 2). 
RESULTS 
Studies selection 
Figure  1 presents a flow diagram  for the  study selection 
process.    Of   the    7550   citations    identified   through 
searches,   6255  titles   were   examined  and   6083  were 
excluded on the  basis of the  title scanning.  The  remain- 
ing  172  abstracts  were  examined  and  55  articles  were 
the   classification   of the   complexity 
population. 
of PH in this 


























































Table  1    Results of quality assessment of studies on mortality and  readmissions for heart  failure in patients with pulmonary  hypertension associated with left heart  disease 
Quality: 
Measurement of                                       Statistical                 Quality         +=high 
Statistical                 Study               Study        prognostic             Assessment of     analysis and          score           ±=moderate 
N    Study                        Country/ethnicity             Design                               methods                   participation     attrition     factors                   outcomes             presentation            ( points)       −=low 
1     Merlos et al 9                   Spain                                       Prospective hospital               KM, Cox regression   13.5                      15                10                               15                             15                                68.5                 + 
based cohort 
2     Agarwal et al 10              USA—ethnicity data  in        Retrospective hospital           KM, Cox regression   13.5                      7.5               12.5                            15                             15                                63.5                 + 
98 patients (63% whites)     based cohort 
3     Agarwal 11                         USA—96% blacks                Prospective hospital               KM, Cox regression   12                         10                10                               15                             15                                62                    + 
based cohort 
4     Aronson  et al 12              USA                                        Prospective hospital               Cox regression          15                         15                15                               15                             12.5                             72.5                 + 
based cohort 
5     Bursi et al 13                     USA                                        Prospective population           KM, Logistic                 15                         12.5             12.5                            12.5                          15                                65                    + 
Caucasians and  blacks        based cohort study              regression 
6     Strange et al 14                  Armadale-Australia           Retrospective population       KM, Logistic and          15                         7.5               10                               12.5                          12.5                             58.5                 ± 
based cohort                           Cox regression 
7     Mutlak et al 15                  USA                                        Prospective hospital               KM, Logistic and          13.5                      15                10                               15                             15                                69                    + 
based cohort                           Cox regression, 
KM 
8     Tatebe et al  16                  Japan                                 Prospective hospital               KM, Logistic and          15                         10                15                               15                             15                                72.5                 + 
based cohort                           Cox regression 
9     Adhyapak et al 8            India                                        Prospective hospital               Cox regression          13.5                      10                10                               12.5                          5                                  53.5                 ± 
based cohort 
10   Stern  et al 17                    USA                                        Retrospective hospital           KM, Cox regression   13.5                      15                12.5                            12.5                          12.5                             66                    + 
based cohort 
11   Lee et al 18                        Korea                                      Prospective hospital               KM, Cox regression   15                         15                15                               12.5                          15                                72.5                 + 
based cohort 
12   Møller et al 19                  USA                                        Prospective hospital               KM, Logistic                 13.5                      15                12.5                            15                             15                                71                    + 
based cohort                           regression 
13   Cappola et al 20              USA, 35% blacks  and          Prospective hospital               KM, Cox regression   13.5                      7.5               12.5                            15                             15                                62.5                 + 
65% whites                            based cohort 
14   Szwejkowski  et al 21    UK                                          Retrospective hospital           KM, Cox regression   13.5                      10                10                               15                             15                                61                    + 
based cohort 
15   Abramson et al 22          USA                                        Prospective hospital               KM, Cox regression   12                         15                10                               15                             12.5                             64.5                 + 
based cohort 
16   Kjaergaard et al 23        Denmark                                 Prospective hospital               KM, Cox regression   13.5                      15                12.5                            15                             15                                71                    + 
based cohort 
17   Shalaby et al 24              USA, 95% Caucasians       Retrospective hospital           KM, Cox regression   13.5                      12.5             15                               15                             15                                71                    + 
based cohort 
18   Damy et al 25                   UK                                          Prospective hospital               KM, Logistic and          15                         10                15                               15                             15                                70                    + 
based cohort                           Cox regression 
19   Ristow et al 26                 USA                                        Prospective hospital               Logistic regression     13.5                      12.5             10                               15                             5                                  48.5                 ± 
based cohort 
20   Grigioni et al 27               Italy                                         Retrospective cohort              KM, Logistic                 13.5                      12.5             12.5                            15                             15                                68.5                 ± 
regression 
21   Levine et al 28                 USA, mainly Caucasians    Retrospective cohort              No Logistic                   12                         10                10                               7.5                            2.5                               42                    − 
(78.3%)                                                                                     regression, no KM 
analysis 
22   Lam et al 29                      USA                                        Prospective observational    KM, Logistic                 12                         15                10                               15                             12.5                             68                    + 
community  based cohort       regression 
23   Khush  et al 30                  Multicentric USA and           Prospective cohort in the      KM                                15                         10                15                               15                             12.5                             68.5                 + 
































































Table  1    Continued 
Quality: 
Measurement of                                       Statistical                 Quality         +=high 
Statistical                 Study               Study        prognostic             Assessment of     analysis and          score           ±=moderate 
N    Study                        Country/ethnicity             Design                               methods                   participation     attrition     factors                   outcomes             presentation            ( points)       −=low 
24   Ghio et al 31                     Italy                                         Prospective cohort                 KM, Cox regression   13.5                      12.5             12.5                            12.5                          12.5                             63.5                 + 
25   Wang et al 32                   China                                      Retrospective cohort              KM                                12                         12.5             12.5                            12.5                          5                                  54.5                 ± 
26   Ghio et al 33                     Italy                                         Prospective cohort                 KM, Cox and                13.5                      10                10                               15                             15                                63.5                 + 
Logistic regression 
27   Naidoo et al 34                South  Africa, Blacks             Retrospective cohort              No Logistic                   12                         7.5               10                               5                               7.5                               42                    − 
regression, no 
Kaplan  Meier 
analysis 
28   Fawzy et al 35                  Saudi  Arabia                          Prospective cohort                 No Logistic                   12                         10                12.5                            15                             7.5                               57                    ± 
regression, no 
Kaplan  Meier 
29   Roseli  et al 36                  USA                                        Retrospective hospital           KM, Cox regression   13.5                      10                10                               15                             12.5                             63.5                 ± 
based cohort 
30   Melby et al 37                   USA                                        Retrospective hospital           KM, Cox regression   13.5                      12.5             10                               15                             15                                66                    + 
based cohort 
31   Le Tourneauet al  38     France, mainly                      Prospective hospital               KM, Cox regression   13.5                      10                10                               15                             15                                63.5                 + 
Caucasians  based cohort 
32   Parker  et al 7                    USA                                        Retrospective hospital           KM, Cox regression   12                         15                12.5                            15                             15                                71                    + 
based cohort 
33   Kainuma  et al 39             Japan, Asians                        Retrospective hospital           KM, Cox regression   10.5                      10                12.5                            12.5                          10                                55.5                 ± 
based cohort 
34   Barbieri et al 40               Multicentric (Europe  and      Prospective hospital               KM, Cox regression   13.5                      15                12.5                            15                             15                                71                    + 
USA) based cohort 
35   Manners et al 41             United Kingdom                    Retrospective hospital           No regression            10.5                      7.5               5                                 5                               2.5                               30.5                 − 
based cohort                           analysis, no KM 
estimation 
36   Malouf et al 42                 USA                                        Prospective hospital               KM, Cox and                10.5                      10                10                               15                             12.5                             58                    + 
based cohort                           Logistic regression 
37   Khandhar et al 43           USA                                        Retrospective hospital           KM, Cox regression   13.5                      10                10                               15                             12.5                             61                    ± 
based cohort 
38   Zuern et al 44                      Germany                           Prospective hospital               KM, Cox regression   15                         7.5               10                               15                             15                                62.5                 + 
based cohort 
39   Ben-Dor et al 45              USA                                        Prospective hospital               KM, Logistic                 15                         10                10                               15                             15                                68                    + 
based cohort                           regression 
40   Yang et al 46                    USA                                        Retrospective hospital           KM, Cox and                15                         7.5               15                               12.5                          15                                65                    + 
based cohort                           logistic regression 
41   Nozohoor  et al 47             Sweden                              Retrospective cohort              KM, Cox and                13.5                      10                10                               15                             12.5                             61                    + 
Logistic regression 
42   Ward and                       UK                                          Retrospective cohort              No KM, no Logistic     12                         5                  2.5                              7.5                            2.5                               29.5                 − 
Hancock 48                                                                                                                                                                   or Cox regression 
43   Ghoreishi  et al 49           USA                                        Retrospective cohort              KM, Cox and                15                         10                10                               10                             15                                60                    + 
Logistic regression 
44   Cam et al 50                     USA                                        Retrospective cohort              KM, Cox and                13.5                      15                10                               10                             12.5                             61                    + 
Logistic regression 
45   Pai et al 51                         USA                                        Retrospective cohort              KM, Cox and                15                         10                10                               10                             15                                60                    + 
Logistic regression 




























































Table  2    Study characteristics of studies on mortality and  readmissions for heart  failure in patients with pulmonary  hypertension associated with left heart  disease 
Diagnostic criteria   Median/mean   HF     Mortality (all-cause) rate at 6, 12, 24 and 36 months or   Adjusted ORs/ 
(RVSP by      (mm Hg)     readmission   at mean duration of follow-up   HRs and CI (or 
echocardiography   Mean/    Proportion   baseline   Prevalence   rate or      36 or at    p value) for 
or mPAP by    Study population (sample  median   Definition of   (%) of    RVSP (echo)   of PH at   adjusted    mean/   all-cause 
Author, year  echocardiography    size, heart disease,   follow-up  Age—years/   outcomes   measurable   or mPAP   baseline   ORs/HRs   median   mortality, 
published      or RHC)   NYHA class, type of HF)     (months)    male sex—%    predicted   RVSP               (RHC)      (%)                   and CI               6                     12                       24   follow-up   outcome 
Studies in patients with heart  failure and  cardiomyopathies 
Merlos et al,    RVSP >35 mm Hg   1210 consecutive patients   12   72.6    All-cause  mortality   41.5   46   35.2   NR   NR   4.89/10   NA   NR                    OR for mild PH 
20139  with HF, stratified into      54.1%   Cardiovascular   persons-year   1.6 (0.7 to 3.74), 
normal (RVSP <35), mild     deaths   in severe PH    moderate PH 
(RVSP 36–45),  moderate    1.34 (0.54 to 
(RVSP 46–60)  and  severe   3.16) and  severe 
PH (RVSP >60 mm Hg)      PH 2.57 (1.07 to 
6.27) 
Agawal et al,   RHC with mPAP   339 patients with PH and   54.2   63 / 21%    All-cause  mortality   NA    43    NA   NR   NR   2.9%   4.4%    6.8%                 UTSW cohort HR 
201210  >25 mm Hg  LHD, 90% with HFpEF,       1.4 (1.1 to 1.9) 
NYHA class NR       and  NU cohort 
HR 1.4 (1.1 to 
1.7) 
Agawal,   RVSP >35   288 patients undergoing      25.8   56.5 vs 53.1 /    All-cause  mortality   NA    44.7 vs 27.2    38   NR   NR   26.4 vs 24.5   48.3 vs 46.3   62.9 vs 56.3    HR 2.17 (1.31 to 
201211  haemodialysis stratified into       65 vs 63%   3.61) 
PH and  NPH- based on 
RVSP 
Aronson   RHC with mPAP   242 patients with acute HF,   6   61; 42%    All-cause  mortality   NA    34 vs 38 vs 44    76.0   NR   8.6 vs 21   NR   NR   NR    HR for passive 
et al, 201112 ≥25 mm Hg and   divided in 3 groups, NPH,      vs 48.3   PH 1.7 (0.6 to 
mPCWP  passive PH and  reactive      4.5) and  reactive 
>15 mm Hg  PH, NYHA class IV      PH 4.8 (2.1 to 
17.5) 
Bursi et al,   RVSP >35 mm Hg   1049 patients with HF     81   76; 49.3%    All-cause  mortality   NR   48   79   NA   NR   4, 10, and    8 vs 19 vs 28    46   HR for tertile 2: 
201213  stratified into tertiles of    17% for   1.45 (1.13 to 
RVSP (<41, 41–54  and   tertiles 1, 2,    1.85) and  tertile 
>54 mm Hg)  and  3,   3: 2.07 (1.62 to 
respectively   2.64) 
Strange    RVSP >40 mm Hg   15633  echo  screening, 636   83    79; 48%    All-cause  mortality   NR   52    NR   NA   NR   NR   NR   Mean   NR 
et al, 201214 PH group 2 stratified into 3      survival 
groups  (group 1 RVSP      4.2 years 
<40 mm Hg, group 2 
between 41 and  60 and 
group 3 >60 mm Hg) 
Mutlak et al,     RVSP >35 mm Hg   1054 patients with acute       12   60 vs 69;   Readmission for HF   NR   32 vs 43   44.6   2.1 vs 9.2;    NR   NR   NR   NR    HR for 
201215  myocardial  infarction      77 vs 64%    All-cause  mortality       OR 3.1 (1.87   readmission 3.1 
divided into NPH and  PH      to 5.14)   (1.87 to 5.14) 
groups 
Tatebe et al,    RHC with mPAP   676 consecutive patients   31.2    64vs  64vs  63;      All-cause  mortality      NR   17 vs 30 vs 35    23   NR   NR   24.5 vs 18 vs   52.5 vs 50 vs    71.0 vs 77   HR for reactive 
201216  ≥25 mm Hg   with chronic HF, NYHA      63vs  48vs  66%   and  readmission for   in NPH,   18.9%  in   60.3%  in NPH,   vs 79.3 in   PH group 1.18 
mPCWP  class ≥2, stratified into 3      HF   passive PH   NPH, passive  passive and    NPH,   (1.03 to 1.35) 
>15 mm Hg  groups, NPH (mPAP <25),    and  reactive   and  reactive   reactive  PH,   passive PH 
passive PH (PH with PVR     PH,   PH,      respectively   and  reactive 
≥2.5  WU) or reactive  PH      respectively  respectively  PH, 
(PH with PVR >2.5 WU)       respectively 
Adhyapak,    Echocardiography   147 patients with HF       11.2   54    Cardiac  death   NR   Group 1 20±5   53.7   19.7, OR and   Overall 5.1 at   NA   NA      HR in PH 2.27 
20108   with mPAP   stratified into: group 1,      91.8%   Readmissions   group 2 24.8    CI NR    11.2 months,   (1.09 to 3.57) 
>25 mm Hg  normal PASP/preserved      ±0.4 group 3   4.5 in group 
RV function; group 2,      56.8±6  and   3 vs 8.8 in 
normal PASP/RV       group 4 58.9    group 4 
dysfunction;  group 3,      ±8.8 
high PASP/preserved RV 
function; and  group 4, high 





























































Table  2    Continued 
Diagnostic criteria   Median/mean   HF    Mortality (all-cause) rate at 6, 12, 24 and 36 months or   Adjusted ORs/ 
(RVSP by   (mm Hg)     readmission   at mean duration of follow-up   HRs and CI (or 
echocardiography      Mean/      Proportion   baseline   Prevalence   rate or      36 or at    p value) for 
or mPAP by    Study population (sample  median   Definition of   (%) of    RVSP (echo)   of PH at   adjusted   mean/   all-cause 
Author, year  echocardiography    size, heart disease,   follow-up  Age—years/    outcomes   measurable   or mPAP   baseline   ORs/HRs   median   mortality, 
published      or RHC)      NYHA class, type of HF)   (months)    male sex—%    predicted   RVSP               (RHC)      (%)                   and CI               6                     12                       24   follow-up   outcome 
Stern  et al,    Echocardiography   68 patients needing      7.1   70   Composite of    NR   Group 1 39.7   NR   NR   NR   Increased   NR   NR    HR of 2.0 (1.2 to 
200717  but criteria for PH   cardiac  resynchronisation       64.7%   hospitalisation for   ±6.7 and  group   mortality in    5.5) for RVSP 
not reported    stratified into group 1       HF and  all-cause    2 60.2±9.2   patients with    ≥50 
(RVSP ≥ 50 mm Hg, n=27)   mortality   RVSP 
and  group 2 (RVSP       ≥50 mm Hg 
<50 mm Hg, n=41) 
Lee et al,   RVSP >39 mm Hg   813 patients with TR       58.8   64    All-cause  mortality   NR   37.1 in patients   NR   NR   NR   NR   10.5 vs 21.9        5-year   HR of 1.024 
201018  stratified into two groups      42.5%   who survived   survival      (1.017  to 1.032) 
based on the RVSP       vs 43.8 in    rates 61.0 
<39 mm Hg (group 1,       patients who    and  80.6% 
n=530)  and  RVSP      died    group 2 vs 
≥39 mm Hg (group 2,       group 1 
n=283)       respectively 
Møller et al,   RVSP >30 mm Hg   536 patients with acute     40   65/ 68%    All-cause  mortality   69   NR   75   NR   NR   NR   5% in group 1     NR    HR 1.22 (1.14 to 
200519  myocardial  infarction      74/54%    52% in       1.38) per 
stratified into group 1      78/44%  in    patients with a      10 mm Hg 
(RVSP <30 mm Hg), group   groups  1, 2   RVSP      increased 
2 mild to moderate PH       and  3,  >65 mm Hg
(RVSP of 31 to 55 mm Hg)   respectively 
and  group 3 severe PH 
(RVSP >55 mm Hg) 
Cappola   RHC with mPAP   1134 patients with      52.8    48    All-cause  mortality   NA    25   NR   NR   NR   NR   NR   33% of             HR 1.86 (1.30 to 
et al, 201220     ≥25 mm Hg   cardiomyopathy stratified      60%   patients died   2.65) for group 2, 
according to PVR: NPH       during the   1.78 (1.13 to 
(<2.5), group 1 PH (2.5–3),   mean FU   2.81) for group 3 
group 2 PH (3–3.5),  group      and  2.04 (1.51 to 
3 PH(3.5–4)  and  group 4      2.74) for group 4 
PH (>4) 
Szwejkowski     RVSP >33 mm Hg   1612 patients with HF      33.6    75.2    All-cause  mortality   32   46    83.3   NR   NR   NR   NR   55.1%  of   HR 1.06 (1.03 to 
et al, 201121 stratified into 5 groups      57.4%   patients died   1.08) for every 
according to RVSP (<33;       during the   5 mm Hg 
33–38;  39–44;  45–52  and      mean FU   increase in 
>52 mm Hg)  RVSP 
Abramson       Echocardiography  108 patients with dilated  28   67.5    All-cause  mortality,     NR   5.6 m/s    26   75% during   NR   NR   NR   17% in   OR for increased 
et al, 199222     with TRV >2.5 m/s  cardiomyopathy, stratified  81%    mortality due  to HF   the study  28 months   TRV 3.77 (1.38 
into 2 groups:  group 1   and   period    vs 57%    to 10.24) 
(TRV <2.5 m/s) and  group  re-hospitalisations   5.76 (1.97 to 
2 (>2.5 m/s), 38.9%  in  for HF   16.90) 
NYHA class III and  IV, 
77.3%  of ischaemic HF 
Kjaergaard   Echocardiography  388 consecutive patients  33.6   75    All-cause  mortality   NR   38   75% and   NR   48% if COPD    NR   57% at   HR 1.09 (1.04 to 
et al, 200723     but cut-off for PH  with known or presumed  60%   50% with   and  21% in   33.6 months   1.14) for every 
not reported HF stratified into quartiles   RVSP >31    HF without   increase of 
of RVSP (<31, 31–38,  39–  and   COPD   RVSP per 
50, >50)  40 mm Hg,   5 mm Hg 
respectively 
Shalaby   RVSP ≥30 mm Hg   270 patients undergoing    19.4   66.5    All-cause  mortality,     NR   40.4    NR   40% in group    NR   NR   NR   12% in   HR 2.62 (1.07 to 
et al, 200824 cardiac  resynchronisation    91%    cardiac   3 vs 9% in    group 1% vs    6.41) 
stratified into 3 groups  on   transplantation   group 1 (6.35   34% in 
the basis of RVSP: group    ( primary end  point)    (2.55 to    group 3 at 
1, (22–29,  n=86); group 2    or re-hospitalisation   15.79))   mean 
(30–44,  n=90) and  group 3   for HF   follow-up 





























































Table  2    Continued 
Diagnostic criteria                                                                                                                                                    Median/mean                          HF                      Mortality (all-cause) rate at 6, 12, 24 and 36 months or     Adjusted ORs/ 
(RVSP by                                                                                                                                                                                            (mm Hg)                                        readmission   at mean duration of follow-up                                              HRs and CI (or 
echocardiography                                              Mean/                                                                                Proportion    baseline            Prevalence   rate or                                                                                               36 or at            p value) for 
or mPAP by                Study population (sample  median                                 Definition of               (%) of               RVSP (echo)     of PH at          adjusted                                                                             mean/           all-cause 
Author, year  echocardiography    size, heart disease,             follow-up  Age—years/     outcomes                 measurable   or mPAP           baseline        ORs/HRs                                                                              median          mortality, 
published      or RHC)                       NYHA class, type of HF)     (months)    male sex—%    predicted                  RVSP               (RHC)                   (%)                   and CI               6                     12                       24                         follow-up     outcome 
 
Damy et al,      Echocardiography     1380 patients with                  66                 72                          All-cause  mortality      30% of all,       25                          46% of            NA                     NR                 NR                     NR                       40.3%  at          HR 1.72 (1.16 to 
201025                  with RVTG                   congestive HF, 1026 with                           67%                                                             26% in                                            HFpEF,50%   (outpatient                                                                                   median              2.55) for RVSP 
>25 mm Hg                 LVSD (EF <45%) and  324                                                                                               patients with                                  of HFrEF         cohort)                                                                                               follow-up of     >45 mm Hg) 
without), further stratified                                                                                              LVSD and                                       and  23% of                                                                                                                66 months 
into quartiles  of RVSP                                                                                                       40% in those                            patients 
without                                           without HF 
Ristow et al,    Echocardiography     717 patients with coronary     36                 65, 74%                Hospitalisation, CV     80                     NR                        22                     6% (group I)    NR                 NR                     NR                       11% (group     OR for all-cause 
200726                  with TR gradient          artery disease, 573 with                              (group 1) 69,       death, all-cause                                                                                  vs 21%                                                                                              1) vs 17%        deaths 1.2 (0.85 
>30 mm Hg                 measurable TR, stratified                           75% (group 2)     death and  the                                                                                                (group II) OR                                                                                    (group 2)         to 1.6) per 
into group 1 (TR gradient                                                           combined end  point                                                                                     per each                                                                                                    10 mm Hg 
≤30 mm Hg, n=447)  and                                                            of all                                                                                                               10 mm Hg                                                                                                                   increase in TR 
group 2 (TR gradient                                                                                                                                                                                           increase of                                                                                                                 OR for combined 
>30 mm Hg, n=126)                                                                                                                                                                                            TR gradient                                                                                                                 endpoint  1.6 (1.1 
1.5 (1.03 to                                                                                                                 to 2.4) 
2.2) 
Grigioni et al,  RHC with mPAP         196 patients with HF               24                 54                          Cardiovascular           NA                    25                          NR                   27% acute       NR                 NR                     20%                      NR                    HR for PH 2.3 
200627                  ≥25 mm Hg                 evaluated for PH and                                   73%                       deaths, acute HF                                                                                          HF, 2.30                                                               cardiovascular                           (1.42 to 3.73) ; 
changes in mPAP                                                                       and  combined end                                                                                        (1.42 to 3.73)                                                      deaths                                     HR for worsening 
point of both                                                                                                                                                                                                                                        >30% in mPAP 
2.6 (1.45 to 4.67) 
Levine et al,    RHC assessed         60 patients with PH owing     10                 50                          Transplant or               NA                    39 vs 57 in          NA                   NR                     NR                 NR                     NR                       90% vs 50%    NR 
199628                  change in PH, no       to HF awaiting heart                                     85%                       all-cause death                                 group A and                                                                                                                                              of death at 
definition transplantation, stratified                                                                                                                     group B,                                                                                                                                                    10months in 
into 2 groups:  group A                                                                                                                                respectively                                                                                                                                   group A and 
( persistent elevated sPAP,                                                                                                                                                                                                                                                                                             group B, 
n=31), group B (decrease                                                                                                                                                                                                                                                      respectively 
in sPAP,  n=29) 
Lam al,             RVSP >35 mm Hg     244 patients with HFpEF        33.6              74/47%  vs 79*/   All-cause  mortality      65 vs 83% in  28 vs                     8 vs 83% in    NR                     NR                 12.2 vs 25.7     18.4 vs 36.2 in   55.1 vs 63.8    HR 1.20 per 
201029                                                                      compared with 719                                       41% in group 1                                          HTN and          48 mm Hg in       HTN and                                                             in group 1         group 1 and         in group 1        each increase of 
subjects with HTN. 203                               and  group 2,                                              HFpEF,             HTN and               HFpEF,                                                               and  group 2,     group 2,               and  group 2,   10 mm Hg in 
patients with HFpEF and                             respectively                                            respectively    HFpEF,                 respectively                                                   respectively     respectively        respectively    RVSP ( p<0.001) 
PH later stratified into:                                                                                                                                respectively 
group 1 (RVSP 
<48 mm Hg) and  group 2 
(RVSP >48 mm Hg) 
Kush et al,       RHC with mixed PH   171 patients with severe       6                   59/75%  vs 54*/   Rehospitalisations      NA                    mPAP:  42 vs       47                     HR for MPH     21 vs 22        NR                     NR                       NR                    HR for MPH 0.89 
200930                  (MPH) defined  as     HFrEF (NYHA class IV,                              71% in MPH        and  all-cause                                    32 in MPH and                              0.8 (0.59 to                                                                                                                 (0.66 to 1.20) 
mPAP ≥25 mm Hg,    LVEF ≤30%,systolic BP                              and  non-MPH,     mortality                                                 non-MPH,                                      1.08) 
PCWP  >15 mm Hg,   ≤125  mm Hg) further                                    respectively                                                                    respectively 
and  PVR ≥3 WU        stratified into 2 groups:                                                                                                                                TPG:17  vs 7, 
MPH group (mPAP                                                                                                                                      respectively 
>25 mm Hg and PVR >3 
WU, n=80) and  non-MPH 
(mPAP <25 mm Hg or PVR 
<3WU, n=91) 
Ghio et al,        RHC with mPAP         377 patients with HF               17.2              51                          Heart                             NA                    27.9                       62.3                  NR                     NR                 NR                     NR                       7.3 vs 12.3       HR 1.1 (1.0 to 
200131                  ≥20 mm Hg,                stratified into: group 1,                                 85.7%                   transplantation and                                                                                                                                                                                                   vs 23.8 vs 40   1.21) per each 
RV systolic                 normal mPAP/preserved                                                      all-cause mortality                                                                                                                                                                                                    in groups  1,     5-mm Hg 
dysfunction  defined    RVEF (n=73); group 2                                                                                                                                                                                                                                                                                                   2, 3 and 4,*     increment 
as RVEF <35%           normal mPAP/low RVEF                                                                                                                                                                                                                                                                                               respectively 
(n=68); group 3, high PAP/ 
preserved RVEF (n=21); 


































































Table  2    Continued 
Diagnostic criteria                                                                                                                                                    Median/mean                          HF                      Mortality (all-cause) rate at 6, 12, 24 and 36 months or     Adjusted ORs/ 
(RVSP by                                                                                                                                                                                            (mm Hg)                                        readmission   at mean duration of follow-up                                              HRs and CI (or 
echocardiography                                              Mean/                                                                                Proportion    baseline            Prevalence   rate or                                                                                               36 or at            p value) for 
or mPAP by                Study population (sample  median                                 Definition of               (%) of               RVSP (echo)     of PH at          adjusted                                                                             mean/           all-cause 
Author, year  echocardiography    size, heart disease,             follow-up  Age—years/     outcomes                 measurable   or mPAP           baseline        ORs/HRs                                                                              median          mortality, 
published      or RHC)                       NYHA class, type of HF)     (months)    male sex—%    predicted                  RVSP               (RHC)                   (%)                   and CI               6                     12                       24                         follow-up     outcome 
Wang et al,      RVSP >30 mm Hg     93 patients with HF                 32 (6 to       59.6                       All-cause  mortality,     NR                    NR                        49.5                  NR                     28 vs 6 vs     NR                     NR                       NR                    Non-significant 
201032                                                                       undergoing cardiac                  60)               81.7%                   HF mortality                                                                                                                              17% in                                                                                             increased in 
resynchronisation stratified                                                                                                                                                                                                groups  1,2                                                                                       all-cause 
into group 1 (RVSP                                                                                                                                                                                                                         and  3,                                                                                               mortality 
>50 mmH, n=29); group 2                                                                                                                                                                                                             respectively                                                                              ( p=0.33), 
(30 <RVSP  ≤50 mm Hg,                                                                                                                                                                                                                                                                                                                         increase in HF 
n=17) and  group 3 (RVSP                                                                                                                                                                                                                                                                                                                       mortality but OR/ 
≤30 mm Hg, n=47)                                                                                                                                                                                                                                                                                                                                   HR not reported 
Ghio et al,        RVSP >40 mm Hg     658 patients with chronic        38                 63                          All-cause  mortality,     83                     38                          35.6                  NR                     17.5%  in        21.4%  in PH     42.3%  in PH       59.4%  in PH   HR 1.90 (2.18 to 
201333                  and  RV dysfunction    HF stratified into group 1                             86%                       urgent  cardiac                                                                                                                           PH vs             vs 8.7% in        vs 20.3%  in        vs 45.2%  in     3.06) for group 3 
defined  as TAPSE      (no PH no RVD, n=256),                                                            transplantation or                                                                                                                     4.5% in          non-PH              non-PH                 non-PH             and  4.27 (3.45 to 
<14 mm                        group 2 (RVD, no PH,                                                                ventricular  fibrillation                                                                                                               non-PH                                                                                             7.43) for group 4 
n=54), group 3 (PH, no 
RVD, n=167),  and group 4 
(RVD and  PH, n=67) 
Studies in patients with heart  valve disease 
Fawzy et al,     Severe PH defined     559 patients with MS              63.6              31/28.1% vs        Reversibility of PH      NR                    38.5 vs 59 vs       62% vs 33%   NR                     0                     0                         0                           0                       No mortality was 
200435                as RVSP                      undergoing MBV stratified                         30/25.1% vs        following MBV                                      97.8 in groups      vs 5% for                                                                                                                                             encountered, PH 
>50 mm Hg                 into three  groups:  group A                          27/16.1% in                                                                         A, B and  C,          groups  A, B,                                                                                                                                        normalised over 
(RVSP <50 mm Hg;                                     groups  A, B                                                                          respectively        and  C,                                                                                                                                                   a 6 to 12 months 
n=345); group B (RVSP                               and  C,                                                                                                                 respectively 
50–79  mm Hg; n=183)  and                          respectively 
group C (RVSP 
≥80 mm Hg; n=31) 
Naidoo et al,    RHC with PASP          139 patients with AR (69        6                   32.9 vs 36.2         Immediate and             NA                    18 vs 43.7 in       63.3                  NR                     3 in group      NR                     NR                       NR                    No increased in 
199134                  ≥30 mm Hg                 undergoing AVS) stratified                         and  69.7 vs          6 months                                                 group 1 and  2,                                                         1 vs 2.8%                                                                                        mortality, HR not 
into group 1 (normal or                                77.8 in group 1   postoperative                                     respectively                                                         in group 2                                                                                        reported 
mild PH) and  group 2                                  and  2,                   mortality 
(moderate PH or marked                              respectively 
PH) 
Manners         RHC with PASP          392 patients who had              48                 NR                        Hospital mortality        NA                    Mean PASP         NR                   NR                     NR                 NR                     NR                       5.4% at            NR 
et al, 197741     >70 mm Hg                 undergone prosthetic valve                                                                                                                        was 93 mm Hg                                                                                                                                         4 years in 
surgery  stratified into 2                                                                                                                                                                                                                                                                                                  both PH and 
PASP  <70 mm Hg, n=336                                                                                                                                                                                                                                                                                             non-PH 
or PASP  >70 mm Hg, 
n=56) 
Roseli et al,     RVSP >35 mm Hg     2385 patients undergoing     51.6              74                          All-cause  hospital        NR                    41                          74                     NR                     15.8 vs           NR                     NR                       NR                    Higher RVSP 
200236                                                                     AVR stratified into 3                                     55%                       and  late mortality                                                                                                                     19.7 vs                                                                                             was predictor of 
groups:  RVSP <35 mm Hg                                                                                                                                                                                                            25.9                                                                                                  5 and  10 years 
n=611; RVSP  35–                                                                                                                                                                                                                                                                                                                                     mortality, HR not 
50 mm Hg, n=1199;  RVSP                                                                                                                                                                                                                                                                                                                      reported 
>50 mm Hg, n=575 
Melby et al,      RVSP >35 mm Hg     1080 patients with AS            48                 72.3 vs 70.2         All-cause  operative    NR                    51 in PH group    46.8                  NR                     NR                 17.1 vs 17.6     25.7 vs 24 vs      25.7 vs 38.4    OR 1.51 (1.16 to 
201137                                                                       undergoing AVR, stratified                         59.1 vs 57.8%     and  long-term                                                                                                                                                   vs 17.1 vs         23.2 vs 32.3        vs 52.7 vs        1.96), persistent 
into NPH, (RVSP                                          in PH and  non     mortality                                                                                                                                                            23.5 for                                           46.1                  PH after AVR 
<35 mm Hg, n=574)  and                              PH,                                                                                                                                                                                                   non-PH,  mild,                                                          was associated 
PH group(mild PH,                                       respectively                                                                                                                                                                     moderate and                                                          with decreased 
moderate and  severe PH)                                                                                                                                                                                                                                     severe PH,                                                               survival 
respectively 
Le Tourneau   RVSP ≥50 mm Hg     256 patients with MR             49.2              63                          All-cause  mortality      NR                    45±14                    32% had          NR                     NR                 NR                     31.6 vs 31.7 in   NR                    HR 1.43 (1.09 to 
et al, 201038                                                          undergoing MVO, stratified                        66%                       Cardiovascular                                                              RVSP                                                                                             groups  1 and                                1.88) per 
into group 1 (RVSP                                                                     deaths                                                                       ≥50 mm Hg                                                                                  2, respectively                           10 mm Hg 
<50 mm Hg, n=174)  and                                                                                                                                                                                                                                                                                                                          increment of 
group 2 (RVSP                                                                                                                                                                                                                                                                                                                                          RVSP 






























































Table  2    Continued 
Diagnostic criteria   Median/mean   HF    Mortality (all-cause) rate at 6, 12, 24 and 36 months or   Adjusted ORs/ 
(RVSP by      (mm Hg)     readmission   at mean duration of follow-up   HRs and CI (or 
echocardiography   Mean/   Proportion   baseline   Prevalence   rate or      36 or at    p value) for 
or mPAP by    Study population (sample  median   Definition of   (%) of    RVSP (echo)   of PH at   adjusted    mean/   all-cause 
Author, year  echocardiography    size, heart disease,   follow-up  Age—years/   outcomes   measurable   or mPAP   baseline   ORs/HRs   median   mortality, 
published      or RHC)   NYHA class, type of HF)     (months)    male sex—%    predicted   RVSP               (RHC)      (%)                   and CI               6                     12                       24   follow-up   outcome 
Parker  et al,    RVSP >35 mm Hg   1156 patients with MR or       87.6   72    All-cause  mortality   52   29    NR   NR   NR   NR   NR   NR    HR for moderate 
20107  AR stratified into normal      51%   or greater PH 
(RVSP <30 mm Hg),      1.95 (1.58 to 
borderline  (31–34 mm Hg),      2.41) in AR and 
mild (35–40 mm Hg) or      1.48 (1.26 to 
moderate or greater      1.75) in MR 
(>40 mm Hg) 
Barbieri et al,  RVSP >50 mm Hg   437 patients with MR, 35%    57.6    67    All-cause  mortality,   45   23   1.70 (1.10 to     NR    NR   23% at the   HR 2.03 (1.30 to 
201040  NYHA class III or IV,      66%    cardiovascular   2.62) and   mean   3.18) and  1.16 
normal LVEF, stratified into      death, heart  failure   1.19 (1.06 to    follow-up    (1.03 to 1.31) for 
NPH (RVSP ≤50 mm Hg)      1.35) for each   each 10 mm Hg 
and  PH (RVSP      10 mm  Hg    increase of 
>50 mm Hg)  increase of   RVSP 
RVSP 
Kainuma   Echocardiography,    46 patients undergoing      36    64    Cardiac    NR   47   NR   30% in the   NR   15.8 vs 11.8   31.6 vs 29.4   47.4 vs 82.4    HR for all 
et al, 201139     PH definition not   MVR, NYHA III or IV, LVEF    35%    death, myocardial   severe PH   vs 20% for    vs 30%   vs 50%   adverse cardiac 
specified <40%, stratified into group     infarction,   but not   groups  1, 2,   events 6.9 (1.1 to 
1 (RVSP <40 mm Hg,      endocarditis,   significant,   and  3,  44) in group 3 
n=19), group 2 (moderate       thromboembolism,   OR and  CI   respectively 
PH (40 <RVSP  <60, n=17)     reoperation   NR 
and  group 3 (RVSP >60,      for recurrent MR, 
n=10)       readmission for 
heart  failure and 
fatal arrhythmia 
Khandhar   Severe PH defined   506 patients with severe    NR   63    All-cause  mortality   100   NR   16% of   NR   NR   NR   21.6 of    NR                    PH was 
et al, 200943    as RVSP   AR stratified into group 1,    47%   severe PH   patients with    associated with 
>60 mm Hg  severe PH with RVSP       severe PH    increased 
>60 mm Hg, n=83 and  mortality in all 
group 2 (RVSP <60,   groups, OR and 
n=423),  NYHA NR  CI NR 
Malouf et al,    Severe PH defined  3171 patients with AS of   15.3   78    All-cause  mortality   63% of the   4.16 m/s   NA   NR   NR   NR   NR   80% vs 32%    OR for mortality 
200242  as peak  TRV   whom 47 with severe PH,  47%   3171 total   in groups  1    risk in severe PH 
≥4 m/s     stratified into group 1 (no   population  of   and  2,   and  AVS 1.76 
AVR, n=10) and  group 2  patients with   respectively,   (0.81 to 3.35) 
(AVR, n=37), 79% in NYHA  aortic    at median 
III and  IV  stenosis   FU 
Zuern et al,    RVSP >30 mm Hg  200 patients with AS   31.2   72.3    All-cause  mortality   NR   36.3   61   NR   NR   10.2 vs 14.1   30.7 vs 40.4   2.6, 15.2       HR for 
201244  undergoing AVR stratified  52.5%    vs 30.4   vs 60.1    and  26.1%    mild-to-moderate 
into NPH (RVSP <30) vs   PH 4.9 (1.1 to 
mild-to-moderate PH (30   21.8) and  severe 
<RVSP  <60) and  severe  PH 3.3 (0.6 to 
PH (>60 mm Hg)  19.7) 
Ben-Dor    RVSP >40 mm Hg  509 patients with AS   6.73   82.3 vs 82.4 vs   All-cause  mortality   NR   33.7 vs 49.3 vs   68.3   NR   NR   NR   NR   21.7 vs 39.3    PH was 
et al, 201145 divided into group 1 (RVSP   80.5 in groups      70.7 in groups    vs 49.1 in   significantly 
<40 mm Hg, n=161); group  1, 2 and  3,      1, 2, and 3,    groups  1, 2     associated with 
2 (RVSP 40–59,  n=175)  respectively,      respectively  and  3,      increase in 
and  group 3 (RVSP >75%   respectively  mortality, OR/HR 
>60 mm Hg, n=173)   at median      not reported 
FU* 
Yang et al,   RVSP >40 mm Hg   845 patients who      39    65.2 vs 67.8    Postoperative   NR   NR   NR   NR   4.6 vs 13.9 in   NR   16.7 vs       OR for mild/ 
201246   underwent valve surgery      78.8 vs 72.6%   complications and   NPH vs PH   30.6* in      moderate PH 
and/or  CABG (444 without    in NPH and  PH   mortality   group,    NPH vs PH    1.475  (1.119  to 
PH or NPH vs 401 PH), all    group,      respectively   group,      1.943) 






























































Table  2    Continued 
Diagnostic criteria   Median/mean   HF    Mortality (all-cause) rate at 6, 12, 24 and 36 months or   Adjusted ORs/ 
(RVSP by      (mm Hg)     readmission   at mean duration of follow-up   HRs and CI (or 
echocardiography   Mean/   Proportion   baseline   Prevalence   rate or      36 or at     p value) for 
or mPAP by    Study population (sample  median   Definition of   (%) of    RVSP (echo)   of PH at   adjusted   mean/   all-cause 
Author, year  echocardiography    size, heart disease,   follow-up  Age—years/   outcomes   measurable   or mPAP   baseline   ORs/HRs   median   mortality, 
published      or RHC)   NYHA class, type of HF)     (months)    male sex—%    predicted   RVSP               (RHC)      (%)                   and CI               6                     12                       24   follow-up   outcome 
Nozohoor    RVSP >50 mm Hg   270 patients with MR   61.2   61.5 vs 66.5   Perioperative   NR   NR   27   NR   NR   7.6 vs 8.2 in   22.4 vs 17.6 in   31.1 in both   HR 4.3 (1.1 to 
et al, 201247 undergoing MVS, stratified   70 vs 54% in   complications and   no PH and   no PH and  PH,   groups      17.4) during the 
into NPH group (RVSP      no PH and  PH    all-cause late   PH,   respectively      initial 3 years 
<50 mm Hg) and  PH group   group,    mortality   respectively  after MVS 
(RVSP ≥50 mm Hg)      respectively 
Ward and   RHC with extreme   Mitral valve disease   69.6   46.2 vs 42.4    All-cause  mortality   NA    105 vs 96.6   8.2   NA   NR   NR   NR   NR    Extreme  PH was 
Hancock    PH defined  as  (n=586),  48 extreme PH      43 vs 29% in   associated with 
197548  SPAP  >80 mm Hg    stratified into group 1 (no       group 1 and 2   higher mortality, 
and  PVR >10 WU:    operation), group 2 (all      respectively  and  surgery 
8.2%   surgical)  and  group 3      improved  survival 
(survive after surgery) 
Ghoreishi          sPAP  >40 mm Hg   873 patients with MR who     35   59   Hospital mortality,   NR   46 (echo),  and   53   NR   NR   16.2 in non   33.9 in non PH   51.8 in non   HR 1.018  (1.007 
et al, 201249     using RHC in 591    underwent MVS, stratified      59%    Late all-cause   sPAP  was 43   PH vs 32% in  vs 48.1%  in   PH vs   to 1.028)  per 
patients and RVSP    into NPH and  PH group      mortality   by RHC   PH group*         PH group*   60.9%  in PH   each 1 mm Hg 
>40 mm Hg using  (mild, moderate, severe)      group*   increment in 
DE  NHYA not reported         RVSP 
Cam A et al,    RHC with severe   317 patients with AS, 35   11.3    71/53.5    All-cause  mortality   NA    22.5   47.0   NR   NR   NR   NR   74.5 vs 75.5    HR 1.008  (0.9 to 
201150  PH defined  as  with severe PH underwent      (mild-moderate    (mild-moderate   1.11) and  early 
mPAP >35 mm Hg   surgery  and  were      PH) vs 75/51.4   PH) vs 45.3   postoperative 
compared to 114 mild       (severe PH)   (severe PH)   reduction  in 
moderate PH and  to 46      mPAP 0.93 (1.2 
severe PH treated      to 12.5) 
conservatively, NHYA not 
reported 
Pai et al,   Severe PH defined   116 patients (of 740 severe  18    75    All-cause  mortality   NR   69   15.7%    NR   NR   NR   30.5 (PH) vs   NR    AVR benefit HR 
200751  as RVSP   AS) with severe PH among      39%   (severe PH)   15.5 (NPH)   0.28 (0.16 to 
>60 mm Hg  which 36 underwent AVR      0.51) 
and  were compare to 83       independent of 
remaining      PH 
*p<0.05. 
AS(R), aortic stenosis (regurgitation);  AVS(R), aortic valve surgery  (replacement); CABG, coronary  artery bypass graft; DE, Doppler echocardiography; eSPAP, estimated systolic pulmonary  artery pressure; HFpEF,  heart  failure (HF) and  preserved ejection 
fraction; LHD, left heart  disease; LVEF, left ventricular  (LV) ejection  fraction; MBV, Mitral Balloon Valvotomy; mPAP,  mean pulmonary  arterial pressure; mPCWP,  mean pulmonary  capillary wedge pressure; MV(R/O), mitral valve (repair/operation); NA, not 
applicable; NPH, non-pulmonary hypertension; NR, not reported; PH, pulmonary  hypertension; PVR, pulmonary  vascular resistance; RV(SP/TG),  right ventricular  systolic pressure/tricuspid gradient);  TPG, transpulmonary gradient;  TRV, tricuspid regurgitation





 Figure 1    Flow diagram  of 
literature  search process. LHD, 
left heart  disease; PH, pulmonary 
hypertension. 
screened  by full  text  of  which 15  were  excluded  for 
studies  were  identified 
Europe ( four  from  UK, three  from  Italy and  one  each 
from  Spain,  Germany,  Denmark, France  and  Sweden), 
6 (13.3%)   from  Asia (two  from  Japan,  one  each  from 
India,  China,  Korea  and  Australia)  and  1  from  South 
Africa.  One  study  was multicentric across  Europe and 
the  USA40  and  another one  was multicentric across the 
USA   and    Canada.30     Only    three     population-based 
various  reasons  ( figure  1).  Five 
via citation  search.  Therefore, 45 articles  were included 
in  the  final  review among  which  86.7% were published 
between   2003   and   2013   (see   online    supplementary 
figure  S1). 
cohorts   were  reported  including two  prospective13 29Study characteristics and methodological quality 
The  characteristics and  methodological quality of the  45 
included studies  are  described in  table  1.  The  overall 
quality  score  ranged  from  29.5  to  72.5  points   with  a 
median of 63.5. Based  on  the  cut-offs of ≥60  and  ≥45 
points,  respectively,  we classified  34 articles  as being  of 
high  quality,  7 as moderate-to-high quality  and  four  as 
low-quality studies (table 1). Studies of high  quality were 
and   one   retrospective  study.14    For  the   remaining   42 
hospital-based   cohort  studies,   20  had   a  retrospective 
design.  The  number of participants ranged from  46 to 
2385   in   hospital-based    and    from   244   to   1049   in 
population-based   studies.    The    proportion   of   men 
ranged from  21% to 91%, and  mean/median age from 
63 to  82 years.  Twenty-six studies  were  in  patients   with 
heart  failure  (HF)  and  cardiomyopathies (two  in  heart 
failure  with  preserved  ejection   fraction   (HFpEF)) and 
19 in patients  with valve disease. 
Twelve studies  defined PH  using  RHC and  32 studies 
using  DE. One  study defined PH  using  both  RHC  and 
DE. Studies applied  variable definitions of PH using both 
recent  and  scored  well on  patient 
measurement,   statistical    analysis 
Studies  classified  as  moderate/low 
selection,   outcome 
and    presentation. 
quality  scored  rela- 
tively well on patient selection,  but poorly on study attri- 
tion,   statistical  analysis  and   presentation.  Twenty-four 
(53.3%)   studies  were  from  the  USA, 12  (26.6%)   from 
11 Dzudie  A, et al. BMJ Open 2014;4:e004843. doi:10.1136/bmjopen-2014-004843 
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RHC (based  on  mPAP >25 or  30 mm Hg, or on  systolic 
pulmonary  artery  pressure  (sPAP)  >50 mm Hg,  or  sPAP 
>40 mm Hg, or on  pulmonary vascular resistance  (PVR) 
>2.5 wood  units  (WU))   and  DE (based  on  RVSP with 
cut-offs  varying  from  35  to  50 mm Hg,  or  based  on  a 
mPAP >25 mm Hg8  or on a right ventricular tricuspid gra- 
dient  (RVTG)  >25 mm Hg).25  Prevalence  of PH  in  HF 
ranged from  22% to 83.3% overall,  22–83.3% in studies 
of PH based  on DE and  23–76% in studies  of PH based 
on RHC (see online  supplementary figure S2). 
DISCUSSION 
An increasing number of studies  have  assessed  the  risk 
of    readmission    and     mortality     in     patients     with 
LHD-related   PH  over  the   last  decade,  and   mostly  in 
North  America  and  Europe.  Available studies  are  mostly 
consistent  on the  adverse effect of PH (whether assessed 
using  DE  or  RHC)  on  mortality  risk  in  patients   with 
heart  failure  as well as those  with mitral  valve disease, 
but  less unanimous in  those  with  aortic  valve disease. 
The  consistent  adverse  effect  of PH  in  this  population 
highlights  the  importance of  early  diagnosis  of  PH  to 
reduce  mortality.   While   available   studies   have  been 
overall of acceptable quality, substantial  heterogeneity in 
the  study population, PH  definition and  measurement, 
outcome definitions as well as other  prognostic factors 
limit  direct  comparisons across  studies.  Information on 
readmission for heart  failure  was limited  and  the  assess- 
ment  of other  prognostic factors in an integrated  multi- 
variable model  was very heterogeneous. 
Outcome of PH 
Admissions for heart 
failure 
The  duration of follow-up ranged from 6 to 87.6 months 
overall, 6–69.6 months  in  studies  of PH  based  on  RHC 
definition and  6–87.6 months  in studies  of PH based  on 
DE   definition.   Readmission    rates,    when    reported, 
ranged  from   9.2%  to   75%   overall  and   9.2–75%   in 
studies  of PH  based  on  DE definition. Only  one  study 
with PH  definition based  on  RHC  reported a readmis- 
sion  rate  of 27% (table 2).  Admissions  or  readmissions 
for  HF  were  reported in  nine  studies  all based  on  DE 
definition among  which seven reported HRs or ORs for 
admission/readmission in  relation with PH.  Effect  esti- 
mates   for   six  of  the   seven   studies   were   statistically 
significant. 
Mortality in patients with PH and heart failure with 
reduced ejection fraction 
While PH was an independent  prognostic factor  for mor- 
tality in fatal-outcome studies,  the  prevalence of PH and 
effects on mortality varied according to LVEF. Differences 
in the prevalence of PH could be explained at least in part 
by population heterogeneity (age,  level of HF, HF centres 
or community study) and  differences in the  criteria  used 
to define  PH across studies with a variety of cut-off values. 
Regardless of the prevalence of PH in HFrEF, there  seems 
to be no uniformity in the association between  the magni- 
tude of reduction in LVEF, and the presence or absence  of 
PH and  the  effects of PH on  mortality risk. It is possible 
that  the  small  size of studies  and  the  short  duration  of 
follow-up precluded the accumulation of a substantial 
number of events to allow the detection of a relationship, 
if any. Furthermore, although the  precise  haemodynamic 
threshold beyond which RVSP is invariably associated with 
mortality is subject to debate;  the  risk of death  associated 
with PH seems to increase  with higher  RVSP.6 12   13   16   A 
possible  pathophysiological explanation  is that  early and 
higher   vascular  remodelling occurs  in  patients  with HF 
and severe PH, causing a reactive or ‘postcapillary PH with 
a precapillary  component’, which  in  turn  has  a greater 
impact  on  the  RV function. Equally, RV systolic function 
has been  shown to be highly influenced by pressure  over- 
load and by vascular resistance  in the pulmonary region50; 
and RV function assessed using RHC or echocardiography 
has been  shown to be associated with mortality.30 31  33  It is, 
however,  remarkable that  one  study30   reported no  inter- 
action  between  PH and  RV function, with both  variables 
being  independently associated  with mortality. This high- 
lights  the  fact  that   RV function  in  HF  does  not  only 
depend on pulmonary pressure  but may also reflect  intrin- 
sic  myocardial  disease.  As suggested   by  Vachiery  et  al6 
there  might  be a spectrum of clinical  phenotypes of RV 
failing  in  PH-LHD  that  might  evolve  from  one  to  the 
other,  from  isolated  postcapillary  PH with little effect on 
Mortality 
Mortality was reported in  all studies  (table 2); however, 
not all studies provided  multivariable-adjusted effect esti- 
mates  of mortality  risk associated  with PH. PH was asso- 
ciated   with  increased  all-cause  mortality   in  24  of  26 
studies  of HF, among  which 6 studies  were of PH based 
on RHC definition, while two studies  failed to report an 
association    between    PH   and    all-cause   mortality    at 
6 months.  Of these  two studies,  one  used  PH definition 
based  on  RHC  and  was a multicentric trial  of HF  that 
reported effect estimates for mortality risk from PH 
(HR=0.89    (95%  CI  0.66  to  1.20));30   while  the  other 
one32    did   not.    When    reported,   mortality    rates   at 
12 months  ranged from  0% to 32% overall,  0% to 32% 
in  studies  of  PH  based  on  DE  and   2.9%  to  18%  in 
studies  of PH based  on RHC (see  online  supplementary 
figure  S3). As summarised in table  3, over 35 potential 
predictors of mortality were tested across studies with 
variable  and  often  inconsistent effects  on  the  outcome 
of  interest.   Age  was  associated   with  mortality   in   14 
studies  (among which  11 studies  of PH  were  based  on 
DE),  male  gender in  3/11 studies  (all  based  on  DE), 
LVEF in 6/10 studies,  right  ventricular (RV) function  in 
3/3 studies and  renal  disease (rising  creatinine, decreas- 
ing glomerular filtration rate  (GFR)  or dialysis) in 6/17 
studies  (all  based  on  DE),  functional  class (New  York 
Heart   Association  (NYHA)  or  WHO)   in  7/12 studies 
( five based  on DE) while the  6 min walking distance  was 
tested  in  only one  study  but  was not  integrated in  the 
multivariable  analysis for outcome risk.32 




the  RV to more  advanced disease where  the  failing RV is 
the key determinant of outcome. 
some,  left  atrium  relaxation and  distensibility  can  lead 
to elevated  pulmonary venous pressure,  triggering vaso- 
constriction  and   arterial   remodelling.4     In  total,  the 
finding  of PH  as an  independent  prognostic factor  for 
mortality  in  patients  with HF tends  to  support the  sug- 
gestion that PH should be considered as a potential 
therapeutic target  at least in the  group  of patients  with 
HF  who exhibit  persisting  PH  after  optimisation of HF 
therapy.  In  this line,  targeting both  pulmonary vascula- 
ture  and the heart  would probably  be more  beneficial. 
5 
Mortality in patients with PH and heart failure with 
preserved ejection fraction 
Over  the   past  decades,   the   increasing  prevalence of 
HFpEF51  has been  paralleled by an  increasing presence 
of  PH  in  patients   with  HFpEF.5         When  compared to 
heart   failure  with  reduced  ejection   fraction   (HFrEF), 
patients  with HFpEF have their  subset of risk factors; but 
finally, PH  conveys similar  morbidity  and  mortality  risk 
in   the   two  subgroups  of  patients.13            The   current 
6
17 Mortality in patients with PH related to valvular heart 
disease 
PH  due  to valvular heart  disease  (VHD)  was not  always 
related  to mortality  risk,38   39  45  which is in contrast  with 
PH  in  patients  with heart  failure.  A simple  explanation 
incomplete understanding of HFpEF limits our ability to 
explain  why these  patients   develop  PH.  However,  it  is 
estimated   that   over  time   left  atrium   and   ventricular 
filling pressure  from  compromised left ventricle  and,  in 
13 Dzudie  A, et al. BMJ Open 2014;4:e004843. doi:10.1136/bmjopen-2014-004843 
Table  3   Other prognostic factors  associated with mortality in patients with pulmonary  hypertension associated with left 
heart  disease 
Number of studies in which 
Number of studies  the  factor was associated with 
reporting     poor outcome 
Studies based   Studies of PH    Studies of PH 
Factor  overall   on DE                   based on DE based on RHC 
Age      14  11 11 3 
Sex  (male vs female)      11  9 3  0 
Racial/ethnic group      2  2 0  0 
HF episodes    5  5  2  0 
Prior hypertension      5  5 1  0 
History of diabetes     8  8  3  0 
Smoking     3  3 0  0 
History of cardiovascular disease      1  1 1  0 
Functional  class (NYHA/WHO)      12  9 5  2 
Killip class for MI     2   2 2  0 
Heart rate     2  2 0  0 
Systolic BP     4  4 2   0 
Diastolic BP      1  1  1  0 
Mean BP      1  1  1  0 
SPO2 3  3 1   0 
Hypotension      1  1  1  0 
Atrial fibrillation      5  5 5   0 
Ischaemic aetiology  of HF      4  4 0  0 
Urea      2   2 1  0 
Kidney disease (by creatinine, GFR or haemodialysis)  17  14  6  0 
BNP      3  3 2   0 
Haemoglobin      2  2 0  0 
Presence of COPD      4  3 3   0 
Use of medications (ACEI and or beta  blockers  or      6  6  3  0 
spironolactone) 
LVEF      10  10  6  NA 
LV end-diastolic diameter/index      6  6 3  NA 
Atrial diameter      1  1 1 NA 
Deceleration time      1  1 0  NA 
RV function (by TAPSE  or other means)      3  3 3 NA 
Functional  mitral regurgitation     5  5  4  NA 
RVSP ≥50  or >60 mm Hg      9  9 5  NA 
End diastolic pulmonary  regurgitation      1  1 1  NA 
ACEI, ACE inhibitors; BNP, brain natriuretic peptide;  BP, blood pressure; COPD, chronic obstructive pulmonary  disease; GFR, glomerular 
filtration rate; HF, heart  failure; LVEF, left ventricular  ejection  fraction; MI, myocardial  infarction; NYHA, New York Heart Association; RHC, 







of  this  difference  could   be  that   the   prevalence and 
severity of  PH  correlates with  the  severity and  type  of 
VHD. Although  mitral  stenosis  (MS)  has  been  the  clas- 
sical  disease  associated  with  PH-LHD  and  reactive  PH 
was initially described in  these  patients4; it is, however, 
noticeable that  PH  due  to  MS has  received  little  atten- 
tion  over the  last decade, probably  because  of the  pro- 
gressive  decline   in  RHD  in  Western  countries. 
Interestingly,   the   two   studies   included  showed   that 
surgery  was safe and  improved  survival in  patients  with 
on  PH-LHD  in  a  population  with  high  prevalence  of 
ischaemic   heart   disease.  This  precludes the  generalis- 
ability of our findings  to developing countries where 
aetiologies  of LHDs are less of ischaemic  origin  and  are 
more  dominated by systemic hypertension, dilated  car- 
diomyopathies   and   RHD  in  a  younger   population.56 
Therefore, PH-LHD  may have a  different prognosis  in 
developing countries.  Second,  studies  included in  this 
review were  defined PH  based  either   on  DE  or  RHC. 
RHC   remains    the   gold   standard   to   diagnose    and 
confirm PH,  but  performing RHC  on  all patients  with 
dyspnoea  would  bear  excessive risks and  be  impractical 
in  resource-limited  settings.  DE  on  the  other   hand   is 
widely available, safe and  relatively cheap  for diagnosing 
PH,  although  the   reproducibility  of  the   approach  in 
some circumstances has been  questioned. However, a sys- 
tematic  review on  the  diagnostic  accuracy  of DE in  PH 
by Janda  et           has  shown  that  the  correlation of pul- 
monary artery systolic pressure  by DE compared to RHC 
was good  with a  pooled  correlation coefficient   of 0.70 
(95%  CI 0.67 to 0.73). However, studies to date  examin- 
ing the  prognostic impact  of PH in LHD have been  per- 
formed  in heterogeneous populations, using variable 
definitions of PH based  both  on RHC and  echocardiog- 
raphy    parameters,   thus    limiting    any   possibility   of 
pooling.    Finally,   readmissions   were    not    frequently 
reported and  multivariable  analysis when performed was 
characterised by a  great  heterogeneity  in  the  number 
and   range   of  candidate  predictors  included  in   the 
models,  thus  limiting  interpretation and  generalisability. 
Therefore,  findings   on  these   other   prognostic  factors 
must  be  interpreted with caution.  For  studies  that  per- 
formed  only univariate  analysis, we cannot rule  out  the 
possibility that  the  reported factors  may not  preserve a 
significant  association  with the  outcome once  adjusted 
for  the  effect  of  other   extraneous  factors.  In  spite  of 
these  limitations,  the  majority  of studies  included were 
recent and  all reported on the  relation of PH-LHD with 
all-cause mortality,  making  the  conclusions  on  this rela- 
tion appropriate for contemporary Western populations. 
MS35  48 PH due  to with PH  regressing  to normal levels 
over    6–12 months     after 
Valvotomy   (MBV).35      In 
successful    Mitral    Balloon 
mitral    regurgitation   (MR), 
on   outcomes  of  severe  PH nearly   all  cohort  studies 
reported increased mortality.38 39   40   46   49   The  relevance 
of this finding  is that  PH can serve both  as an indication 
for  proceeding  to  surgical  or  catheter-based  interven- 
tions, and  also as an operative  risk factor  for mitral  valve 
interventions.54  By contrast,  PH is not as common in the 
aortic  valve surgical  cohort. Mortality  rates  in  different 
studies  of patients  with VHD depends on  comorbidities, 
exclusion   criteria   and   definition  for  PH.  Studies  that 
also  evaluated   changes   in  PH  following  valve surgery 
showed   a   decline   in   pulmonary  pressures   following 
surgery.35  45  50  55  It is worth  noting  that  the  pathophysi- 
ology of the pulmonary vasculature  in PH due to VHD is 
similar to that in patients  with HF.1 
al
57 
Hospitalisations and other prognostic factors 
The  paucity of information on the  effect of PH-LHD on 
hospitalisations or  rehospitalisations as has  been  shown 
in  this study highlights  the  need  for more  evidence  on 
this outcome. Such information is important to fully 
characterise and  quantify  the  contribution of PH-LHD 
to the global burden of disease, and assess future 
improvement from  treating the  underlying LHD and/or 
controlling PH in patients  with LHD. 
Of the  35 other  potential prognostic factors of mortal- 
ity in patients  with PH that  were tested  in multivariable 
models   across   studies,   investigations   on   echocardio- 
graphic  parameters suggested  that  PH  >60 mm Hg  was 
associated   with  worse  mortality   in  seven  of  the   nine 
studies.  Similarly, a greater degree of MR, deceleration 
time when reported26 and  RV function  were almost con- 
stantly associated  with adverse  outcome while LVEF was 
associated  with adverse  outcome in  6 of the  10 studies. 
In the  evolution  of LHD, RV dysfunction  usually occurs 
as a turning point.  It  shall  be  noted   that  PH  incorpo- 
rates information on diastolic function, MR and pulmon- 
ary vascular  disease,  and  this  might  explain  the  pivotal 
role of PH in gauging the prognosis  of patients  with HF. 
Strengths and limitations of the review 
First, by restricting our  search  strategy to full-report  arti- 
cles published in  English  and  French,   and  in  journals 
available  in  the   used  electronic  databases,   we  cannot 
rule  out  the  possibility of language  or  publication  bias. 
Second,  we used  the  QUIPS  instrument,  designed   for 
prognosis   studies,  to  address  common sources  of  bias. 
The QUIPS, however, lacks discriminative power; we 
addressed this by using  the  scoring  algorithm suggested 
by de  Jonge  et  al.6   This  scoring  algorithm can  still be 
subject to criticisms, especially because  the  cut-off points 
used  to  determine the  quality  of the  studies  are  quite 
arbitrary.  Third,  because  of important heterogeneity in 
the  included studies,  we were  not  able  to  pool  data  to 
perform a  meta-analysis  or  to  stratify data  by clinically 
important subgroups (such  as mild,  moderate or severe 
PH).  However,  to the  best of our  knowledge,  this is the 
Strengths and limitations of the studies included in the 
review 
The  first limitation  of the  studies included in our  review 
is the  possibility of study population bias. The  majority 
of   studies    originated   from    Western    countries  and 
included predominantly Caucasians and  reported mostly 
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CONCLUSION 
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1.6. Current treatment options for patients with pulmonary 
hypertension due to left heart disease 
Overall, treatment options for patients with PH differ according to PH classification, 
etiologies and severity. Treatment options can be divided into two steps:  
1) Primary therapy; 
2) Advanced therapy. 
Primary therapy refers to any treatment that is directed at the underlying cause of the PH, 
and is therefore warranted in nearly all patients with PH.  Advanced therapy is directed at the 
PH itself. Five medication classes targeting PH have been evaluated in different groups of PH 
and are listed in advanced therapy. These include: prostanoids, endothelin receptor 
antagonists, phosphodiesterase 5 inhibitors, soluble guanylate cyclase stimulants and some 
calcium channel blockers. In the paragraphs below, we briefly discuss the use of these 
medications in PH-LHD. 
1.6.1. Primary therapy for PH-LHD 
The goal of primary therapy of PH-LHD is to improve global management of the underlying 
condition (HF due to reduced ejection fraction, HF due to preserved ejection fraction or 
valvular heart disease) before considering advanced therapy of specific measures to treat PH.  
In HFrEF, there is strong evidence for aggressive therapy including medications for HF, cardiac 
resynchronization therapy of use of left ventricular assist device (31, 54). Likewise, in patients 
with valvular heart disease, a repair is absolutely recommended (88). In contrast, there is less 
strong evidence for treatment of HFpEF in general and for strategies to improve PH and 
outcomes in patients with HFpEF (54). 
1.6.2. Advanced therapy for PH-LHD 
Advanced therapy for PH-LHD is supported by its adverse outcomes and the rationale that in 
some patients, PH-LHD progresses from the passive and reversible post capillary PH to a 
67 
 
mixed and irreversible component with pulmonary arterial remodeling (86). This has justified 
the implementation of studies using prostanoids, endothelin receptor antagonists, and 
phosphodiesterase 5 inhibitors.  In Table 11 below, we summarize these studies.  Overall, two 
major observations are worth noting: 
1) Methodological limitations: These include the small sample and single-center nature 
of the trials, a variation in the inclusion criteria including the absence of requirement 
of a preliminary optimization of volume status and a variation in the stratification of 
patients with some based on PH and others on HF without consideration for 
pulmonary pressures. 
2) Controversial results on the primary endpoint with two trials that suggested an 
improvement (101, 102), four others suggested an absence of effect (103-106) and 
two trials showed a negative effect (107, 108). 
In summary, all trials using medications targeting PH or approved for PAH failed to 
demonstrate a benefit in the context of HF. Current available evidence does not therefore 
provide enough support for use of these drugs in clinical management of patients with PH-
LHD. This results in an absence of a validated evidence based approach for advance treatment 
of PH-LHD. New trials are warranted to advance the field of PH-LHD. 
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Table 11: Completed Randomized Controls Trials using pulmonary hypertension-targeted medications in patients with pulmonary 
hypertension due to heart failure (modified from Vachiery et al (109) 
Drug/Author 
Primary 
Study Acronym Patients Design Primary Endpoint Results 
Prostanoids : Epoprosterenol 
Califf 1996 (108) FIRST n=471, severe HF 1:1 randomization 
Even-driven, 4ng/kg/min 
Survival Early termination  (trend to 
decreased 
Endothelin receptor antagonist : Bosentan 
Bosentan 
Packer 2005 (107) 
REACH-1 n=174, severe HF 2:1 randomization 
26 week duration, 500 mg bid 
Change in clinical 
state 
Early termination (drug induced 
fluid retention in treated group) 
Kalra, 2002 (103) ENABLE n=1613, HF 1:1 randomization 
18 month duration, 125 mg bid 
Mortality + hospital 
days 
No effect 
Endothelin receptor antagonist : Darusentan 
Lüscher, 2002(102) HEAT n=179 
NYHA III 
3:1 randomization 





Increased cardiac output 
No change in PAWP 
Anand, 2004 (104) EARTH n=642, NYHA II-IV 3:1 randomization 
6-month duration, dose 10, 25,
50, 100, 300 mg
LV changes by MRY 
clinical events 
No effect 
Phosphodiesterase 5 inhibitor: Sildenafil 
Guazzi, 2011 (101) None n=44, HFpEF 1:1 randomization 
50 mg bid, 12-month duration 
Change in mPAP Reduction in mPAP 
Redfield, 2013 (105) RELAX n=216, HFpEF 1:1 randomization 
20 tid 12 weeks, then 60 mg 
tid, 12-weeks 
change in exercise 
capacity or clinical 
status 
No improvement 
Soluble guanylate cyclase stimulator: Riociguat 
Bonderman, 2013(106) None n=201 4:1 randomization 
Riociguat 0.5, 1, or 2 mg tid for 
16 weeks 
Change in mPAP No improvement 
ENABLE, Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure trial; Flolan, International Randomized Survival Trial; HF, heart failure; HFpEF; HEAT, 
Heart failure ET(A) Receptor blockade Trial; HF with preserved ejection fraction (EF); HFrEF, HF with reduced EF; LV left ventricular; MRI magnetic resonance imaging; NYHA 
New York Heart Association functional class; PAWP pulmonary artery wedge pressure; REACH 1, Research on Endothelin Antagonism in Chronic Heart Failure trial;  RELAX, 
RasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure trial. 
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1.7. Knowledge gaps and implications for Africa    
The review presented in this chapter has provided a contemporary synopsis of PH with 
emphasis on its major etiology; PH-LHD. Since the first descriptions of PH at the end of the 
19th century (4), our understanding of the etiological risk factors of the disease, its diagnostic 
strategy and classification has improved considerably, leading to new effective therapies for 
at least for some forms of PH. However, PH remains a life-threatening condition if untreated, 
the time interval between the onset of symptoms and eventual diagnosis is still unacceptably 
long, up to 27 months (69) and several unanswered questions remain.  
Available evidence derived essentially from specific registries of PAH in high income countries 
and mainly from the European or USA perspective. The systematic review presented in 
section 1.5 showed that PH-LHD is the most common group of diagnosed PH, even though it 
has to date received very little attention when compared to the abundant literature on PAH. 
It shall be noted that only one out of forty five articles included in this review was from an 
African setting. The worldwide epidemiology of PH as a whole is yet to be fully characterized 
and African data may differ.  
Indeed, it is estimated that almost 98% of the global PH burden occurs in low income 
countries with a population of up to 64 million people at risk but who are undiagnosed. The 
epidemiology of PH in Africa and the distribution of its multitude of etiologies has not yet 
been described, but limited reports suggest that the incidence of PH in Africa is higher than 
that reported from developed countries, owing to the pattern of diseases prevalent in the 
region(110). Many known risk factors for PH are hyperendemic in this part of the world, 
including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), 
rheumatic heart disease (RHD), hereditary hemoglobinopathies, schistosomiasis and other 
parasitic infections, and chronic hepatitis B and C infection. On the other hand, a high 
prevalence of tuberculosis (TB), poorly treated asthma, high levels of pollution in urban areas 
and exposure to mining, may subsequently lead to various forms of pulmonary diseases, PH 
and, often, to right heart failure (HF) with premature death(110). Also a lack of specialist 
pediatric services to diagnose and manage congenital heart disease (CHD) potentially also 
leads to PH(111). Furthermore, the high prevalence of RHD and endomyocardial fibrosis, the 
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latter possibly also due to the high burden of parasitic infections, may contribute to secondary 
PH(112). Lastly, Africa is in epidemiological transition with increased prevalence of non-
communicable forms of heart disease such as hypertensive and ischemic heart disease. Left 
heart disease is the most common cause of heart failure in Africa and most likely a major 
contributor to PH and consecutive right HF (110, 113). We are not aware of any registry of PH 
in Africa and data is scanty at best.  
In the next chapter, we present the hypothesis, aims and specific questions investigated in 
this doctoral research.
71 
Chapter 2. Hypothesis, Aims and specific 
questions 
2.1. Hypothesis 
We hypothesized that PH-LHD is the common cause of PH in SSA, and affected patients 
present with advanced disease, and ECG may have a diagnostic and/or prognostic role in 
screening for PH risk in this setting. 
2.2. Aims 
The primary aim to be achieved in this doctoral research project was to investigate the 
determinants and short-term outcomes of PH-LHD in the sub-Saharan African (SSA) context 
as well as the diagnostic utility of the widely used diagnostic tool versus echocardiography 
considered as the reference diagnostic test for PH in limited settings. 
2.3. Specific research questions 
Our specific research questions were: 
1. What are the established predictors of major outcomes of PH-LHD including
hospitalizations for heart failure and mortality reported in currently existing literature? 
2. What are the different types of PH, clinical characteristics and 6-month outcome of
patients with pulmonary hypertension in sub-Saharan Africa? 
3. What are the determinants of pulmonary pressures, clinical profile and short term
outcomes in patients with PH-LHD? 
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4. What is the prevalence and predictive utility of a simple, available and cheap tool like 
of electrocardiogram (ECG) for diagnosis of PH? 
5.  What is the prognostic significance of ECG for mortality risk in patients with acute 
heart failure, one of the major contributor to the etiology of PH-LHD? 
Through systematic literature reviews, we have answered the first question, identifying 
pulmonary hypertension due to left heart disease as the most prevalent cause of pulmonary 
hypertension, and investigating established determinant of PH-LHD and related outcomes.  
We have subsequently investigated questions 2 to 4 in a cohort of PH patients from a number 
of countries across Sub-Saharan Africa. We have to this end investigated the effects of a range 
of environmental and phenotypic factors including among others, level of education, income, 
functional class, six minutes’ walk test, echocardiographic parameters and NT-pro BNP on the 
presence and profile of patients with PH-LHD, as well as 6-month prognosis of the condition. 
Question 5 was answered through a large multicenter cohort of Sub-Saharan African patients 
with heart failure. The next chapter described the methods of the two major prospective 
multicentric cohort studies used to answer these questions. 
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Chapter 3. OVERVIEW OF STUDY METHODS 
3.1. Introduction 
Analyses presented in this thesis used data derived from two major cohort studies conducted 
in Sub-Saharan Africa (SSA) using similar methodological approaches. The Sub-Saharan Africa 
Survey of Heart Failure (THESUS-HF) was a clinical registry of the etiology, treatment and 
outcome of acute heart failure in 1006 Africans from 9 SSA countries. The Pan African 
Pulmonary hypertension cohort study (PAPUCO) was a multinational and multicentre clinical 
registry of pulmonary hypertension across 04 SSA countries.  
An overview of the design of each of the two studies analysed in this thesis is presented here; 
more details relating to the methods of specific publications are provided in relevant 
chapters. 
3.2. The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF) 
3.2.1. Rationale and objectives 
Over the past few decades, heart failure (HF) has emerged as a worldwide epidemic and an 
established cause of morbidity and mortality in high income countries, imposing a huge 
burden on their health care systems. Indeed, in some European countries and the U.S, up to 
1% of the health budget is spent on the management of HF (114). Before the THESUS-HF, 
there was very little data on HF in Africa where most of the published data originated from 
single centre hospital based study and were conducted in the pre-echocardiographic era 
(115). It is in this context that, following a call for action (116), the THESUS-HF was established 
in 2007 with the aim of providing reliable evidence regarding the contemporary etiology, 
treatment and outcome of HF in the SSA region, through a prospective cohort study.  
74 
 
3.2.2. Participating centers 
THE Sub-Saharan Africa Survey of Heart Failure (THESUS-HF) was a prospective, multicentre, 
international observational survey conducted in 12 cardiology centers from 9 countries in the 
southern, eastern, central, and western regions of SSA (Figure 5). The countries and 
participating centers were selected on the basis of availability of a trained physician in clinical 
cardiology and echocardiography, and previous participation in research projects. The study 
was coordinated at Momentum Research Inc., Durham, North Carolina, USA where all data 
were transferred, processed, cleaned and centrally analysed. All participating centers 
obtained an ethical approval before joining the study. 
3.2.3. Inclusion criteria 
Between July 2007 and June 2011, all patients admitted with dyspnea as the main complaint 
in each of the participating centers, were consecutively screened for inclusion in the study. 
Kenya, Ethiopia and Senegal joined the study late and therefore recruited fewer patients 
(Figure 5).  Patients were included if they were 12 years of age or older and had physical signs 
of congestive heart failure (i.e., pedal oedema, raised jugular venous pressure, pulmonary 
congestion, and tender hepatomegaly).   
3.2.4. Exclusion criteria  
Exclusion criteria were: 
 acute ST segment elevated myocardial infarction; 
 severe known renal failure (patients on dialysis or creatinine> 4 mg/dL); 
 nephrotic syndrome, or hepatic failure or other cause of hypoalbuminemia; 
 refusal to provide informed consent. 
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Figure 5: Patients included in THESUS-HF per country, analyses at the data lock 
3.2.5. Baseline evaluation 
Ethical approval was obtained from the local Ethics Committee of the participating 
institutions and the study conformed to the principles outlined in the Declaration of Helsinki. 
Written informed consent was obtained from each eligible participant before inclusion. In 
total, study participants consisted of 1006 patients recruited across 12 cardiovascular centers 
of the nine above named countries. 
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3.2.6. Study visit 1  
At the time of admission, demographic information was collected (patients’ initials, date of 
birth, age, sex, area of residence, level of education) with detailed medical history, which 
included preadmission history of heart failure (number of acute heart failure admissions in 
the last year prior to index admission, date of last admission for HF and New York Heart 
Association (NYHA) classification one month prior to admission). An echocardiographic 
assessment of ventricular function, valvular structure and function and regional wall 
abnormalities was performed. All echocardiographic procedures were undertaken by trained 
physicians and measurements made according to the American Society of Echocardiography 
Guidelines (39). For all patients in whom a 12-leads electrocardiogram (ECG) was recorded 
irrespective of the date and time of recording, ECG tracings were scanned and read centrally 
for conduction or rhythm disturbances and for evidence of myocardial ischemia/infarction or 
hypertrophy. Laboratory evaluations provided by the local institution and intravenous and 
oral medications were recorded at admission. Baseline characteristics of the 1006 patients 





Table 12: Demographic, clinical and biological characteristics of the 1006 patients 









Age, years 52.3 (18.3) 54.0 (16.9) 50.7 (19.5) 0.004 
Number of AHF admissions in last 12 months 0.37 (0.78) 0.41 (  0.77) 0.34 ( 0.78) 0.152 
Number with hyperlipidaemia*  90 (9.2) 52 (10.8) 38 (7.6) 0.085 
Number with a history of smoking, % 98 (9.8) 85 (17.3) 13 (2.6) <.0001 
Number with a history of hypertension, % 556 (55.5) 296 (60.0) 259 (51.0) 0.004 
Number with a history of diabetes mellitus, 
% 
114 (11.4) 58 (11.8) 56 (11.0) 0.679 
Body mass index, kg/m2 25.2 ( 9.0) 24.7 (  4.9) 25.7 ( 11.6) 0.082 
Systolic blood pressure, mmHg 130.4 ( 33.5) 132.4 ( 33.7) 128.4 ( 33.3) 0.061 
Diastolic blood pressure, mmHg 84.3 ( 20.9) 85.5 ( 21.2) 83.2 ( 20.7) 0.084 
Heart rate, bpm 103.7 ( 21.6) 101.6 ( 21.4) 105.7 ( 21.6) 0.002 
Left ventricular ejection fraction, % 39.5 ( 16.5) 37.8 ( 16.2) 41.1 ( 16.6) 0.002 
Creatinine, mg/dL 1.44 (  1.19) 1.57 (  1.21) 1.30 (  1.16) 0.0004 
Sodium, mmol/L 135.1 (  6.6) 134.9 (  6.5) 135.3 (  6.8) 0.3294 
eGFR< 30 mL/min/1.73 m2 73 (7.7%) 35 (7.5%) 38 (7.8%) 0.8290 
Haemoglobin, g/dL 12.2 (  2.6) 12.6 (  2.6) 11.8 (  2.5) <.0001 
Haemoglobin< 10 g/dL 147 (15.2%) 68 (14.3%) 79 (16.1%) 0.4347 
Total WBC, x 109/L or 103/mm3 7699.3 ( 4092) 7484.1 ( 3505) 7914.2 ( 4581) 0.1032 





Presented are mean (SD) for continuous variables and n (%) for categorical variables.  Statistics are computed from non-missing 
values, the number of which may vary from variable to variable. * [total cholesterol > 200 mg/dL (5.2 mmol/L), or LDL ≥ 130 mg/dL 
(3.37 mmol/L), or HDL < 30 mg/dL]. **Comparison of positive HIV test with Negative/Unknown 
78 
3.2.7. Ascertainment of diagnosis and follow-up 
After baseline evaluation, investigators provided the diagnosis of heart failure. 
Cardiomyopathy was classified according to the position statement from the European 
Cardiac Society (117). Hypertensive heart failure, right heart failure and ischemic heart failure 
were defined by standard criteria. 
As previously described (118), during admission, patients were systematically evaluated at 
days 1, 2, and 7 (or discharge whichever occurred first). Vital signs (blood pressure, heart rate, 
respiratory rate, and temperature), and signs and symptoms of heart failure (including oxygen 
saturation; degrees of edema and crackles; body weight; levels of orthopnoea) were assessed 
at the same time points.  Changes in dyspnea and well-being relative to admission were 
assessed on days 1, 2, and 7 (or discharge whichever occurred first). Subjects discharged after 
admission were evaluated at 1 and 6 months of follow-up. At these time points patients were 
evaluated for signs and symptoms of heart failure, laboratory evaluations were performed, 
and oral medications recorded. Of the 1006 patients evaluated at baseline, 936 were 
reevaluated at six months.  Reasons for loss to follow-up were provided for 35 of these 
patients and included lack of telephone contact (2.3%), financial constraints (0.3 %), 
unwillingness to come for follow-up (0.3%), lack of transportation (<0.1%), and others, e.g., 
transferring care to other facilities (0.5%). 
3.2.8. Outcomes 
During the follow-up period of patients discharged from the hospitals, readmissions and 
death, with respective reasons and cause, through 6 months follow-up were collected. A total 
of 159 (15.8%) patients died without completing a 6-month assessment; an additional 316 
(31.4%) patients had a last date known alive provided. One-month follow-up assessments 
were completed for 578 (57.5%) patients and 6-month assessments for 461 (45.8%) patients. 
3.2.9. Strengths 
Even though THESUS-HF was an observational study, the use of a prospective and consecutive 
enrolment helped limiting the selection bias and acquiring a more accurate and generalizable 
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assessment of demographics, HF aetiologies and comorbidities as well as HF severity in the 
SSA region. The methodological rigor associated with standardized collection of baseline 
information by cardiovascular specialists and outcomes ascertainment is a major advantage 
as well as the large number of participants from a variety of regional ethnic groups and 
countries enhance the generalizability of the conclusions.  
3.2.10. Weaknesses   
There are some limitations to the THESUS-HF. First, in spite of the short duration of follow-
up, 70 patients (7.0%) did not return for follow-up assessments for various reasons including 
moving to different regions of a country. This is common in the population studies due to a 
number of factors such as employment opportunities (migrant workers), or need to be taken 
care of if not well. Some of these remote regions have no phone contact. Also, although we 
systematically applied echocardiography and 12-lead ECG, clinical data were obtained 
according to the nature of the presentation and we cannot rule out the possibility of missing 
some cases of acute heart failure. Finally, ECGs tracings were not systematically conducted 
upon admission and this could limit our evaluation of ECG abnormalities during acute HF in 




3.3. The PAPUCO registry 
3.3.1. Rationale and objectives 
Currently, available evidence on etiologies and the adverse effects of PH have been derived 
essentially from western clinical registries (69, 119, 120). Little is known about PH in Africa, 
but limited reports suggest that PH is more prevalent in Africa compared to high income 
countries, due to the high prevalent predisposing conditions in the region (110). The Pan 
African Pulmonary hypertension Cohort (PAPUCO) registry was designed and tailored to 
resource-constrained settings to describe disease presentation, disease severity and 
aetiologies of PH, comorbidities, the diagnostic and therapeutic management, and the natural 
course of PH in Africa. The objectives and methods of the PAPUCO, the largest contemporary 
cohort study of PH in Africa have been described in detail in a previous report (41). 
3.3.2. Ethics 
The PAPUCO study was a prospective, multicentre, international observational survey 
conducted in 12 cardiology centers from 4 countries (Cameroon, Nigeria, South Africa and 
Mozambique). Ethical approval for the study was provided by the Human Research Ethics 
Committee of the University of Cape Town, South Africa; the Comité National d’Ethique de la 
Recherche pour la Santé Humaine of Cameroon; the Comité Nacional de Bioética para a Saúde 
of Mosambique; the Abeokuta Health Research Ethics Committee, Nigeria; the Ethical 
Committee of the Aminu Kano Teaching Hospital, Nigeria, the Health Research and Ethics 
Committee of the Lagos University Teaching Hospital, Nigeria; the Health Research Ethics 
Committee of the Federal Medical Centre at the Queen Elizabeth Hospital in Umuahia, 
Nigeria; and the Health Review Committee of the University of Uyo Teaching Hospital, Nigeria. 
The PAPUCO registry complied with the revised World Medical Association Declaration of 
Helsinki (121, 122) and written informed consent was obtained from all participants prior to 
enrolment into the PAPUCO registry. The study was registered on https://clinicaltrials.gov and 
its identifier number is NCT02265887 (123). 
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3.3.3. Participating centers 
Nine specialist care referral centres from Cameroon, Mozambique, Nigeria, and South Africa 
participated in the PAPUCO study. At the last data-lock (December 2013), 254 patients have 
been evaluated at baseline. Following data cleaning, 34 (13%) patients were excluded from 
the analysis, the remaining 220 have been included in the analysis among which 109 (50%) 
from the three centers in Cameroon. Because Cameroon was the largest contributor in the 
recruitment, the Cameroon centres is described in more detail below.   
The country: 
The PAPUCO Cameroon study took place in both urban and rural areas in the Central African 
country of Cameroon. As shown in (Figure 6) below, Cameroon is bordered by Nigeria to the 
west; Chad to the northeast; the Central African Republic to the east; and Equatorial Guinea, 
Gabon, and the Republic of the Congo to the south. Cameroon's coastline lies on the Bight of 
Bonny, part of the Gulf of Guinea and the Atlantic Ocean. The country hosts diverse 
microclimates and topographies including beaches, deserts, mountains, rainforests, and 
savannahs. The highest point is Mount Cameroon in the southwest, and the largest cities are 
Douala, Yaoundé and Garoua. Cameroon is home to over 200 different linguistic groups. 





Figure 6: Location of Cameroon and the PAPUCO-Cameroon urban centers (Douala) 
and the rural center (KUMBO).  
According to the 2013 Human Development Report presenting Human Development Index 
(HDI) values and ranks for 187 countries and UN-recognized territories, Cameroon’s HDI value 
for 2013 is 0.504. The country is characterised in a low human development category 
positioning the country at 152 out of 187. This is quite similar to the average HDI value of the 
SSA region which is the lowest of any world region (0.475), but the pace of improvement is 
rising. Between 2000 and 2012, the SSA region registered average annual growth of 1.34 
percent in HDI value, placing it second only to South Asia. Between 1980 and 2012, 
Cameroon’s HDI value increased from 0.373 to 0.504, an increase of 38.8 percent or average 
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annual increase of about 0.9 percent (124).  Figure 7 below shows the contribution of each 
component index to Cameroon’s HDI since 1980. 
 
Figure 7: Trends in Cameroon’s HDI component indices 1980-2012 (125)    
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Urban characteristics: The Douala General Hospital and Douala Cardiovascular Centre 
Douala is the largest and most populated city in Cameroon with a population of approximately 
2,146,844  in 2010 (126). The population of the city is heterogeneous, made up of people 
from all educational and professional backgrounds, all of the regions of Cameroon, 
immigrants and tourists. It is therefore representative of the diverse ethnicity of Cameroon. 
As the economic capital of Cameroon, Douala is also the largest urban center in the country.  
The Douala General Hospital (DGH) is the most structured and best equipped state health 
care facility in Douala and receives about 25 000 (twenty five thousand) patients per annum 
including about 9000 (nine thousand) cases of internal medicine. Investigations for cardiac 
diseases in this centre include all non-invasive cardiac investigations, but cardiac 
catheterization is not available. An average of 500 patients undergo cardiac ultrasound each 
year and patients visiting DGH are usually referred from other hospitals in Douala or from 
other health care facilities in the country. During the study period, eight specialists trained to 
recognize clinical signs suggestive of PH worked at DGH including 4 cardiologists, 1 chest 
physician and 3 rheumatologists. Patients diagnosed with PH by other healthcare providers 
in Douala are likely to be referred to see these specialists for specialized management of their 
condition.   
The Douala cardiovascular centre is the city most structured, equipped and specialized private 
centre with inpatients and outpatient services. During the study period, there was one full 
time cardiologist, 3 visiting cardiologists, and 1 visiting pulmonologist and 1 visiting 
rheumatologist. This centre receives up to 2000 (two thousand) patients per annum. 
Investigations for cardiac diseases in this centre include all non-invasive cardiac 
investigations. Patients visiting this centre are usually referred for cardiac care from other 
health facilities across Douala and beyond.  
The rural area: The Shisong Cardiac Centre 
Shisong, at the outskirts of Kumbo town (Figure 6), is about 400 kilometers (Km) north of 
Douala. It is the host of a Cardiac Centre, the Shisong Cardiac Centre (SCC), the first cardio-
surgical unit in Central Africa well equipped with ultramodern technology (including cardiac 
catheterization and cardiac surgery) to diagnose and manage a variety of cardio surgical cases 
including various aetiologies of pulmonary hypertension. This centre receives about 6000 (six 
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thousand) patients per annum. Patients visiting the Shisong Cardiac Centre are usually from 
the surrounding rural areas but are also periodically referred from any health care facility in 
the country. 
Training of the sites in Cameroon 
Clinical research in SSA and Cameroon in particular is daunting due to the combined effects 
of several factors, including the poor training of clinicians in research, the absence of 
adequate infrastructure or health care system for the conduct of research, as well as funding 
constraints that could directly affect the conduct of the PAPUCO. To address the lack of 
training of clinicians and raise the interest of policy makers in clinical research, Professor 
Karen Sliwa, project coordinator of PAPUCO and primary supervisor of this thesis, visited the 
Cameroon sites for two days to provide a training seminar in research methodology with 
reference to the PAPUCO project, diagnosis of heart failure and pulmonary hypertension. This 
unprecedented event brought together three local investigators of three PAPUCO sites in 
Cameroon for small meetings as well as over 200 other clinicians with interest in clinical 
research. It was largely supported by the highest authorities of both the Douala General 
Hospital and the Hatter Institute of Cardiovascular Research in Africa (Figure 8). It is hoped 
that this first step will enhance clinical research and the dissemination of research findings to 
improve evidence-based clinical practice in the country (127). 
 
86 
Figure 8: Official photo of the first scientific and research day held at the Douala 
General Hospital (128)  
Other participating centers 
Other participating centers included the Hatter Institute for Cardiovascular Research of the 
University of Cape Town, Cape Town, South Africa, the Khayelitsha District Hospital, Cape 
Town, South Africa, the Instituto Nacional de Saúde, Maputo, Mozambique and the 
department of Medicine, Bayero University and Aminu Kano Teaching Hospital, Kano, Nigeria. 
3.3.4. Inclusion and exclusion criteria 
Patients were included in the PAPUCO cohort study if they were 18 years or older, and had 
an echocardiographic measurement of RSVP above 35 mm Hg. Patients who refused to give 
inform consent or who were unable to return for 6 month follow up visits were excluded. 
3.3.5. Questionnaire and baseline clinical assessment 
3.3.5.1. The Interview 
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All patients for whom an echocardiographic diagnosis of PH was made by the 
echocardiographer, were invited to participate. After consent, patient were then interviewed 
using a standardized questionnaire conceived and pretested by the PAPUCO steering 
committee. Information was recorded and entered onto a central research web platform 
(www.papuco.org) designed and conceived by integer Africa team 
(http://www.integerafrica.org) and pretested by the PAPUCO team during a training session 
of the first investigator meeting. The platform was developed with the aim of enabling 
investigators to track, analyse, and report on an individual-case level. The platform allowed 
researchers to enter data from multiple sites using one centralized database and provided 
tools for real-time data analysis. Using a geo-location aware data system, researchers were 
also able to study disease distribution and to identify risk factors. This created strong 
commitments and bridges for networking between centre investigators and the coordinating 
centre at the Hatter Institute of Cardiovascular Research in Africa, University of Cape Town. 
At the coordinating centre, the system was appropriately administered by integer Africa, to 
ensure the confidentiality, integrity and security of electronic health information. The online 
platform was 24-hour accessible and the architecture was developed according to clinical 
workflows and chronological procedures. Data was validated at the point of data entry. 
Multimedia data formats, i.e. electrocardiogram, chest x-rays, and echocardiography could 
be uploaded on the platform allowing storage of complete clinical records, which guarantees 
completeness of data. Tools for education, training, and communication were also installed 
within the web-portal.  A questionnaire of the PAPUCO registry is available in the appendix 
section of this thesis. Briefly, the collection of information collected of: 
 Demographics: Age, gender, ethnicity, occupation, educational level and income, 
residency, patients’ contact number and that of a close relation (spouse, child). 
 Clinical Variables: Family history of cardiovascular disease, presence of hypertension 
(defined as subject having systolic (diastolic) blood pressure of ≥ 140(90) mmHg, or 
physician documented history of hypertension or patient on anti-hypertensive 
medication), presence of diabetes (defined as past history of diabetes, or fasting 
blood sugar ≥ 126 mg/dL, or physician documented history of diabetes or patient on 
blood sugar lowering medication). Smoking status was defined as never smoked, or 
ex-smoker: if subject had smoked for at least 3 years in the past, but had stopped at 
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time of consultation, and current smoker: one who smoked at least one cigarette per 
day at time of consultation. Alcohol abuse was defined as intake of either more than 
3 (2 for women) standard glasses of wine per day or more than 10 (5 for women) local 
beers (1 local beer contains 28g of alcohol) per week. Presence of symptoms 
(dyspnoea, fatigue, cough, palpitation) was also recorded. The World Health 
Organization (WHO) functional class (FC) applied (Table 13). 
Table 13:  World Health Organization functional assessment classification (129) 
Class I: Patients with PH but without resulting limitation of physical activity. 
Ordinary physical activity does not cause undue dyspnea or fatigue, chest 
pain, or near syncope. 
Class II: Patients with PH resulting in slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity causes undue dyspnea or 
fatigue, chest pain, or near syncope. 
Class III: Patients with PH resulting in marked limitation of physical activity. They 
are comfortable at rest. Less than ordinary activity causes undue dyspnea 
or fatigue, chest pain, or near syncope. 
Class IV: Patients with PH with inability to carry out any physical activity without 
symptoms. These patients manifest signs of right-heart failure. Dyspnea 
and/or fatigue may even be present at rest. Discomfort is increased by 
any physical activity. 
 Physical examination: Jugular vein distension, presence or absence of heart murmur,
hepatomegaly, ascites and pedal oedema, blood pressure (BP), pulse and respiratory
rate. BP was measured using an automated electronic device with the patient in a




 Anthropometric measurements: The height and weight of the subjects were 
measured by the clinic nurses with the participants standing, wearing indoor clothes 
with no shoes. Body mass index was calculated as weight in kilograms divided by the 
square of height in meters square. Body surface area (BSA) in meters2 (m2) was 
calculated using the formula by Dubois and Dubois: 
BSA = (0.0001) x (71.84) x (weight in kg) 0.425 x (height in cm)0.725. 
 At the end of the examination, a 6 minutes’ walk test (6MWT) was performed. Patient 
was taken to a corridor in hospital premises with already marked distance and less 
interference from other hospital staff or patients. The patient had to be at rest for at 
least 10 minutes prior to the test, during which time the procedure and importance 
of the test were again explained to the patient. Before walking, patient was assessed 
for the presence of fatigue, dyspnea and the heart rate and oxygen saturation (with 
pulse oximeter. Patient was then timed for six minutes and asked to walk the 
maximum distance within the corridor. At the end of the six minutes, patient was 
stopped, re-assessed for dyspnea, fatigue severity, heart rate and oxygen saturation 
(SpO2). The cumulative distance covered was then recorded as “6MWT distance”.  
 All chest X-Rays and electrocardiograms were scanned, and uploaded on the central 
web platform for a central analysis by the PAPUCO data management committee. 
 All other tests (pulmonary function tests, Ventilation/perfusion scan, etc…) were 
performed at the discretion of the investigator and results were still reported on the 
PAPUCO web platform.   
3.3.6. Echocardiographic assessment 
3.3.6.1. General Assessment 
The echocardiographic examination started with a general assessment during which a nurse 
recorded the current height and weight of the patient, the systolic and diastolic blood 
pressure and the heart rate at the time of the echocardiogram. If a patient presented with 
signs of acute pulmonary or peripheral congestion or hemodynamic instability, the exam was 
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postponed until hemodynamic stability achieved. Patients with acute right heart failure and 
no evidence of left heart disease were excluded at this stage.  
3.3.6.2. Echocardiographic images acquisition and measurements 
In all centers, echocardiographic and Doppler studies were performed with a 3-5 MHz sector 
transducer and all echocardiographic images acquisition and measurements were done 
according to the recommendations by the American Society of Echocardiography (ASE) (130). 
Hemodynamically stable subjects were positioned at 30° left lateral position (Figure 9). All 
echocardiographic measurements were performed by experienced cardiologist who have 
been trained in right heart assessment. Values were obtained directly from the screen 
monitor with the aid of calipers and the instrument’s trackball. When heart rhythm was 
irregular (such as atrial fibrillation or frequent ectopic beats), each measurement was made 




Figure 9: Echocardiography in a 30 years old patient positioned at 30° left lateral 
position 
An integrated M-mode and two-dimensional study was done to determine the postero-
anterior left atrial diameter (Figure 10), the septal wall thickness (SWT), posterior wall 
thickness (PWT), LV end-diastolic diameter (LVEDD) and LV end-systolic diameter (LVESD), 
consistent with the recommendations of the American Society of Echocardiography(130). 
Particular effort was made not to include overlying trabeculations in the ventricular septum 
or posterior wall measurements, which may overestimate wall thickness (Figure 11), left 
panel).  
Ejection fraction was calculated automatically from measurements of LV diameters using the 
formula by Teicholz et al or estimated visually or by SIMPSON biplane method (131, 132) in 
case of regional wall abnormalities (Figure 11, right panel). 
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LV outflow tract (LVOT) diameter was measured from the systolic freeze frame of the 
parasternal long-axis view as the distance from where the anterior aortic leaflet cusp meets 
the interventricular septum to the point where the posterior leaflet meets the mitral leaflet, 
and perpendicularly to the anterior wall of the aortic root. 
Other measurements in the left lateral position and in parasternal long axis view included 
aortic root diameter (Figure 10).  
  
Figure 10: Echocardiographic measurements in the left lateral position and in 
parasternal long axis view.  
Ao indicates aortic root diameter while LA indicates postero-anterior left atrial diameter. 
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Figure 11: Measurements of the ejection fraction using the formula by Teicholz (left 
panel) and using by SIPMSON method (right panel). 
 IV(D/S) indicates Interventricular septum (diastole/systole), LVED(S)d: Left ventricular end 
diastolic(systolic) diameter, PWd(s): Posterior wall in diastole (systole). LVED(S)vol indicates 
LVED(S) volume. EF indicates ejection fraction. 
We measured the LV diastolic filling velocities in an apical four-chamber view by positioning 
the pulsed Doppler volume sample just below the mitral annulus. Early peak flow velocity (E), 
late peak atrial flow velocity (A) and deceleration time (DT) were measured (Figure 12). The 




Figure 12: Measurements of LV diastolic filling velocities in an apical four-chamber 
view by positioning the pulsed Doppler volume sample just below the mitral 
annulus.  
E (A) indicates early (late) peak atrial flow velocity, DT indicates deceleration time. In this 
patient, E/A ratio indicates a restrictive pattern of the mitral inflow. 
Other parameters recorded included the aortic flow velocity, LV outflow tract time velocity 
integral (LVOT TVI) measured from the apical long-axis view using pulsed wave (PW) Doppler 
with the PW sample volume placed 3 to 5 mm below the aortic valve or at the annulus. In 
patients with atrial fibrillation, the average of 3 consecutive measurements from 3 
consecutive cardiac cycles was considered. 
Right cardiac cavities (atrial and ventricular) dilatation was diagnosed visually by the 
echocardiographer in four chamber apical view and classified as normal, mild, moderate, or 





Figure 13: Visual assessment of right cardiac cavities in apical four chamber view 
showing mildly dilated right cavities (left panel) and severely dilated right cavities 
(right panel). 
The assessment of RV systolic function was done visually and also using the tricuspid annular 
plane systolic excursion (TAPSE). TAPSE was measured as the distance of RV systolic 
contraction from base to apex along the longitudinal plane. To obtain this, an M-mode cursor 
was placed through the lateral tricuspid annulus in the 4 chamber view. The TAPSE 
measurement was considered as the absolute distance from systole to diastole (Figure 14). 
As described elsewhere (133), a TAPSE <15 mm (Figure 14) was considered as an indice of RV 







Figure 14: Measurement of the tricuspid annular plane systolic excursion (TAPSE) as 
indicated by the bold yellow line.  
A normal TAPSE indicates a normal right ventricular (RV) systolic function (left panel) as 
compared to a RV impaired systolic function (right panel) 
3.3.6.3. Measurement of right ventricular systolic pressure. 
The RVSP was obtained by the addition of the pressure gradient between the right ventricle 
and the right atrium, to the pressure in the right atrium. In the absence of any significant 
stenosis at the right ventricular outflow tract, or the pulmonic valve, the RVSP was considered 
equal to systolic pulmonary artery pressure (SPAP). 
To obtain the RV-RA pressure gradient, TR jet was first identified by a duplex imaging probe, 
in priority from the apical four chamber view (Figure 15). We then measured the maximum 
velocity of the tricuspid regurgitation (TR) by continuous wave (CW) spectral Doppler and the 
TR maximal instantaneous gradient (TR MIG) or maximum RV-RA pressure gradient was 
automatically calculated and listed on the screen (Figure 15). If not, TRMIG may be calculated 
using the Bernoulli equation as: TR MIG = 4(TR velocity)². TR velocity was obtained with 
patient’s respiration held at end expiration and particular efforts were made to get a good 
envelope of the regurgitant jet, a necessary condition for accuracy of the measurement. We 
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Figure 15: Measurement of the right ventricular systolic pressure 
Step 1 identifying the tricuspid regurgitant (TR) jet (right panel) and step 2 using the 
continuous wave Doppler to obtain the maximum instantaneous right ventricular-right atrial 
gradient as indicated by the yellow bold line (left panel). The yellow dotted line indicates 
measurement of over-gained (shaggy) signals with significant overestimation in the RVSP TR 
jet indicates tricuspid regurgitant jet, TR MIG indicates the TR maximal instantaneous 
gradient. If the TR velocity signal was weak or not adequate, right ventricular inflow view, 
parasternal short axis view at the basal level, para-apical four chamber view or the subcostal 
view was then assessed and the best view considered.  
3.3.6.4. Inferior vena cava assessment for estimating right atrial pressure 
Right atrial pressure (RAP) was estimated from the inferior vena cava (IVC) caliber and 
respiratory collapsibility. With the patient lying supine, knees bent to relax the abdominal 
muscles, the IVC was brought into view in the long axis and measurement of the IVC diameter 
was made just proximal to the junction of the hepatic veins that lie approximately 0.5-3.0 cm 
proximal to the ostium of the right atrium (Figure 16).  
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Figure 16: Estimation of the right atrial pressure from inferior vena cava (IVC) caliber 
and respiratory collapsibility. 
The diameter of the IVC is indicated by the yellow bold line. Left panel shows a normal size 
IVC with estimated RAP < 5 mm Hg as opposed to the left panel showing an estimated a 
dilated and non-collapsing IVC with RAP > or = 20 mm Hg.  
IVC diameter was measured at end-expiration (widest diameter) and end inspiration. When 
there was no change with inspiration, we asked the patient to sniff and measure the smallest 
diameter while sniffing. RAP was then estimated as described in Table 14 below: 
Table 14: Estimation of the right atrial pressure from inferior vena cava caliber and 
respiratory collapsibility. Adapted from Beigel et al (40) 
Estimated RAP (mmHg) IVC diameter (cm) IVC collapse with inspiration (sniff) 
5 <2.1 >50%
10 <2.1 <50% 
15 ≥2.1 >50%
20 ≥2.1 <50% 
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Estimated right ventricular systolic pressure (RVSP) was calculated as follows: RVSP = TR MIG 
+ RAP or RVSP = 4(TR velocity)² + RAP and estimated RVSP = estimated pulmonary artery 
systolic pressure. 
3.3.7. Measurement of NT-pro Brain Natriuretic Peptide Levels 
Blood samples were taken from 65 subjects with PL-LHD from the PAPUCO Cameroon centers 
who gave their informed consent prior to blood extraction. At first, blood samples were 
collected by venipuncture into a tube containing ethylene diamine tetra acetic acid (EDTA) (1 
mg/mL blood) with aprotinin (50 kallikrein inactivator units per mL of blood) and immediately 
centrifuge at 2,220 rpm for five minutes. The top clean serum was removed from the 
centrifuged tube using a pipette and taking care not to take up any of the red blood cells and 
1.4 ml of serum was transferred into three barcoded tubes. Serum samples were then frozen 
at -20 degre C until day of transfer to the laboratory of the Hatter Institute of Cardiovascular 
Research in Africa (HICRA), University of Cape Town, South Africa. During transfer, samples 
were transported into a dry ice in a cooler box and remained frozen until arrival in the 
laboratory at the HICRA (Figure 17). Upon arrival in the laboratory, the frozen samples were 
again placed in a -80 degre C freezer until analysis were performed.  
 
Figure 17: Blood samples upon arrival at the laboratory of the Hatter Institute of 
Cardiovascular Research in Africa. 
Yellow tubes indicates serum samples and purple tubes indicates plasma samples. 
At the HICRA, we used the enzyme immunoassay for the quantitative determination of NT-
proBNP in human EDTA plasma or serum. First, all reagents and samples were kept at room 
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temperature (18-26°C) before use in the assay. In a first step, sample and conjugate (sheep 
anti-human NT-proBNP-HRPO) were pipetted into the wells of the microtiter strips (Figure 18, 
left panel), which were precoated with polyclonal sheep anti NT-proBNP antibody. This 
allowed the NT-proBNP present in the sample to bind to the precoated antibody in the well 




Figure 18: Pipetting the sheep anti-human NT-pro BNP-HRPO into the wells of the 
microtiter strips (left panel), and which results into to binding of the NT-pro BNP to 
the precoat and colored red (right panel). 
In the washing step, using an ELISA micro plate washer, all nonspecific unbound material were 
removed. In a second step, the substrate (TMB Tetramethylbenzidine) was pipetted into the 
wells. This allowed a color change of the substrate which is directly proportional to the 






Figure 19: Color change of the substrate following pipetting of the substrate (TMB 
Tetramethylbenzidine) into the wells.  
The color change is directly proportional to the amount of NT-proBNP present in the 
sample. This color change was detected with a standard microtitter plate Elisa reader. 
Absorbance was measured after 30 minutes at 450 nm with reference 650 nm using a 
spectrophotometer (Figure 20).  
 
  
Figure 20: Measurement of optical densities using a spectrophotometer (left panel), 
the readings are viewed on the screen (right panel). 
Calculations of NT-proBNP results from optical densities were conducted by subtracting the 
blank extinction from all other values and we constructed a standard curve from the 
standard values using the prism software. We then read the sample concentration from the 





3.3.8. Follow up and outcomes 
All patients included in the PAPUCO registry were entered into the study from the date they 
gave their inform consent to participate and were followed up until death or 31st December 
2013 (which ever occurred first) when all patients still actively followed up were censored. 
For all patients, follow-up evaluations were performed by telephone interview with the 
patient, the patient’s family, the patient’s primary physician or cardiologist. The two 
outcomes considered were heart failure admission and all cause death within 6 months with 
an allowable window of 5 to 9 months from baseline. Questions asked to participants or their 
proxies included recent emergency room visits, hospitalizations, or death. The verbal autopsy 
then investigated whether 1) patient was alive on 31st December 2013. 2) if alive, we 
recorded number and dates of admissions, as well as time lapse from recruitment to the first 
admission. If the patient died, we recorded date of death and calculated time lapse from 
recruitment to death. Admission (all-cause mortality) was defined as any heart failure 
admission (all-cause death) during the follow up period of 6 months with allowable window 
of 5 to 9 months from baseline. Patient was considered lost to follow up if unreachable by 
phone after more than 15 attempts on 3 different days.  The above information was 
documented in the PAPUCO web base platform. 
3.3.9. Data cleaning, case and outcome ascertainment  
The method of case ascertainment was standardized for all centers and based on the 
investigator report. All cases were reviewed by two investigators, Anastase Dzudie (AD) and 
Friedrich Thienneman (FT) to check for missing values and data consistency. In case of 
inconsistency, a query was addressed to the investigator and corrections were made on the 
patient’s case report form with investigator signature below. If queries were satisfactorily 
addressed, and there was no inconsistency, patient’s data was included in the analysis. In case 
of inconsistency, a discussion via Skype call with the investigator was organized and a 
consensus was reached.  
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 The method of outcome ascertainment was the same across centres. Investigators 
questioned participants or their proxies regarding recent emergency room visits, 
hospitalizations, or death and entered the information on the PAPUCO web based platform. 
Additionally, whenever possible, admissions or deaths were always identified using hospital 
records, particularly for the two centers in Cape Town where outcomes could always be 
tracked through clinicum, the hospital record system. Again, when the outcome was 
imprecise or inconstant, a query was sent to the investigator and a consensus decision was 
only taken after failure to answer the query following a discussion via Skype call between AD, 
FT and the centre investigator. All disagreement between the two adjuticators (AD and FT) 
were resolved by consensus and if consensus was not achieved, a third opinion (Karen Sliwa 
(KS) or Ana Olga Mocumbi (AOM) was requested.       
3.3.10. PH classification 
In a first step, clinical history, physical examination, chest X-ray, ECGs, biology, 
echocardiography, and lung function tests, computed chest pulmonary angiography, V/Q scan 
(when available) for all patients were reviewed by two investigators (AD and FT) for 
completeness, data verification and validation of PH classification. In case of any 
disagreement, a query was addressed to the investigator, and if consensus on the WHO 
classification of PH could not be reached, a third investigator’s (KS or AOM) opinion was 
requested. During this process, transthoracic echocardiograms were particularly reviewed to 
assess the cardiac morphology and function and valvular anatomy and function.  
3.3.11. Study limitations  
Potential methodological limitations should be acknowledged to facilitate the interpretation 
of our results.  
1) Validity of right ventricular systolic pressure for diagnosis of pulmonary 
hypertension 
First, our diagnosis of PH was echocardiographic based on RVSP measurement as the sum of 
TR maximal instantaneous gradient and right atrial pressure. There is absolutely no doubt that 
right heart catheterization (RHC) is the standard to accurately diagnose PH and determine its 
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severity as well as impact on right ventricular function. However, RHC is an invasive 
procedure, it is expensive and not always available, particularly in SSA. There is an abundant 
literature on the validity of echocardiographic RVSP estimates in patients with left heart 
disease using RHC values as the gold standard. Lanzarini et al reported(134) a concordance 
correlation coefficient of 0.88 between RHC and RVSP, with ±20 mm Hg 95% limits of 
agreement. Other studies reported a narrower limit of agreement (<10 mm Hg) and good 
correlation between RHC and RVSP (r=0.82–0.97) in HF (135-137). In their study of 
echocardiographic evaluation of hemodynamics in patients with decompensated systolic 
heart failure, Nagueh et al (138) reported that echocardiography identified patients with 
invasive systolic pulmonary artery pressure >35 mm Hg with 94% sensitivity and 90% 
specificity. In an analysis of data from the ESCAPE trial, McClanahan and M. Guglin (139) 
suggested that the accuracy of echocardiographic RVSP estimates in systolic HF might be 
inaccurate in presence of RV systolic dysfunction. However, at least two reasons could have 
explained this lack of accuracy: 1) first, patients included in the ESCAPE trial (140) were in 
acute heart failure and not hemodynamically stable; 2) echocardiography in ESCAPE was not 
protocol driven, and the time differential between RHC and RVSP evaluation using 
echocardiography was widely variable.  
As described in Chapter 1 of this thesis, Doppler echocardiography is recommended by the 
ESC/ERS guidelines (141) and the ACCF/AHA 2009 expert consensus as the reference 
screening method to detect PH in population at risk. We have also reported in Chapter One 
that regardless of method of PH determination (echocardiography or RHC), PH is associated 
with adverse outcomes. Therefore, provided that patients are hemodynamically stable and a 
rigorous echocardiographic technique is used by experienced observers, it is acceptable and 
pragmatic to detect PH using echocardiographic estimates of RVSP. 
2) Sample size and follow-up
We acknowledge the short duration of follow-up (6 months) and the small number of 
participants included in our registry with blood samples in only 65 patients. An explanation to 
the sample size is that contrary to other registries which included both new and old cases, we 
included only newly diagnosed cases of PH. This small sample size would not allow us to have 
reliable information on prevalence data, but is unlikely to affect the direction of associations. 
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The planned PAPUCO 2 will hopefully address this shortcoming by recruiting more 
participants and allowing for extended follow-up.  
3.3.12. Strengths of the PAPUCO registry 
Strengths of this study include the prospective and consecutive nature of data collection in 
the real world practice of SSA by cardiovascular specialists. The web based platform provided 
a networking opportunity for all investigators from different countries and a standardised 
collection of baseline information and outcomes ascertainment. The inclusion of participants 
from a variety of ethnic groups and different countries enhances the generalizability of the 
conclusions. Also data was rigorously cleaned by reviewing each case by two investigators 
(Anastase Dzudie and Friedrich Thienneman) and disagreement resolved by consulting a third 
one (Karen Sliwa). This approach enhances its internal validity, and the non-selective nature 
of participants enhances the external validity. Further, we relied on rigorous validated 
Doppler echocardiography techniques to diagnose PH and associated LHD.  
3.4. Details of rationale and design of the PAPUCO study (Second 
publication) 
This section on the details of PAPUCO objectives and study methods has been published as a 
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Introduction: Pulmonary hypertension (PH) is a 
devastating, progressive disease with increasingly 
debilitating symptoms and usually shortened overall life 
expectancy due to a narrowing of the pulmonary 
vasculature and consecutive right heart failure. Little is 
known about PH in Africa, but limited reports suggest 
that PH is more prevalent in Africa compared with 
developed countries due to the high prevalence of risk 
factors in the region. 
Methods and analysis: A multinational  multicentre 
registry-type cohort study was established and tailored 
to resource-constraint settings to describe disease 
presentation, disease severity and aetiologies of PH, 
comorbidities, diagnostic and therapeutic management, 
and the natural course of PH in Africa. PH will be 
diagnosed by specialist cardiologists using 
echocardiography (right ventricular systolic pressure 
>35 mm Hg, absence of pulmonary stenosis and acute 
right heart failure), usually accompanied by shortness 
of breath, fatigue, peripheral oedema and other 
cardiovascular symptoms, ECG and chest X-ray 
changes in keeping with PH as per guidelines 
(European Society of Cardiology and European 
Respiratory Society (ESC/ERS) guidelines). Additional 
investigations such as a CT scan, a ventilation/ 
perfusion scan or right heart catheterisation  will be 
performed at the discretion of the treating physician. 
Functional tests include a 6 min walk test and the 
Karnofsky Performance Score. The WHO classification 
system for PH will be applied to describe the different 
aetiologies of PH. Several substudies have been 
implemented within the registry to investigate specific 
types of PH and their outcome at up to 24 months. 
Data will be analysed by an independent institution 
following a data analyse plan. 
Ethics and dissemination: All local ethics 
committees of the participating centres approved the 
protocol. The data will be disseminated through peer- 
reviewed journals at national and international 
conferences and public events at local care providers. 
INTRODUCTION 
Pulmonary hypertension (PH) is a  devastat- 
ing, progressive disease with increasingly 
debilitating symptoms  and  usually shortened 
overall life expectancy  due  to a narrowing  of 
the  pulmonary  vasculature   and  consecutive 
right   heart   failure   (RHF).1    The   epidemi- 
ology of PH in Africa and  the  distribution  of 
its multitude of aetiologies  have not  yet been 
described,  but  limited   reports   suggest  that 
the  incidence of PH in Africa is higher than 
that    reported   from    developed   countries, 
owing to the  pattern of diseases prevalent  in 
the  region.2–5  Many  known  risk  factors  for 
PH  are   hyperendemic  in  this  part   of  the 
world, including HIV/AIDS,  rheumatic heart 
disease  (RHD), hereditary haemoglobinopa- 
thies, schistosomiasis and other parasitic 
infections,  and chronic hepatitis  B and C 
infection. On  the  other  hand,  a high  preva- 
lence   of  tuberculosis   (TB),   poorly   treated 
asthma,   high   levels  of  pollution  in  urban 
areas   and   exposure  to  mining   may  subse- 
quently  lead  to  various  forms  of pulmonary 
disease,  PH  and  often  to  RHF  with  prema- 
ture  death.  Also, a lack of specialist  paediat- 
ric  services  to  diagnose   and  manage 
congenital  heart   disease  (CHD) potentially 
also  leads  to  PH.6    Furthermore,  the   high 
▸  Prepublication  history for 
this paper is available online. 
To view these files please 
visit the journal online 
(http://dx.doi.org/10.1136/ 
 bmjopen-201-005950). 
Received 20 June 2014 
Revised 7 September 2014 
Accepted 9 September 2014 
For numbered affiliations see 
end of article. 
Correspondence to 
Dr Friedrich Thienemann; 
friedrich.thienemann@uct.ac. 
za. 
1 Thienemann  F, et al. BMJ Open 2014;4:e005950. doi:10.1136/bmjopen-2014-005950 
Strengths and limitations of this study 
▪    The Pan African Pulmonary hypertension Cohort 
(PAPUCO) study is the first multinational registry 
on pulmonary hypertension in Africa. 
▪    PAPUCO centres have different levels of medical 
infrastructure and not all patients underwent the 







prevalence  of  RHD  and   endomyocardial  fibrosis,  the 
latter  possibly also due  to  the  high  burden of parasitic 
infections,  may contribute to secondary PH.6–8 However, 
Africa is in epidemiological transition with increased 
prevalence of non-communicable forms of heart  disease 
such  as hypertensive and  ischaemic  heart  diseases.  Left 
heart  disease is the  most common cause of heart  failure 
in Africa and  most likely a major  contributor to PH and 
consecutive  RHF.4   9  Thus,  within the  registry,  we expect 
the  entire  spectrum of aetiologies  of PH. In this manu- 
script,  we aim  to  provide  an  overview  of  PH  in  Africa 
and  the  epidemiology  of  risk  factors  prevalent  in  the 
region,   and   answer  the   question   why  Africa  needs   a 
registry for PH  just as much  as most  other  parts  of the 
world  and   how  we  implemented  it  in  the   setting   of 
scarce resources. 
for  PH;  a  screening  study  of  patients   with  sickle-cell 
disease  (SCD)  in  Nigeria  showed  a  PH  prevalence  of 
25%16;  a  study  from  Egypt  indicates  that  patients   with 
β-thalassaemia  are  at  risk of PH.17  Another study  from 
Egypt found  a PH prevalence of 9% in patients  seroposi- 
al
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tive  for  schistosomal   antibodies.  Ahmed   et from 
Sudan  described 14 consecutive  cases of PH with previ- 
ously treated pulmonary TB and  concluded that  PH can 
even occur after resolution of TB, most likely due to per- 
sistent  lung   destruction.  These   data   suggest  that   left 
heart  disease,  chronic lung  disease,  RHD,  HIV, schisto- 
somiasis  and  SCD might  be  the  most  common under- 
lying  diseases   to   cause   PH   within   the   spectrum   of 
aetiologies   of  PH   that   we  will  find   within   the   Pan 
African Pulmonary hypertension Cohort  (PAPUCO) 
Preliminary evidence of a significant burden of PH and its 
risk factors in Africa 
In recent years,  there  has been  an  increasing awareness 
of the  clinical  significance  of PH and  cor  pulmonale in 
Africa. This applies equally to the recognition of the 
importance of PH and  RHF as a primary  diagnosis  and 
as a poor  prognostic marker for those  primarily  affected 
by left-sided  heart  failure.  Data  on  the  precursors and 
risk  factors  of  those   conditions  are  limited   to  a  few 
reports.  The   largest  study  on  PH/RHF  in  Africa  has 
been  conducted within the Heart of Soweto Study in South 
Africa;  2505  patients   presented  with  de   novo  heart 
failure  between  2006  and  2008.5   Of  those,  697  (28%) 
were diagnosed with PH/RHF. PH/RHF was the primary 
diagnosis  in  50%  of  those  patients.   The  majority  pre- 
sented  with dyspnoea  and  a mean  right  ventricular sys- 
tolic   pressure    (RVSP)   above   50 mm Hg.   Left   heart 
disease (31%),  chronic lung disease due to chronic 
obstructive  pulmonary disease  and  TB (26%),  and  pul- 
monary arterial  hypertension (PAH;  20%)  due  to  HIV 
(HIV-PAH),   CHD   or   idiopathic  PAH  were  the   most 
common causes of PH. Sani et al10   described the  preva- 
lence  of PH in patients  with RHD at a tertiary centre in 
Nigeria.   Of  1312  Echocardiography (ECHO)  studies, 
10% had evidence  of RHD; secondary PH was present in 
80%  of patients   with RHD.  The  same  centre reported 
on  53  patients   with  PH  on  ECHO  among  80  patients 
admitted  with  heart   failure,   with  hypertensive  heart 
disease    (25%),    peripartum   cardiomyopathy  (25%), 
dilated  cardiomyopathy  (17%)   and  RHD  (13%)   being 
the  most common causes of PH.11 A study from  Uganda 
showed  a prevalence of PH in patients  with newly diag- 
nosed  RHD  (n=309)   of  33%.12    A smaller  survey  from 
Lagos, Nigeria,  investigated  the  prevalence of cardiovas- 
cular  disease  in  an  HIV-positive  cohort  and   found   1 
patient of 100 patients  to  have HIV-PAH.      An ECHO 
study on 102 HIV patients  presenting with cardiac  symp- 
toms in Tanzania  revealed PH in 13%.14  PH with an 
RVSP>30 mm Hg  was present in  4% of long-term  survi- 
vors  in  a  Zimbabwe  cohort of  vertically  acquired  HIV 
infection.15  Haemolytic  anaemia   is a known  risk factor 
RATIONALE AND OBJECTIVES 
Worldwide,  PH  has  received  a great  increase  in  aware- 
ness at the  beginning of the  21st century, but  less than 
1% of the  publications are  from  Africa ( figure  1). It is 
expected  that   PH  is  more   prevalent   in  Africa  com- 
pared  with developed countries, but  little  information 
is available  about  African  patients   with  PH.  Exposure 
to risk factors, human genetic  variation, different 
socioeconomic backgrounds, lifestyles, comorbidities, 
nutrition  and   disparities   in  access  to  health   services 
makes  the   African  population  unique  but   heteroge- 
neous  at the  same  time.  Therefore, most research data 
and   clinical   guidelines   from   high-income  countries 
cannot  be  translated  into   the   African  context.   It  is 
within  the  context   described  above  that   PAPUCO,  a 
Pan  Africa  registry-type  cohort   study,  was established 
( figure  2). 
Scientific  and  clinical  research has been  fundamental 
in improving  human health.19 In fact, research has been 
demonstrated to  be  an  excellent vehicle to  implement 
new technologies and  to facilitate  training  for its use, as 
well as to develop  new systems and  establish  the  services 
around  it—jointly  leading   to  technical  improvement, 
sharpening  of   skills  and   capacity   development.20 
21 
Besides the  main  objectives  of the  PAPUCO  registry  to 
define  and  understand PH in Africa (box 1), this multi- 
national and multicentre research project  therefore aims 
to also develop  sustainable  clinical and  research capacity 
across the  African continent as well as raising  awareness 
for PH and its risk factors. 
The  prevalence of PH  in Africa varies geographically, 
according  to  the  underlying risk  factors  and  diseases, 
and  the  diagnosis  of PH is most likely often  missed, not 
only during  the  early stages due  to the  subtle  nature of 
presentation of PH, but also at a more  advanced  stage of 
the  disease,  due  to a lack of awareness  by primary care 
doctors   and  low index   of  suspicion,   limited  access  to 
ECHO services and tertiary care. However, it is crucial to 
diagnose  PH in Africa early and  reliably to ensure  better 
care for these  patients  (box 2). 
13 
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Figure 1    Number  of publications on pulmonary  hypertension per annum  since  1970 (grey bars)  with moving average (blue line). 
Less  than 1% (0.7%) of the publications were from Africa (not displayed). Title search terms  in PubMed were ‘pulmonary 
hypertension’, ‘pulmonary arterial hypertension’ or ‘pulmonary venous hypertension’ and Africa and  African country names; 
results  are displayed annually  between 1970 and 2013. 
PH.22         Once  definitive  assessment  and  treatment  has 23METHODS AND ANALYSIS 
Study design and setting 
The  PAPUCO  research  group   was established  in  2011 
with  the   aim  of  implementing  a  registry-type  cohort 
study on  PH in Africa. The  registry aims to recruit  con- 
secutive  patients   (1)   with  newly  diagnosed  PH-based 
clinical and  ECHO  criteria,  (2)  who are able or likely to 
return  for  a  6-month   follow-up,  (3)   who  are  at  least 
18 years old  (except for  those  in  paediatric centres   in 
Mozambique and  Nigeria)   and  (4)  who  consented in 
writing to participate in the registry. Centre  eligibility 
includes  (1)  availability of ECHO  and  training  in asses- 
sing right  heart  function, (2)  experience in  diagnosing 
PH according to the  WHO classification,  (3)  experience 
in  clinical  management of  patients   with  RHF  and  (4) 
resources  to review patients  at 6-month  follow-up. 
Participating centres  will be invited to join the  registry at 
African cardiac  meetings  and conferences. 
been  applied,   the  following  specific  data  will be  docu- 
mented for each  individual:  (A) all major  cardiovascular 
diagnoses  according to the International Classification of 
Diseases (ICD) 10 coding, and (B) up to five non- 
cardiovascular  diagnoses  according to ICD 10 coding.24
Figure  3 shows the  diagnostic  algorithm to diagnose  PH 
in  resource-constraint  settings   without   access  to  right 
heart  catheterisation that  has been  developed following 
the  ESC/ERS  guidelines  for the  diagnosis  of PH.22  Key 
information collected  will include  information on demo- 
graphic  profile,  socioeconomic background, medical 
history, comorbidities, cardiac  risk factors  and  environ- 
mental  exposures. The  clinical aspects of the  assessment 
include  symptom scoring, a full clinical examination, 
physical  and  clinical  status;  functional tests include  the 
WHO  functional  class  (WHO   FC),  a  6 min  walk  test 
(6MWT)    and    the    Karnofsky    Performance   Score. 
Technical procedures include  ECHO, CXR and a 12-lead 
ECG. Further investigations  are  at the  discretion of the 
treating  physician  and  typically  include   lung  function 
tests,  ventilation/perfusion  lung  scans,  high  resolution 
CT and CT pulmonary angiography, and right heart  cath- 
eterisation, if available ( figure  3).  Data  on  heart  failure 
treatment and  co-medication, hospitalisation and  death, 
and 6-month outcome will also be collected. 
Definition of PH, diagnostic algorithm and data points 
As shown in box 3, PH is defined as documented elevated 
RVSP>35 mm Hg on transthoracic ECHO  in the absence 
of pulmonary stenosis and acute  RHF, usually accompan- 
ied  by shortness  of breath, fatigue,  peripheral oedema 
and  other   cardiovascular   symptoms,  and  possibly  ECG 
and  chest  X-ray (CXR)  changes  in  keeping  with PH  as 
per  the  European Society of Cardiology  and  European 
Respiratory  Society  (ESC/ERS)  guidelines   on  PH.5 22 Echocardiography 
Echocardiography in adults 
ECHO    modalities    applied    included   M-mode,    two- 
dimensional (2D)  and  Doppler   studies.  ECHO  will be 
Right   heart   catheterisation  is  optional.  The   updated 
WHO classification  system for PH (Dana  Point 2008) will 
be   applied    to   describe    the   different  aetiologies   of 





Figure 2    The Pan  African Pulmonary hypertension Cohort  (PAPUCO)  map displays countries currently participating  in the 
PAPUCO  registry (number  of centres per country in brackets). 
performed  with  3–5 MHz  sector  transducer.  Complete 
2D ECHO  examination will be  performed according to 
the recommendations of the American  Society of ECHO 
(ASE).25     M-mode   ECHO   will  be   derived   from   2D 
images. The  M-mode cursor  on the 2D scan will move to 
specific   areas   of  the   heart   to   obtain   measurements 
according to the  recommendation of the  committee on 
M-mode  standardisation of the  ASE. Doppler  indices  of 
left ventricular (LV)  diastolic  filling  will be  obtained. A 
complete Doppler  study will be carried  out according to 
the  recommendations  of  the  ASE. From  the  M-mode 
(EF),   and   LV  mass,  cardiac   output  and   relative wall 
thickness.   ECHO   examinations  include    (A)   valvular 
assessment,  (B)  left atrial size, (C)  LV size and  function, 
(D)  a semiquantitative estimate  of the severity of valvular 
regurgitation, (E)  size and  function  of the  right  atrium 
and  the  right  ventricle (RV; figure  4A) and  (F) evidence 
of PH.  Doppler will be  used  to  examine the  valves on 
suspicion  of  any  valvular  lesion.  ECHO  findings   asso- 
ciated  with PH  include  a dilated  pulmonary artery and 
dilation  and  hypertrophy of the  RV, diastolic  flattening 
of the  interventricular septum  and  Doppler  evidence  of 
PH.
26 
Doppler ECHO estimates the pulmonary artery 
systolic  pressure   (PASP).  By measuring  the  maximum 
measurements, indices  of  LV function will be 
These   include    shortening  fraction,    ejection 
derived. 
fraction 




velocity  of  the  tricuspid   regurgitant  jet  (v,  figure  4B), 
the  transtricuspid  pressure   gradient  will be  calculated 
using   the   modified  Bernoulli   equation  (4v²).27   The 
PASP is approximated by adding  the transtricuspid gradi- 
ent  to the  right  atrial  pressure  (RAP)  as applied  in the 
formula   [PASP=4v2+RAP].  The   PASP  is  equivalent   to 
RVSP in the  absence  of pulmonary outflow  obstruction. 
The  RAP is estimated  by the  respiratory variation  size of 
the vena cava inferior  in M-mode.28  In our study, the  sys- 
tolic  regurgitant  tricuspid   flow  will be  assessed  in  the 
parasternal RV inflow,  parasternal short-axis  and  apical 
four-chamber  views to  determine  the   highest   velocity, 
which  reflects   PASP/RVSP.29    PH  is  defined  as  mild if 
RVSP  was  36–50 mm Hg,   moderate   if  RVSP  was  51– 
60 mm Hg and  severe if RVSP was >60 mm Hg.30  In add- 
ition,  we further assessed RV function  by measuring the 
systolic displacement of the  lateral  portion of the  tricus- 
pid  annular  plane   excursion   on  the   M-mode  tracing 
under the  2D-echo  guidance ( figure  4C).31  Peak  mitral 
early  diastolic  velocity (E  in  m/s), the  E-wave  deceler- 
ation  time  (DCT  in  ms)  and  the  velocity at  atrial  con- 
traction  (A  in  m/s) are   measured  using  pulsed-wave 
Doppler.  LV filling pressure  classes were defined in 
accordance with the  ASE 2009 guidelines.32  In  patients 
with heart  failure  and  reduced EF (HFrEF),   raised  LV 
filling  pressure  is defined as E/A  ≥2  if in sinus rhythm 
or DCT <150 ms if in atrial  fibrillation (AF); normal LV 
filling pressure  is defined as E/A  <1 in patients  in sinus 
rhythm   or   DCT   ≥200 ms  for   those   in   AF;  patients 
between  these  limits will be  classified  as undetermined. 
In  heart   failure  and  preserved EF (HFpEF), LV filling 
pressure  is classified as follows: raised  LV filling pressure 
if the  left atrium  is dilated  and  normal LV filling  pres- 
sure if the left atrium  is of normal size. 
Echocardiography in infants and children 
Translating the  definitions of PH  in  adults  to  children, 
especially to infants,  is controversial. Within the  paediat- 
ric cardiology  community, experts  suggest that  the  ratio 
of the  PASP to the  systemic systolic blood  pressure  >0.4 
should be the diagnostic criterion.33 The fact that the 
threshold   of   pulmonary   vascular   resistance    (PVR) 
increase  has  not  been  included in  the  aforementioned 
definition is another limitation  of its use in children or 
infants,    since   paediatric   PH   is   mainly   caused    by 
left-to-right shunt  CHD; and  if PVR shows no significant 
increase  in  such  cases,  the  patient may be  considered 
only as a dynamic  PH case led  by increased pulmonary 
blood flow, rather than  pulmonary vascular disease. 
Paediatric  guidelines  suggest that  mPAP >25 mm Hg and 
PVR>3 Wood units remain in the definition of PAH.34  In 
our  cohort of children with congenital heart  malforma- 
tions, we used not only tricuspid  and pulmonary regurgi- 
tation  envelopes,  but  also the  flow across the  ventricular 
septal  defect  or  persistent ductus  arteriosus  to  measure 
the  gradient between  the  two circulations  and  therefore 
estimate  the  pulmonary pressure.  Indirect signs of PH, 
such  as dilation  of the  RV, RV-hypertrophy  and  dilation 
of the  main  pulmonary artery, were  added   to  Doppler 
data to confirm the diagnosis. 
Accuracy of echocardiography in the diagnosis of PH 
Diagnosing  PH  is challenging when  relying  on  bedside 
tests. RHC is the  gold standard to diagnose  and  confirm 
PH, but  performing RHC on  all patients  with dyspnoea 
would bear excessive risks and be impractical  in any cost- 
constrained environment. Also, RHC is only available at 
very few centres  in Africa. A viable device to diagnose  PH 
in Africa needs  to be widely available, accurate, safe and 
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Box 2   The significance of pulmonary hypertension (PH) 
in Africa: Why we need to diagnose? 
The right to know. 
Prognostic implications. 
Access to tertiary care: heart failure management, 
anticoagulation, home oxygen, chronic obstructive pulmonary 
disease  manage- ment, access to PH-specific drugs (sildenafil). 
Access to cardiothoracic surgery: valve repair/replacement, cor- 
rection of congenital heart disease, heart transplantation. 
Access to social and disability grants. 
To raise awareness of PH and its risk factors. 
Box 3   Evidence to diagnose pulmonary hypertension in 
resource-constraint settings 
Symptoms:  shortness   of  breath,  fatigue,  cough,  chest  pain, 
palpitations. 
Clinical examination: raised  jugular  vein  pressure,  peripheral 
oedema, ascites, loud p2, systolic murmur, central cyanosis. 
ECG:  sinus tachycardia, p-pulmonale, right axis deviation, right 
bundle branch block, right ventricular hypertrophy. 
Chest X-ray: cardiomegaly,  pleural effusion, prominent pulmonary 
arteries. 
Echocardiography: dilated right atrium and ventricle, interventricu- 
lar    septal    flattening,   right    ventricular   systolic    pressure 
>35 mm Hg, tricuspid annular plane systolic excursion <15 mm 
( figure 4).
Box  1   Pan   African  Pulmonary  hypertension  Cohort 
(PAPUCO) objectives 
Primary objective 
To describe disease presentation, disease severity and aetiologies 
of pulmonary hypertension (PH), comorbidities, diagnostic and 
therapeutic management, and the natural course of PH in Africa. 
Secondary objectives 
To describe the overall 6-month survival rate. 
To   describe   the   24-month   survival  rate   in   patients   with 
HIV-pulmonary arterial hypertension. 
To  compare 6-month survival rates between different groups of 
PH. 
To  determine the  predictors  of  mortality access  the  different 
groups. 
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Figure 3    Diagnostic  algorithm to diagnose pulmonary  hypertension in resource-constraint settings. PH, pulmonary 
hypertension; TB, tuberculosis; PCP,  pneumocystis pneumonia; COPD,  chronic obstructive pulmonary  disease; LHD, left heart 
disease; ECHO, echocardiography; US, ultrasound; LFT, liver function tests; HRCT, high-resolution CT; CTEPH,  chronic 
thromboembolic pulmonary  hypertension; CTPA, CT pulmonary  angiography; V/Q, ventilation/perfusion lung scan. 
cause  a  laminar   flow  which  invalidates   the   Bernoulli 
equation; (3)  volume status and  systemic blood  pressure 
cost-effective. ECHO has become  increasingly available in 
Africa and  reliably allows the  measurements to describe 
are  other  factors that  potentially  influence the  measure- 
ment  of PASP and  (4)  the  highest  value of RAP in  the 
ASE guidelines  is 15 mm Hg, but RAP measured by RHC 
can exceed  15 mm Hg. In spite of all these shortcomings, 
several studies have been  published in the literature dem- 
onstrating the  good  sensitivity and  specificity of ECHO 
functional  and   morphological  features   of  PH  and   to 
indirectly measure the pressures  in the pulmonary artery; 
hence, to diagnose  PH. Nonetheless, the  exact measure- 
ments  of the mean  and systolic pulmonary artery are not 
possible,  the  PASP remains  an  estimate,  and  the  use  of 
ECHO  to  diagnose  PH  questionable.35        A number  of 
possible  explanations  for  this  ‘inaccuracy’  merit  atten- 
tion: (1) conditions for a reproducible calculation of 
PASP/RVSP include  the  presence of sufficient  tricuspid 
regurgitation (TR)  to produce a Doppler envelope  and 
appropriate gain adjustments. An ‘undergained’ spectral 
signal will tend  to result in underestimated PASP, whereas 
an ‘overgained’ spectral signal might overestimate the 
measurements; (2)  careful  adjustment of the  transducer 
position and the use of colour flow Doppler  are critical in 
order   to  reduce the  Doppler   angle  and  to  obtain  the 
maximal   regurgitant  flow  velocity  and   severe  TR  will 
36
RHC.37–39 versus In  the  REVEAL registry,  there   was a 
good  correlation in  PASP between  ECHO  and  RHC  at 
baseline,  even  if repeated ECHO  measurements alone 
were not  sufficient  to monitor changes  in PASP or  pro- 
gression   of  PH.40   In   the   first   systematic  review  and 
meta-analysis   addressing   the    diagnostic    accuracy   of 
ECHO in PH by Janda et al41, the authors  concluded that 
the  correlation of PASP by ECHO  compared with PASP 
by RHC was good with a summary correlation coefficient 
of 0.70 (95%  CI 0.67 to 0.73). Also, the  authors  showed 
that  the  diagnostic   accuracy  of  ECHO  in  PH  was also 
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Figure 4    Diagnosing pulmonary  hypertension using transthoracic two-dimensional Doppler echocardiography. 
(A) Four-chamber view showing  grossly  enlarged RV and  RA; with right ventricularisation of the LV, and bulging of the RA into 
the LA; (B) Colour-wave and continuous-wave Doppler across the TV in the four-chamber view showing  severe TR, despite the 
deceivingly  less  impressive colour-flow jet seen across the valve; (C) M-mode measurement of TAPSE  depicting  right ventricular 
systolic dysfunction;  (D) Long-axis  view of right ventricular  apical thrombus. RA, right atrium; RV, right ventricle; LA, left atrium; 
TV, tricuspid valve; TR, tricuspid regurgitation;  TAPSE,  tricuspid annular  plane  excursion. 
 
acceptable with a summary  sensitivity and  specificity  of AD,  KS, AOM)  for  completeness  and   data   validated. 
Query reports  will be sent to the sites and resolved by the 
site investigators.  If consensus  on the  WHO classification 
of PH cannot be reached, a third  investigator’s  opinion 
will be  requested. Data  will then  be  verified and  trans- 
ferred  to SPSS Statistics V.17.0 for all analyses by an inde- 
pendent team  at  Preventative  Health,  Baker  IDI  Heart 
and  Diabetes  Institute,   Melbourne, Australia.  Normally 
distributed continuous data  will be  presented as mean 
±SD and  non-Gaussian   distributed variables  as median 
+IQR. Categorical  data  will be presented as percentages 
with 95% CI where  appropriate. For patient group  com- 
parisons,  we will use χ2   analysis with calculation of ORs 
and  95%  CI (where  appropriate) for  discrete  variables 
and  Student t test and  analysis of variance  for normally 
distributed continuous variables. Multiple  logistic regres- 
sion  analyses (entry model) will be  performed on  age, 
sex and  baseline  risk factors to derive  adjusted  ORs for 
the risk of presenting with PH/RHF overall, chronic lung 
disease  and   PH  WHO  Group   1.  Significance   will be 
accepted at the  two-sided level of 0.05. ECG analysis will 
be subject to blinded coding  according to the  published 
Minnesota     criteria    to    determine   any    pathological 
83% (95%  CI 73% to 90%)  and  72% (95%  CI 53% to 
al42 85%),   respectively.  Additionally,   Damy  et demon- 
strated  in their  recent work that PASP when measured in 
‘good  ECHO  hands’  is a strong  predictor of mortality. 
Last  but  not   the   least,  easily  obtainable  ECHO   para- 
meters  like the  E/A  ratio,  DCT and  LA size can  reliably 
distinguish  between  PH due  to lung disease and  PH due 
to  left  heart   disease,  allowing  for  the  rapid   triage  of 
patients  with a need  for RHC. In summary, ECHO  is far 
beyond a good  modality  to  confirm both  the  presence 
and  aetiology  of PH  in  the  majority  of suspected  cases 
when performed and interpreted by the requisite  expert- 
ise  under  incorporation  of  all  information  obtained 
during  a detailed ECHO  assessment.  ECHO  will always 
provide  incremental information in  PH  that  cannot be 
obtained using  RHC, whether  in developed or develop- 
ing countries. 
Data cleaning process and statistical analysis 
All study data will be collected  on electronic case report 
forms and stored  on a dedicated secure  central  database. 
Cases will be  reviewed  by at  least  two investigators  (FT, 




abnormalities.43  We aim to adhere to the  Strengthening 
the  Reporting of Observational Studies  in Epidemiology 
disease will be published after recruitment and follow-up 
has  been  completed.  Laboratory-based research  will be 
published after the work is completed. (STROBE)   guidelines   for  this 
possible.44
type  of  study  wherever 
The online data collection platform 
A tailor-made database  has been  developed by integerafrica 
research  and  development  to  fulfil  the  study requirements. 
Open-source  technology   was used  to  develop  the  web- 
based   system  that   allows  investigators  to  collect,  store, 
analyse, report on and  export  clinical research data.  The 
interface is simple  and  user-friendly and  leads  the  user 
through the  data  entry  process.  It  anonymises  personal 
patient  data:  data  are  stored   as  electronic  case  report 
forms on a secure, encrypted and backed-up  server. It pro- 
vides hierarchical permissions  and  validation at the  point 
of data  entry.  Multimedia  data  formats,  that  is, scans  of 
ECGs, CXRs and  ECHO  images, can be uploaded on the 
platform,  allowing the storage of complete clinical records 
and  data together. Tools for education, training and  com- 
munication are installed  within the web-portal. Frequently 
Asked Questions  serve as a guide  on how to use the  plat- 
form.  After secure  login,  documents such  as paper  case 
report forms, informed consent  forms, study information 
sheets  and  patient education sheets  on  PH  are  available 
for download.  All data can be exported in various formats 
for further analysis. The  platform  has been  developed to 
cater  for  mobile  internet connectivity available  in  most 
parts of Africa and a unique research platform  far beyond 
a simple web-based database. 
PAPUCO substudies 
Several   substudies   have   been established  within   the 
PAPUCO registry. The  ECHO  substudy aims to describe 
in detail the ECHO characteristics of RV function  in PH. 
The  HIV-PAH substudy  aims to describe  the  phenotype 
of  HIV-PAH in  Africa. The  CHD  and  RHD  substudies 
aim  to  describe  the  contribution of CHD  and  RHD  to 
PH  in  Africa.  In  addition,  serum   will be  collected   at 
selected   centres   for  studies  on  the  biomarker  profile. 
The HIV.INFLAME substudy aims to examine the role of 
inflammatory markers  and  oxidative  stress on  the  devel- 
opment of  HIV-PAH. We hypothesise   that  HIV-positive 
patients   with  PH   have  a  proinflammatory  state   and 
raised markers  of oxidative stress compared with healthy 
HIV-positive controls  and that increased markers  of 
inflammation and  oxidative stress and decreased antioxi- 
dant  capacity  are  predictors of outcome and  indicators 
of disease severity. 
Ethics and dissemination 
All PAPUCO centres  require ethical  approval  from  their 
local  ethics  committee review board.  Written  informed 
consent must  be obtained from  every patient participat- 
ing in the registry. 
Study  results   will  be  disseminated  in  peer-reviewed 
journals.  The  first publication will include  baseline  and 
6-month  follow-up data from  all centres.  Substudy publi- 
cations  on  the  HIV  cohort with  a  24-month   follow-up
Recruitment process 
Twelve centres  have received  ethics approval  and are cur- 
rently  recruiting actively; an additional six countries are 
registry  ( figure  2). and the cohort of patients with PH due to left heart showing interest in joining the All 
patients; X
1
, patients have  to cover the costs for the service (out of pocket  payments). 
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Table  1    Medical infrastructure at PAPUCO  centres—diagnostic equipment and medical  services 
Centre   ECG CXR   ECHO RHC  CS  HRCT  CTPA LFT  V/Q  Lab 
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SA01  X  X X X   X  X  X  X  X  X 
SA02  X  X X X  X  X 
CM01, Douala  General Hospital, Douala,  Cameroon; CM02, Cardiac  Centre, Shisong Hospital, Kumbo, Cameroon; CM03, Douala 
Cardiovascular Centre, Douala,  Cameroon; CS, cardiac  surgery;  CTPA, CT pulmonary  angiography; CXR, chest X-ray; ECHO, 
echocardiography; HRCT, high-resolution CT; Lab, laboratory  facility for haematology, chemistry, and microbiology; LFT, lung function tests; 
MZ01, Instituto Nacional  de Saúde, Maputo, Mozambique; MZ02, Division of Cardiology,  Maputo Central  Hospital, Maputo, Mozambique; 
NG01, Department of Medicine, Federal Medical Centre, Abeokuta, Nigeria; NG02, Department of Medicine, Bayero  University and  Aminu 
Kano Teaching Hospital, Kano, Nigeria; NG03, Department of Medicine, College  of Medicine, Lagos,  Nigeria; NG04, Department of Medicine, 
University of Uyo Teaching Hospital, Uyo, Nigeria; NG05, Federal Medical Centre, Umuahia, Nigeria; RHC, right heart  catheterisation; SA01, 
Division of Cardiology,  Department of Medicine, Groote  Schuur Hospital, University of Cape Town, Cape Town, South  Africa; SA02, Infectious 
Diseases Referral  Clinic, GF Jooste Hospital, Mannenberg, South  Africa and  Rapid Assessment Unit, Khayelitsha District Hospital, 








Figure 5    Pan  African Pulmonary hypertension Cohort  (PAPUCO)  registry—monthly enrolment until December 2013.  Number  of 
patients recruited  per month since  the launch  of the registry in May 2011. 
centres   are   government-run  public   healthcare  institu- 
tions  with different medical  infrastructure profiles,  and 
all but one  are cardiac  centres  within tertiary care hospi- 
tals (table 1); one  centre is an  infectious  diseases refer- 
ral  clinic  in  South  Africa. A total  of 254 patients  have 
been  recruited until December 2013 ( figure  5). 
development in  the  healthcare sector.  It  interconnects 
health  centres  far beyond PH. 
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LIMITATIONS 
The  PAPUCO  registry  is an  example   of  a  functioning 
registry   in   low-resource    settings.    Limited    resources 
should  therefore not  be seen  as a limitation,  but  rather 
as a development opportunity. PAPUCO centres  have 
different  levels  of  medical   infrastructure  but   not   all 
patients   will undergo the  same  rigorous  workup  in  all 
centres,  especially when compared with developed coun- 
tries.  Therefore, the  clinical  skills of the  treating phys- 
ician are  often  more  important (and valuable!)  than  an 
additional diagnostic  test in order  to pin  down the  aeti- 
ology of PH  in a patient. Moreover,  patients  often  have 
to pay out of their  pocket  for diagnostic  tests, and  there- 
fore  accessibility to  tests is limited  due  to  the  financial 
means  of the  patient. Although  we aim  for consecutive 
patient enrolment at  each  centre, we understand  that 
this is often  not  feasible due  to the  high  patient volume 
and workload of doctors. 
SUMMARY 
PAPUCO  is  a  contemporary registry  on  PH  in  Africa 
using  high  international  standards to  diagnose   PH.  It 
will provide  new insight  on  PH in Africa and  ultimately 
improve  diagnosis   and   care   of  patients.   PAPUCO   is 
already  a showcase for registry  activities in Africa and  a 
vehicle to capacity generation and sustainable 
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3.5. Handling of missing data 
Missing data is a challenge in studies with longitudinal follow-up. In a review of cohort studies, 
it was found that the majority of studies included at least 10% of participants with some 
missing data and the amount of missing data ranged from 4 to 80% with a median of 25% 
(142). To overcome this both in the THESUS-HF and the PAPUCO registry, investigators 
systematically tracked all patients. Furthermore, in the PAPUCO study, a patient was 
considered loss to follow up only if he (or his next of kin) did not responded to telephone after 
more than 15 attempts on 3 different days. Also, data was rigorously cleaned and a query 
addressed to investigators in case of missing values. For variables that were insufficiently 
collected, there were theoretically two options to handle them. First, imputation of missing 
data; Second, excluding participants with missing data from analysis. In the THESUS-HF, 
multiple imputation was used while for the PAPUCO study we excluded participants with 
missing data in the analysis.  
 
In the next four chapters we present the results of this PhD thesis in terms of condensed 
publications when the paper is under review in a peer-review journal or in terms of 
publications in peer-reviewed journals when already published. 
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Chapter 4. Baseline characteristics and outcome 
of patients with pulmonary hypertension in 
Africa: results of the Pan African Pulmonary 
hypertension Cohort study (PAPUCO). 
4.1. Introduction 
Chapter One of this thesis revealed that the epidemiology of pulmonary hypertension (PH) in 
Africa has yet to be fully characterized, although limited reports suggest that the incidence of 
PH in Africa is higher than that from high income countries, owing at least in part to the 
distinctively high prevalence of some risk factors of PH in the region (10, 110, 143) . Indeed, 
many known risk factors for PH are hyper endemic in Africa, including Human 
Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), rheumatic heart 
disease (RHD), hereditary hemoglobinopathies, schistosomiasis and other parasitic infections, 
and chronic hepatitis B and C infection. On one hand, a high prevalence of tuberculosis (TB), 
poorly treated asthma, high levels of pollution in urban areas and exposure to mining, may 
subsequently lead to various forms of pulmonary disease, PH and, often, to right heart failure 
(HF) with premature death. Furthermore, the high prevalence of RHD and endomyocardial 
fibrosis, the latter possibly also due to the high burden of parasitic infections, may contribute 
to secondary PH (144). On the other hand, Africa is in epidemiological transition with 
increased prevalence of non-communicable forms of heart disease such as hypertensive and 
ischemic heart disease. Left heart disease is the most common cause of heart failure in Africa 
and most likely a major contributor to PH and consecutive right HF (110, 118).  
In this section we present data from the Pan African Pulmonary Hypertension Cohort 
(PAPUCO) study documenting the characteristics of PH in Africa, with a specific focus on the 
distribution of aetiologies of PH on the continent. 
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4.2. Methods 
The methods relevant for this chapter has been described in details in Chapter 3. Below we 
focus on the statistical analysis for the data presented in the results section. 
Statistical analysis 
Data was transferred to SPSS Statistics 20.0 for all analyses. Continuous variables are 
presented as mean ± standard deviation or median (25th - 75th percentile), and categorical 
variables as percentages with the accompanying 95% confidence intervals (CI) where 
appropriate. Group comparisons used chi square (χ2) or Fisher exact test for categorical 
variables and Students t-test and analysis of the variance (ANOVA) or equivalent non-
parametric tests (Kruskal-Wallis test) for continuous variables. To assess the predictors of 
mortality in the overall cohort, logistic regression was initially performed in a univariable 
analysis for each variable; then in an age and sex adjusted multivariable regression analyses 
with all variables in the model. Predictors entered into the model included distance walked in 
6 minutes (alternatively as a continuous or categorical), TAPSE, RVSP and right HF. A p-value 
< 0.05 was used to characterize statistically significant results.  
4.3. Results 
4.3.1. Study cohort 
At total of 254 patients with newly diagnosed pulmonary hypertension were included in the 
cohort study by 31st December 2013 (Figure 21). Thirty four patients were excluded from data 
analysis due to either not meeting the inclusion criteria, or presence exclusion criteria or 
incomplete data. Eleven patients were below 18 years of age and were also excluded from 
analysis. Overall, 209 patients with newly diagnosed pulmonary hypertension were included 




Figure 21: Flowchart showing the derivation of the overall cohort of 209 adult 
patients with pulmonary hypertension (PH) and the contribution of each center. 
CM, Cameroon; MZ, Mozambique; NG, Nigeria; SA, South Africa.  
4.3.2. Socio-demographic characteristics of the cohort members 
The age of the cohort participants ranged from 19 to 98 years (mean age 48 years), 124 (59%) 
were women, and 203 (97%) African or of Black race (Table 15). 122 (58%) had completed 
only primary education or had no formal education and 63 (30%) lived in non-solid housing 
structures. Compared with men, women were more likely to live below the poverty threshold 
(42% vs. 25%, p=0.012). Table 15 shows the cardiovascular risk profile and co-morbidities of 
the cohort. Six patients had chronic liver disease, four Hepatitis B, one Hepatitis C, and one 
had schistosomiasis. 167 (80%) patients lived in areas endemic for schistosomiasis, 47 (22%) 
had a history of tuberculosis with 10 (5%) being on specific treatment at the time of their 
enrolment. HIV testing was performed in 134 (64%) patients of whom 47 (35%) were HIV-
positive. Women were more likely to be exposed to indoor smoke from cooking or heating 
(without chimney) compared to men (p=0.0001), but men were more likely to be tobacco 
120 
smokers (<0.0001) and alcohol users (p=0.0004). Self-reported recreational drug abuse was 
rare (Table 15). 
Table 15: Socio-demographic characteristics and risk factor profile of 209 adults (≥18 









Median age, years (25th-75th percentiles) 48 (19-98) 54 (19-98) 43 (20-91) 0.094 
African or black race 203 (97%) 83 (98%) 120 (97%) >0.999 
Education 
Completed only primary education 









Income <30 USD per month 73 (35%) 21 (25%) 52 (42%) 0.012 
Housing conditions  










Risk factor profile 
Cardiovascular risk factors 























Chronic liver disease* 






















Chronic infectious diseases 
Previous* or concurrent tuberculosis 
Concurrent tuberculosis 
HIV testing performed 

















Exposure to smoke and recreational drugs 
Indoor cooking/heating without 
chimney 
History of smoking 
Alcohol abuse 

















Data are presented as number (%) except for age presented as median (25th-75th percentiles). 
*diagnosed condition prior to presentation. Abbreviations: USD, US dollar; CVD, cardiovascular




4.3.3. Clinical characteristics 
Table 16 summarizes important clinical findings. The most prevalent symptoms were 
shortness of breath (93%), fatigue (88%), palpitations (73%), and cough (60%). Women were 
more likely to experience dizziness compared to men (37% vs. 22%, p=0.0382). 66% of our 
cohort presented at WHO FC III or IV. The median Karnofsky performance Score was 70 (25th-
75th percentiles: 50-80) and 71 (34%) patients could not walk further than 300 meters. Clinical 
parameters such as body mass index (BMI), heart rate, respiration rate, pulse oxymetry were 
similar in men and women. Systolic murmurs (n=119, 57%) and loud P2 (n=86, 41%) were the 
common pathological heart sounds.  
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Symptoms at presentation 








































WHO functional class (FC) 
WHO FC I/II 
WHO FC III 













Karnofsky Performance Score 70 (50-80) 70 (60-80) 65 (50-80) 0.403 
Distance walk in 6 minutes 252 (120-350) 275 (110-351) 234 (120-345) 0.803 
6MWT <300 meters 71 (34%) 25 (29%) 51 (41%) 0.107 







Heart rate at rest (beats per min) 91 (76-100) 90 (72-98) 93 (80-102) 0.170 
Systolic blood pressure (mmHg) 120 (108-133) 121 (110-137) 117 (107-130) 0.046 
Diastolic blood pressure (mmHg) 77 (68-86) 78 (70-89) 76 (67-86) 0.130 
Respiration rate at rest (breaths per min) 24 (20-29) 24 (20-28) 25 (20-30) 0.555 












Data are presented as number (%) or median (25th-75th percentiles); *diagnosed condition 
prior to presentation. Abbreviations: WHO FC, World Health Organization functional class; 
6MWT, 6-minutes’ walk test. 
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4.3.4. Electrocardiographic, echocardiographic findings and signs of right heart failure 
at baseline  
On electrocardiogram, 30 (14%) patients presented with atrial fibrillation, 48 (19%) with left ventricular 
hypertrophy and signs of right ventricular strain occurred in 30 (14%) and 39 (19%) for P-pulmonale and 
right ventricular hypertrophy respectively (Table 17). The median left ventricular ejection fraction was 
46% (25th-75th percentiles: 35-65%), RVSP was 58 mmHg (25th-75th percentiles: 49-74 mmHg), and 
tricuspid annular plane systolic excursion (TAPSE) 13 mm (25th-75th percentiles: 11-17 mm). TAPSE was 
decreased (<15 mm) in 92 (44%) of patients. 78 (37%) presented in heart failure, defined as TAPSE <15mm 
and at least one clinical sign of heart failure (raised JVP or peripheral oedema). The median RVSP was 58 
mmHg (25th-75th percentiles: 49-74 mmHg), and tricuspid annular plane systolic excursion (TAPSE) was 13 
mm (25th-75th percentiles: 11-17 mm). Echocardiographic findings and signs of right are presented in 
Table 17 below, and were mostly similar in men and women. 
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Right ventricular hypertrophy 





































Median LVEF (%) 
Median RVSP (mmHg) 













TAPSE <15 mm** 92 (44%) 35 (41%) 57 (46%) 0.570 
Signs of right heart failure at baseline 
presentation 
Raised JVP 150 (72%) 63 (74%) 87 (70%) 0.639 
Peripheral edema 134 (64%) 61 (72%) 73 (59%) 0.058 
Raised JVP or peripheral edema 174 (83%) 75 (88%) 99 (80%) 0.132 
Diagnosis of right heart failure*** at baseline 
presentation 
78 (37%) 33 (39%) 45 (36%) 0.771 
JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; RVSP, right ventricular systolic 
pressure; TAPSE, tricuspid annular plane systolic excursion. **TAPSE was assessed in 160/209 (77%) of 
patients. ***Right heart failure was diagnosed in patients meeting the following criteria: TAPSE <15 mm 
and at least one clinical sign of right heart failure (raised JVP or peripheral oedema). 
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4.3.5. Classification of pulmonary hypertension 
Figure 22 below displays the distribution of our cohort by sex and by main groups of PH. In all, 34 (16%) 
were classified as Group 1: Pulmonary arterial hypertension. Table 18 provides details on the subgroup 
classification. HIV-associated PAH was the most common cause of PAH in Group 1 (n=17; 8%). 144 (69%) 
cases were classified Group 2: Pulmonary hypertension due to left heart disease (PH-LDH). Left ventricular 
systolic dysfunction was the most frequent cause of PH-LDH (n=80; 38%). 23 (11%) patients were 
diagnosed Group 3: Pulmonary hypertension due to lung disease and/or hypoxia. Tuberculosis-associated 
obstructive pulmonary disease (TOPD) was the most frequent cause of lung disease in our cohort. Four 
cases (2%) were classified Group 4: Chronic thromboembolic pulmonary hypertension and, again, 4 cases 
(2%) Group 5: Pulmonary hypertension with unclear multifactorial mechanisms. 
 
Figure 22: Distribution of main groups of pulmonary hypertension by sex 
PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; PH-LD (LHD): PH due to lung disease 
(left heart disease); CTEPH: Chronic thromboembolic pulmonary hypertension. 











Table 18: Subgroup classification of pulmonary hypertension 
Number Percentage 
Group 1: Pulmonary arterial hypertension (PAH) 
Idiopathic PAH 
HIV-associated PAH 
Congenital Heart Disease associated with PAH 











Group 2: Pulmonary hypertension due to left heart disease (PHLHD) 
Left ventricular systolic dysfunction 










Group 3: Pulmonary hypertension due to lung disease and/or hypoxia 
Chronic obstructive pulmonary disease 







Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH) 4 2% 
Group 5: Pulmonary hypertension with unclear multifactorial mechanisms 
Systemic disorders: vasculitis 







Data are presented as number (%). Abbreviation: HIV, Human Immunodeficiency Virus. 
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Table 19, we compare the clinical findings between the three major groups of PH. Patients in group 1 
(PAH) were the youngest (median age 36 years) and those in group 2 (PH-LHD) were the oldest (median 
age 53 years). Female sex predominance was also noted in these two groups while patients in group 3 
(PH due to lung disease) were more likely to be men and presented at a more advanced stage of the 
disease (87% in WHO functional class III/IV and median Karnofsky score = 70%). Group 1 exhibited the 
highest RVSP (median RVSP = 71 mm Hg) compared to group 2 and 3 (median RVSP = 58 and 59.5 mm Hg 
respectively). Lowest left ventricular ejection fraction was seen in group 2 (median EF = 40%), meanwhile, 
there was no difference in distance walked in 6 minutes nor in TAPSE between the three groups. 
 
128 













Age (years) 36 (20-69) 53 (19-98) 43 (21-91) <0.001 
Female (%) 22 (65%) 85 (59%) 10 (43%) 0.261 
WHO FC III/IV 17 (50%) 107 (74%) 20 (87%) 0.004 
Karnofsky Performance Score 80 (62.5-90) 70 (60.0-80.0) 70 (50.0-80.0) 0.033 
Distance walk in 6 minutes 315.0 (120-401.3) 240 (120.0-
345) 
298.0(132-320) 0.777 
Distance walk in 6 minutes <300 meters, n(%) 8 (23.5) 37 (25.6) 6 (26.1) 0.862 
Echocardiography 
Median LVEF (%) 











Median TAPSE (mm) 14.5 (8.5-19.5) 13 (10-16) 12.5(11-18.5) 0.996 
TAPSE <15 mm** 14 (50%) 65 (61.3%) 12 (60.0%) 0.601 
Signs of heart failure at baseline presentation 
Raised JVP 21 (63.6%) 105 (75%) 18 (81.8%) 0.267 
Peripheral edema 17 (50%) 97 (67.4%) 15 (65.2%) 0.699 
Raised JVP or peripheral edema 27 (79.4%) 121 (84.0%) 20 (87.0%) 0.132 
Diagnosis of right heart failure*** at baseline 
presentation 
12 (44.5%) 54 (50.5%) 10 (50.0%) 0.485 
Data are presented as number (%) or median (25th-75th percentiles) except for age (minimum-maximum); 
Abbreviations: PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; LHD, left heard disease, LD, 
lung disease; WHO, World Health Organization; FC, functional class; 6MWT, 6-minutes’ walk test; LVEF, left 
ventricular ejection fraction; RVSP, right ventricular systolic pressure; TAPSE, tricuspid annular plane systolic 
excursion. ***Right heart failure was diagnosed in patients meeting the following criteria: TAPSE <15 mm and at 




4.3.6. Clinical management 
Prescription rates for Angiotensin Converting enzyme inhibitors/Angiotensin receptors blockers, beta 
blockers and digoxin showed a significant difference between the three groups and were especially higher 
in patients with PH-LLHD. Contrarily, prescription rates of calcium channel blockers targeting PH were 
higher in group 1 and 3, while there was no difference in prescription rates for anticoagulants and 
phosphodiesterase 5 inhibitors. Prescription rates of calcium channel blockers for systemic blood 
pressure lowering therapy also demonstrated a difference between groups with higher rate in PH-LHD. 
Medication use is presented in Figure 23. 
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Figure 23: Pharmacotherapy according to pulmonary hypertension (PH) group in 209 sub-
Saharan Africa patients with PH in the PAPUCO registry 
ACEI: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptors blockers; CCB: Calcium 
channel blockers; PED5i: Phosphodiesterase 5 inhibitors; PH: pulmonary hypertension. * indicates p 
value < 0.05; ** indicates p-value < 0.001.


















4.3.7. Follow-up and outcomes 
Survival data at 6-month of follow-up was available for 91% of patients (189/209). In addition, 110 
patients were followed up until data lock (31st December 2013). Median survival was 8.6 months (25th-
75th percentiles: 6-15.2). 60/209 (29%) were reported dead. The Kaplan Meier curve for the overall 
cohort, for WHO functional class (I/II and II/IV), for PH groups 1, 2 and 3 and for hemodynamic grading 





Figure 24: Kaplan Meier curves for survival by group in the PAPUCO registry. 
Overall cohort (4a), by WHO functional class (4b), by PH groups 1, 2 and 3 (4c) and by PH hemodynamic grading (4d). 
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4.3.8. Predictors of mortality 
In univariable analysis, none of the variables including age, sex, and distance walked in six 
minutes, RVSP, TAPSE were predictors of mortality. In an expanded multivariable analysis, 
with all the variables entered into the equation, only right heart failure [OR 3.501, CI (1.023 – 
11.984), p= 0.046], but not RVSP [OR 1.022, CI (0.997 – 1.046)] and not TAPSE [OR 1.005, CI 
(0.926 – 1.091)] was an independent predictor of mortality (Table 20). 
Table 20: Multivariable analysis predicting mortality in the overall pulmonary 
hypertension cohort from the PAPUCO registry  
Variables Univariable analysis Age and sex adjusted multivariable 
analysis 
Odd ratio (95% CI) Odd ratio (95% CI) 
Age 1.008 (0.992 – 1.025)  0.698(0.229 – 2.129) 
Sex 1.205 (0.641 – 2.265) 0.990(0.958-1.022) 
Distance walk in 6 
minutes 
0.997 (0.994 – 1.000) 0.998 (0.994-1.002) 
RVSP 1.012 (0.997 – 1.028) 1.022 (0.997 – 1.046) 
TAPSE 0.960 (0.901 – 1.023) 1.005 (0.926 – 1.091) 
Right heart failure** 0.537 (0.260 – 1.106) 3.501(1.023 – 11.984) 
RVSP: right ventricular systolic pressure; TAPSE: tricuspid plan annular excursion; **Right 
heart failure was diagnosed in patients meeting the following criteria: TAPSE <15 mm and at 
least one clinical sign of right heart failure (raised JVP or peripheral oedema). 
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4.4.  Discussion 
The Pan African Pulmonary Hypertension Cohort (PAPUCO) represents the largest registry-
type cohort study in patients diagnosed with PH ever conducted in Sub-Saharan Africa. It was 
designed to prospectively collect newly diagnosed cases of PH. Cases were collected between 
June 2011 and December 2013 and classified according to the updated Dana Point 
classification (53). At the data lock-point of the first phase of the registry 2013, 254 incident 
cases of PH were included and 220 patients analysed after a rigorous review process as pre-
specified in the protocol to ensure highest data quality. An important difference between this 
registry and previous national or multinational registry designs is the broadening of the 
enrolment criteria to include patients of all groups of PH.  
4.4.1. The distribution of PH aetiologies  
The characterization of the multiple aetiologies of PH in Africa is leading to major advances in 
the understanding of this disease. We suspected that many known risk factors for PH that are 
hyper endemic in Africa including HIV/AIDS, rheumatic heart disease, hereditary 
haemoglobinopathies, schistosomiasis, other parasitic infections, and chronic hepatitis B and 
C infection were the primary cause of PH. This could be confirmed only partially. HIV/AIDS 
contributed to 17 cases (8%) accounted for a sizable proportion of PH in our cohort, although 
almost three times more patients were HIV-infected. Therefore, in Sub-Saharan Africa, the 
epicentre of the HIV epidemic, HIV should be considered more as co-morbidity than causative 
factor for PH, especially in the context when other risk factors of PH related to 
immunosuppression such as tuberculosis are present. In fact, most patients in Group 3 LH-
LHD where found to have tuberculosis as the potential cause of PH, an expected finding for 
an endemic region for tuberculosis with disease notification rates reaching 1,500 per 100,000 
population per year (145). In our study, PH-LHD was the most common type of PH, in line with 
existing reports, although studies on comparable prevalence amongst different groups of PH 
are lacking. Indeed, most existing registries had focus on a single group of PH (2, 146), except 
the European registry COMPERA (147), which is expected to be completed by May 2016 (148). 
The prevalence of PH-LHD in our study is similar to the 67.9% reported in the Armadale 
echocardiography cohort (61). In a large Italian echocardiographic cohort, Enea and 
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colleagues (149) reported that 52.6% had left heart disease, 7.5% lung disease, 1.3% chronic 
thromboembolic pulmonary hypertension, while 10.5% had unknown PH etiology. 
Differences in the prevalence of PH groups between studies are likely due to regional 
differences in the distribution of risk factors for PH, but also to variations in PH classification. 
That heart failure with reduced ejection fraction was the most common cause of PH-LHD in 
our cohort is consistent with the predominance of systolic heart failure in sub-Sahara Africa 
as reported in the THESUS-HF (118). Unlike previous reports in high income countries, our 
results showed that rheumatic valvular heart disease is still a frequent cause of PH in Sub-
Sahara Africa, and this reflects not only the endemicity of the disease in this part of the world, 
but also late diagnosis. Indeed, in the Rheumatic Heart Disease Global Registry (REMEDY), 
Zühlke and colleagues (150) reported that up to 28% of cases present with PH-LHD. 
4.4.2. The clinical profile of patients with PH 
From a clinical standpoint, our findings revealed that PH is likely to affect poorly or 
uneducated women who are exposed to indoor fume.  Moreover, patients presented late as 
illustrated by the high proportion of those with right heart failure, in severe WHO functional 
class (III/IV) and the short median distance on six minute walk tests. There is strong 
epidemiological evidence to support the female preponderance in Group 1 PH and the 
predominance of women particularly observed in "isolated" pulmonary arterial hypertension 
(PAH) (7, 69, 151). It remains unclear why PAH affects more women than men, but one of the 
most likely explanations is the predominance of connective tissue disorders in women, the 
role of sexual hormones as well as autoimmunity  (152). Unlike PAH, one would expect sex 
distribution in other groups of PH to be largely influenced by the epidemiological features of 
the specific predisposing conditions. Yet, the female predominance was still evident in our 
cohort with dominance of left heart disease. The predominance of rheumatic heart disease 
in women (150) only partially accounts for this observation which merits further studies. The 
late detection of PH has been reported by several authors in PAH (69, 153). In the heart of 
Soweto study, Stewart et al reported that 28% of de novo cases of patients present with right 
heart failure (110). The reasons for this late presentation may include worldwide poor 
awareness of PH among physicians and the paucity of symptoms at the initial stage of the 
disease (2), but we cannot rule out some characteristics of health systems in SSA like a poor 
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referral system and socioeconomic issues. We believe efforts towards improving early 
diagnosis of the disease are warranted because at a late stage, response to therapy might not 
be optimal (154). 
4.4.3. Medication and survival 
Medication use in our cohort showed a high prescription rate for loop diuretics and 
spironolactone, a lower prescription rate for calcium antagonists and beta blockers, while 
very few patients were on disease modifying agents and anticoagulation. This medication use 
profile is largely influenced by the predominance of PH-LHD in our cohort. Diuretics are the 
basis of medical treatment for fluid control and relief of congestion, whereas angiotensin-
converting enzyme inhibitors and β-blockers have proven efficacy in improving morbidity and 
long-term survival in patients with heart failure (54). The low uptake of anticoagulants is 
probably justified by difficulties in monitoring the treatment in SSA where limited access to 
high quality medical laboratories is common (155). Spironolactone was highly prescribed for 
its beneficial effect suggesting that endogenous aldosterone has an important role in the 
process of left ventricular remodeling in nonischemic patients with heart failure (156). 
However, in spite of this medication use, mortality rates were high in our cohort, highlighting 
the remaining diagnostic and treatment gaps. It is of note that except sildenafil and high dose 
calcium channel blockers which were essentially prescribed in group 1 and 3 PH of our cohort, 
other drugs approved for pulmonary arterial hypertension are not yet widely available across 
SSA. In addition, even if the hypothesis of targeting PH-LHD using these drugs has been very 
attractive, as described in Chapter 1 of this thesis, the results of randomized trials have been 
largely unsatisfactory.  Regarding the high mortality rate in our cohort, only right heart failure 
was an independent predictor.  In other registries of PH with larger sample and longer follow 
up, authors reported WHO functional class and PH severity to be significantly associated with 
poor outcome (69, 157). In the Armadale cohort (61), PH-LHD was associated with poor 
outcomes compared with other groups after a  mean follow-up of 1060 days.   
We recognize that our study had limitations. First as discussed in Chapter 2, right heart 
catheterization remains the gold standard for diagnosing PH but could not be used in this 
study due to its cost and unavailability in several centers. It shall be noted that, by including 
only patients with RVSP>35 mm Hg in a stable hemodynamic state we have increased our 
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chances of selecting true cases of PH. We did not systematically investigate all cases of PH 
using pulmonary function test which could have been justified to rule out COPD in women 
exposed to indoor fume. Our small sample size and short term follow up might have limited 
our capacity to carefully explore predictors of PH and outcome in this study. Last but not the 
least, the distribution of our data may not be entirely representative of all sub-Saharan Africa, 
as 50% of the patients were from Cameroon and, of nine cardiovascular centers contributing 
to this registry, only one was a rural centre. This limitation has to be understood in the context 
that very few health facilities in African countries have cardiac ultrasonography and 
cardiologists are rare. The contribution of the doctoral candidate has also driven this 
Cameroon dominance in the recruitment. Hopefully, these limitations will be addressed in the 
next phase of the registry, the PAPUCO 2 (123). 
4.5. Conclusion 
Findings from this first PAPUCO registry showed that all PH groups are present on the 
continent with PH-LHD being the dominant group, followed by group 1 and group 3. People 
affected are more likely to be young women who are poorly or uneducated and exposed to 
indoor fume, and they present at an advanced stage of the disease. A high short-term 
mortality was observed, principally driven by the occurrence of right heart failure, despite an 
acceptable use of medications for heart failure. We strongly believe a larger registry is 
warranted, more information on risk factors and specific PH groups profiles will lead to simple 
and affordable intervention studies. This is important to improve the quality of care and well-
being of our patients and reduce the overall impact of disease in resource-constrained 
settings through more effective diagnostic and treatment strategies adapted to SSA. 
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Chapter 5. Pulmonary hypertension due to left 
heart disease: determinants of pulmonary 
pressures, clinical features, echocardiographic 
profiles and outcomes. 
5.1. Introduction 
In Chapter 1 of this thesis, we highlighted the importance of pulmonary hypertension due to 
left heart disease (PH-LHD) as the predominant type of pulmonary hypertension (PH), more 
frequently occurring as a manifestation of left heart systolic or diastolic dysfunction, but also 
to a lesser extend valvular disease. The existing reports have almost exclusively focused on 
selected groups of Caucasian patients with heart failure (HF), few using RHC, but the majority 
using non-invasive assessment of the right ventricular systolic pressure (RVSP) with 
echocardiography. Several studies of HF have reported that, compared with western 
countries, HF in sub Saharan Africa (SSA) populations occurs two decades earlier and is 
predominantly of non-ischemic origin, including some conditions that are now exceptional in 
western countries, but still has a poor prognosis (115, 118, 158, 159). How this particular 
phenotype of HF affects the landscape of PH-LHD and conversely how PH-LHD could influence 
HF prognosis in our region is still unknown, yet this information is needed to assist the 
stratification of patients with PH-LHD risk in daily clinical practice.  
In this chapter, we investigated the determinants of pulmonary pressure, clinical and 
echocardiographic profile, outcome and their predictors in the specific population of patients 
with PH-LHD using the PAPUCO registry. 
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5.2. Methods 
Study design, patients and clinical settings of the PAPUCO study were described in Chapter 2 
of this thesis.  
5.2.1. Definitions of terms 
For all confirmed and enrolled patients with PH-LHD, additional data collection included the 
type of underlying left heart disease. HF with reduced ejection fraction (HFrEF) was defined 
as a clinical syndrome with 1) at least 2 of the following: paroxysmal nocturnal dyspnea, 
orthopnoea, elevated jugular venous pressure, pulmonary crackles, a third heart sound, 
cardiomegaly on chest radiography, or pulmonary edema on chest radiography and 2) in the 
presence of a left ventricular ejection fraction (LVEF) <45%. HF with preserved EF (HFpEF) as 
presence of clinical HF with LVEF ≥45% and an echocardiographic evidence of elevated LV 
filling pressure evidenced by a dilated left atrium(160). Valvular heart disease (VHD) was 
diagnosed in patients with evidence of clinical and echocardiographic criteria (88). 
Participants were excluded from the PH-LHD sub-study if they had evidence for significant 
non-Group 2 causes of PH according to the WHO clinical classification. 
5.2.2. Measurement of NT-pro Brain Natriuretic Peptide Levels 
All subjects recruited in the study were invited to give their informed consent before 
extraction of blood for storage at the laboratory of the Hater Institute of Cardiovascular 
Research in Africa and subsequent testing for NT-PROBNP. In Chapter 2, we described the 
measurement technique of this biomarker. 
5.2.3. Statistical analysis 
Data were processed and analysed using the SPSS software version 20.0 for Windows. Based 
on previous studies, severe PH is usually defined by a RVSP >60 mmHg (161, 162). Patients 
with mild to moderate were arbitrarily categorized according to RVSP level as: mild if RVSP 
was 36-50 mmHg and moderate if RVSP was 51-60 mmHg. Categorical variables are presented 
as frequencies and percentages, while continuous variables are presented as means and 
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standard deviation (SD), or median (25th to 75thpercentiles). Comparison between groups 
used appropriate parametric and non-parametric tests. Linear regressions were used to 
identify the independent predictors of RVSP. Kaplan Meier estimators was employed to depict 
the outcome (mortality or admissions) over time across major subgroups and differences 
assessed with the log rank test. Cox regressions were used to investigate the effect of PH on 
admissions within and between the three PH groups during follow up. Age, sex, EF, RVSP and 
TAPSE were first explored in a univariable and then in multivariable model after adjustment 
for age and sex (Table 26).  A p-value <0.05 was considered statistically significant. 
5.3. Results 
5.3.1. General baseline characteristics of the study population 
In Figure 25 below, we show the sequence for deriving the 202 patients with PH and the final 
PH-LHD cohort of 144 (71.3%) patients.  
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Figure 25: Flowchart showing the derivation of the pulmonary hypertension (PH) due 
to left heart disease cohort from the original PAPUCO all causes PH cohort. 
5.3.2. PH, pulmonary hypertension; PH-LHD, PH due to left heart disease. 
Table 21 depicts the socio-demographic and risk factor profiles of the PH-LHD cohort by sex. 
Women were more likely to be less educated and unemployed. Hypertension was found in 
50.0% of patients, with predominance in men (59.3% vs. 43.5%, p=0.006). Women were more 
exposed to indoor cooking fumes (43.5% vs. 13.6%, p<0.001). 
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Table 21: Socio demographic and risk factor profiles of sub-Saharan African patients 
with pulmonary hypertension due to left heart disease in the PAPUCO registry 
Characteristics Overall Men Women p-value
N (%) 144 59 (40.9) 85 (59.0) 
African or black race 140 (97.2) 57 (96.6) 83 (97.6) 0.543 
Income below 30 USD 52 (36.1) 15 (25.4) 37 (43.5) 0.094 
Never went to school 34 (23.6) 9 (15.3) 25 (29.4) 0.041 
Unemployed 62 (43.1) 48 (56.5) 14 (23.7) <0.001 
Housing conditions 
Traditional housing or huts 9 (6.3) 3 (5.1) 7 (8.2) 0.192 
Shack without sanitation 8 (5.5) 3 (5.1) 5 (8.6) 0.201 
Cardiovascular risk factors 
Family history of CVD 49 (34.0) 21 (35.6) 28 (32.9) 0.220 
Diabetes 16 (11.1) 8 (13.6) 8 (9.4) 0.347 
Hypertension 72 (50.0) 35 (59.3) 37 (43.5) 0.006 
Smoking 14 (9.9) 11 (18.6) 3 (3.5) 0.708 
Hypercholesterolemia 12 (8.3) 8 (13.6) 4 (4.7) 0.102 
Comorbidities 
COPD 4 (2.8) 2 (3.4) 2 (2.3) 0.842 
Previous and/or 
concurrent tuberculosis 
19 (11.8) 7 (8.5) 12 (14.1) 0.705 
Concurrent tuberculosis 1 (0.7) 0 1 (1.2) 0.741 
HIV-infected 16 (11.1) 7 (11.8) 9 (10.6) 0.711 
Indoor cooking/heating 
without chimney
45 (31.2) 8 (13.6) 37 (43.5) <0.001 
Chronic liver disease 2 (1.4) 2 (3.4) 0 0.066 
Alcohol abuse 19 (13.2) 15 (25.4) 4 (4.7) 0.014 
Data are presented as number (%) or mean ± SD; Abbreviations: COPD, chronic obstructive 
pulmonary disease, CVD, cardiovascular disease; USD, US dollar; HIV, human 
immunodeficiency syndrome. 
Table 22 depicts the baseline clinical features of the overall PH-LHD cohort by sex. The mean age 
(53.5±18.4 years) was similar between men and women. In all, 97 (67.4%) patients presented with 
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advanced stage disease, symptoms of WHO functional class III or IV, and reduced 6MWT distance 
(median 231.0 m and 33.3% less than 300 m). However, compared with women, men were more likely 
to present with late symptoms. 
 
Table 22: Clinical findings of 144 sub Saharan African patients with pulmonary 
hypertension due to left heart disease in the PAPUCO registry 
Clinical characteristics All (n=144) Men (n=59) Women (n=85) P value 
Age (years) 53.5±18.4 56.4±15.5 51.1±20.0 0.093 
Shortness of breath 138 (95.8) 59 (100) 79 (92.9) 0.034 
Cyanosis 12 (8.3) 5 (8.5) 7 (8.2) 0.406 
Fatigue 132 (91.7) 55 (93.2) 77 (90.6) 0.744 
Dizziness 43 (29.9) 15 (25.4) 28 (32.9) 0.421 
Palpitations 104 (72.2) 45 (76.3) 59 (69.4) 0.391 
Shortness of breath 138 (95.8) 59 (100) 79 (92.9) 0.034 
Cough 85 (59.0) 42 (71.2) 43 (50.6) 0.016 
Peripheral edema 97 (67.4) 49 (83.1) 48 (56.5) 0.002 
Raised jugular venous pressure 105 (72.9) 48 (81.4) 57 (67.1) 0.154 
Heart rate (b.p.m) 89.4±19.7 87.9±21.1 90.4±18.7 0.458 
Oxygen saturation (%) 95 (91 – 98) 97 (96 – 98) 95 (88 – 97) 0.546 
Body mass index (kg/m²) 25.1±5.6 26.4±6.1 24.1±5.9 0.027 
Systolic BP (mmHg) 125.8±28.7 131.3± 29.7 122.1± 27.8 0.063 
Diastolic BP (mmHg) 79.2±18.2 79.2±16.5 81.1±18.7 0.373 
WHO functional class III or IV 97 (67.8) 48 (82.8) 49 (57.6) 0.002 







6 minute walk test distance < 300 m 48 (33.3) 16 (27.1) 32 (37.6) 0.248 
6 minute walk test not done 73 (50.7) 36 (61) 37 (43.5) 0.116 
Data are presented as number (%), mean ± SD or median (25th – 75th percentile); statistical significance 




In Table 23, ECG and biological characteristics of our study population are presented with no 
significant difference between men and women. 
Table 23: ECG and biological characteristics of our PH-LHD cohort 
 All (n=144) Men (n=59) Women (n=85) P 
value 
Sinus rhythm 113 (78.4) 47 (79.7) 66 (77.6) 0.931 
Sinus tachycardia 32 (22.2) 12 (20.3) 20 (23.5) 0.404 
P-pulmonale 11 (8.6) 6 (11.3) 5 (6.7) 0.270 
Right ventricular 
hypertrophy 
16 (11.1) 9 (15.3) 7 (8.2) 0.187 
Left ventricular 
hypertrophy 
50 (34.7) 25 (42.4) 25 (29.4) 0.236 
Atrial 
fibrillation/flutter 
31 (21.5) 12 (20.3) 19 (22.4) 0.848 
Haemoglobin (g/dL) 11.5±2.2 12.2±2.4 11.9±2.0 0.532 
Serum creatinine 
(µmol/l) 
96 (86.6 – 185)  
 
97 (96 – 246) 89 (84.5 – 102) 0.410 
CRP (mg/l) 29 (8.25 – 75.5) 12 (11.5 – 31) 46 (23 – 99) 0.627 
NT-proBNP* 1196.8(424.4-2293.8) 1257.7(470.3-2376.1) 987.3 (416.0-1964.2) 0.440 
 
Data are presented number (%) or mean ± SD; Abbreviations: CRP, C reactive protein. 
ECG features and biological findings were similar between men and women. * Blood samples 
were available in 65 subjects with PH-LHD. 07 samples were haemolysed and not usable, 




The medication used is presented in Figure 26 below. The prescription rates did not vary 
significantly in accordance with PH severity. 
 
Figure 26: Pharmacotherapy according to pulmonary hypertension (PH) severity in 
144 Sub-Saharan Africa patients with PH due to left heart disease in the PAPUCO 
registry.  
Percentages represented are within PH categories. Abbreviations: ACE, angiotensin-
converting-enzyme; ARB, angiotensin II receptor blocker; HBP, high blood  
Medications used did not vary significantly according to PH severity, and overall, less than 
10% received a PH targeted therapy. 
  



















Baseline features and correlates of RVSP 
As shown in Table 24 below, none of the clinical characteristics such as age, sex, hypertension 
and other risk factors, BMI, arrhythmia, heart rate, BP, haemoglobin, and serum creatinine 
correlated with RVSP in the PH-LHD cohort.  
5.3.3. Baseline echocardiographic characteristics according to PH severity 
Baseline echocardiographic variables according to PH severity are shown in Table 25. Mean 
baseline RVSP was 60.4±16.8 mm Hg, and values ranged from 36 to 107 mm Hg. Overall, 
patients with PH-LHD showed enlarged LA (LA diameter = 50.2±10.5 mm), dilated LV (LVEDD 
= 57.3±12.3), low EF (41.7±17.3 %), a high proportion of moderate-to-severe functional MR 
and TR (85.1 and 92.9% respectively), poor RV function (70.2 % with TAPSE < 15 mm and 
66.7% with moderate-to-severely dilated RV).  
There was no difference between the three groups with respect to LV dimensions, LV mass or 




Table 24: Baseline characteristics across pulmonary hypertension (PH) associated 
with left heart disease categories in the PAPUCO registry 









(n=144)Age, years ) 52.2±17.1 53.6 ±17.4 53.9±20.4 0.660 53.5±18.4 0.081 
Men, n (%) 15 (36.6) 23 (59.0) 21 (32.3) 0.506 59 (40.9) 0.395 
Family history of CVD, n (%) 19 (13.5) 10 (7.1) 19 (13.5) 0.641 48 (34.0) 0.512 
Diabetes, n (%) 8 (19.5) 3(7.7) 5 (7.8) 0.11 16 (11.1) 0.25 
Hypertension, n (%) 21 (26.1) 22 (29.2) 29 (40.3) 0.219 72 (50.0) 0.318 
Smoking, n (%) 8 (5.7) 5 (3.5) 1 (0.7) 0.703 14 (9.9) 0.708 
BMI (kg/m2) 25.6±4.7 24.5±4.4 25.7±7.1 0.690 25.2±5.7 0.703 
Atrial fibrillation/flutter, n (%) 12 (8.3) 6 (4.2) 13 (9.1) 0.664 31 (21.5) 0.648 
Haemoglobin (g/dL) 11.7±2.9 11.2±2.0 12.2±1.8 0.438 11.6±2.2 0.532 
Serum creatinine (micromol/l) 151.3±69.2 132.4±91.1 125.5± 94.1 0.785 135.4±23.9 0.791 










Heart rate (b.p.m.) 83.5±21.1 90.3±19.5 91.6±19.4 0.138 89.6±19.8 0.211 
Systolic BP (mmHg) 128.6± 31.4 127.4± 26.5 123.8±29.6 0.451 125.4±28.7 0.467 
Diastolic BP (mmHg) 81.1±18.7 79.2±16.5 78.3±16.5 0.326 79.2±18.2 0.373 
6 min walk test distance (m) 222.4±138.8 211.3±139.6 235.1±139.6 0.549 221.1± 141.0 0.471 
Data are presented as number (%) or me-an ± SD or median (25th – 75th percentiles); 
Abbreviations: BMI, body mass index; BP, blood pressure; b.p.m, beat per minute; COPD, 
Chronic obstructive pulmonary disease; CVD, cardiovascular disease; RVSP, right ventricular 
systolic pressure; 6MWT, 6-minutes’ walk test. * (trend in the 3 groups); ** compared 1 vs. 3. 
*** NT-PROBNP results were available in 58 subjects.  
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Table 25: Echocardiographic characteristics across pulmonary hypertension 
associated with left heart disease (PH-LHD) categories and correlates of PH-LHD in 
the PAPUCO registry 
Characteristics 

















 RVSP >35 
mmHg 
(n=144) 
 R P 
Aortic root (mm) 29.8±4.1 29.7±5.4 30.1±5.7 0.997 29.9±5.3 0.991 0.48 0.587 
Left atrium 
diameter (mm) 
47.5±8.0 49.2±9.2 53.8±12.5 0.024 50.2±10.5 0.016 0.227 0.008 
IVSd (mm) 11.4±2.7 11.0±2.8 10.6±3.1 0.201 10.9±2.9 .0187 -
0.098 
0.250 
PWd (mm) 11.5±2.9 11.2±2.7 10.4±2.7 0.054 10.4±2.7 0.051 -
0.108 
0.211 
LVEDD (mm) 55.4±11.6 59.7±11.5 58.4±13.4 0.065 57.3±12.3 0.078 0.014 0.870 
LVESD (mm) 43.7±13.4 48.3±13.9 44.3±16.0 0.478 44.8±14.5 0.527 -
0.074 
0.321 




129.5±56.2 113.7± 36.9 0.072 117.4±38.2 0.081 -
0.079 
0.353 
LVEF (%) 41.4± 
19.9 
40.1±16.6 45.0±16.3 0.071 41.7±17.3 0.061 .12  0.271 
E wave (cm/s)# 97.8±28.2 70.5±53.1 99.9±55.2 0.297 85.2±51.9 0.312 0.093 0.431 
A wave (cm/s) # 36.8±17.6 37.7±38.2 45.2±43.3 0.242 39.7±36.9 0.265 0.024 0.844 
E/A ratio# 2.3± 1.3 2.6± 2.6 2.3± 2.2 0.806 2.2± 2.2 0.689 0.012 0.871 
DT (ms) 115.6±34.
0 
145.9±64.2 137.4±44.6 0.657 139.5±54.8 0.549 0.083 0.517 
RVSP (mmHg) 41.6±3.1 53.1±4.4 78.1±12.7 0.000 60.4±16.8 0.000 - - 
TAPSE (mm)*** 17.4±7.8 15.5±6.0 12.5±3.8 <0.0010 14.4±5.8 0.001 -
0.374 
<0.001 
TAPSE < 15 mm 9 (19.1) 12(37.5) 43(69.4) <0.001 73 (70.2) <0.001  - 
RV size, mild, 
moderately to 
severely dilated 
15 (31.9) 16 (50.0) 35 (56.5) 0.012 94 (66.7) 0.036 0.283 0.005 
Mild, moderate 
to severe MR 
34 (24.1) 27 (19.1) 59 (41.8) 0.001 120 (85.1) 0.001 0.252 0.003 
 
Data are presented as number (%) or mean ± SD; Abbreviations: DT, deceleration time; IVSd, interventricular septum 
in diastole; LVEF, left ventricular (LV) ejection fraction; LVEDD, LV end diastolic diameter; LVESD, LV end systolic 
diameter; MR, mitral regurgitation; PH, pulmonary hypertension; PWd, posterior wall in diastole; RV, right 
ventricular; RVSP, RV systolic pressure; TAPSE, Tricuspid annular plan systolic excursion; * (trend in the 3 groups); 
** compared 1 vs. 3; ***TAPSE available in 101 subjects.   # Doppler pattern of mitral inflow (E, A, E/A ratio) available in 
99 subjects. 
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Figure 27 shows the prevalence of different aetiologies of PH-LHD by PH severity. Overall, 
HFrEF and HFpEF were observed in 55.6% and 24.3% respectively with no sex difference 
(29.9% and 13.2% in women vs. 26.4% and 10.4% in men, all p>0.05). VHD was predominant 
in women (overall 20.1%, 16.0% in women vs. 4.2% in men, p= 0.044). HFrEF was associated 
with a higher proportion (19.4%) of severe of PH-LHD. Mean RVSP according to LHD etiology 
was 57.6±15.5, 58.6±14.0 and 70.8±18.9 mmHg for HFrEF, HFpEF and VHD respectively 
(p<0.001 for linear trend). 
Figure 27: Classification of different type of left heart diseases in patients with 
pulmonary hypertension associated with left heat disease in the PAPUCO registry. 
(Chi square, p=0.009). HFpEF: Heart failure with preserved ejection fraction; HFrEF: Heart 









Mild PH Moderate PH Severe PH All
Percentage
HFrEF HFpEF Valvular heart disease All
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5.3.3.1. Echocardiographic correlates of pulmonary hypertension in the PAPUCO registry 
RVSP correlated with LA diameter (r=0.227, p= 0.008, Figure 28 right panel) and TAPSE (r=-0.374, p<0.001, Figure 28 left panel). Of note, RVSP 
did not correlate with EF (p=0.271). In age and sex adjusted analysis, LA diameter (OR=0.58, 95% CI 0.31-0.85), grade of MR (OR=10.14, 95% CI 
0.15-20.22) and TAPSE (OR=-0.98, 95% CI -1.55 to -0.46) were independent predictors of RVSP. 
 
 
Figure 28: Correlations between right ventricular systolic pressure and left atrial size (left panel), and right ventricular function, as 
measured by the tricuspid annular plane systolic excursion (right panel).
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5.3.4. Follow-up, mortality, admissions and predictor of admissions 
The median follow-up period (25th-75th percentiles) for the overall cohort was 202 (58 - 231) 
days; during which 35 (cumulative incidence 24.6%) patients died and 43 (cumulative 
incidence 29.9%) were readmitted for heart failure. There was no significant difference in all-
cause mortality between the three PH groups (² = 1.84, p = 0.392). However, as shown in 
Figure 29 below, there was a positive association between PH severity and admissions (log 
rank test, p=0.014).  
Figure 29: Kaplan Meier curves showing admissions by hemodynamic grading among 
patients with pulmonary hypertension associated with left heart disease in the 
PAPUCO registry.  
(² from log rank test =8.47; p= 0.014).
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In age adjusted Cox’s regression models, age [HR: 1.01 (95% CI: 0.99 – 1.03), p= 0.425], 
ejection fraction [ HR: 0.99 (0.98-1.02), p= 0.836] and TAPSE [HR: 1.05 (0.99-1.12), p= 0.094] 
were not significant predictors of admissions for HF; only RVSP [HR: 1.03 (1.01-1.07), p= 
0.034] was an independent predictor of admissions for heart failure (Table 26). 
Table 26: Multivariable analysis predicting admissions in the PH-LHD cohort from the 
PAPUCO registry 
Variables Univariable analysis Multivariable analysis 
  Hazard ratio (95% CI) Hazard ratio (95% CI) 
Age 1.02 (1.01 - 1.04)  0.98 (0.96 – 1.01) 
Sex 0.79 (0.53 – 1.21) 0.63 (0.36 – 1.09) 
EF 1.01 (0.99 – 1.03) 0.99 (0.98-1.02) 
RVSP 1.03 (1.01 – 1.05) 1.03 (1.01 – 1.07) 
TAPSE 1.02 (0.95 – 1.08)  1.05 (0.99 – 1.12) 
 





Data from this first prospective echocardiographic cohort-type registry of PH-LHD across four 
Sub-Saharan African countries revealed three major findings: First, PH-LHD is the main cause 
of PH and is commonly associated with LV dysfunction in Africa; Second, left atrial size and 
TAPSE are strong correlates of PH and; Third, patients present when they are symptomatic 
and PH is a predictor of admission risk within 6 months.  
5.4.1. The clinical profile of patients with PH-LHD 
In our study, PH-LHD affects relatively young people and our study indicates that it is 
especially predominant in unemployed women with low education. Hypertension was the 
most common cardiovascular risk factor with HFrEF the most frequent cause of PH-LHD and 
patients tend to present at advanced stages of disease. The latter is likely in part because they 
present when they are symptomatic, as it is not common for individuals to seek healthcare 
when they are well in many resource-constrained environments like those covered in this 
study. The young age of our population with PH-LHD is largely driven by early occurrence of 
LHD, especially HF in SSA. Female predominance has been inconsistently reported across PH-
LHD studies. In the Heart of Soweto study, women were almost two-fold more likely to 
present with PAH (110). In one large community-based cohort study of PH-LHD in Minnesota, 
Bursi et al (62) reported equal sex representation, but more severe disease among women. 
Female preponderance in our study likely reflects poverty-related conditions such as indoor 
fumes from cooking, occurrence of rheumatic VHD with predominance in women and 
concurrent poor access to health care (163). A large number of hospital studies in high-income 
countries have shown male predominance of PH-LHD ranging from 54 to 68% (64, 67, 80, 161, 
164). The dominance of HFrEF reflects the HF profile in low and middle income countries 
where the main contributors to the etiology of HF remain hypertensive heart disease, dilated 
cardiomyopathy and rheumatic valvular heart disease (VHD) which  predominantly impact on 
systolic function (118, 165).  
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5.4.2. Determinants of pulmonary hypertension 
Previous studies in patients with various left heart disease aetiologies have reported a close 
relation between elevated pulmonary artery pressures and elevated LV end diastolic 
pressures (67, 78, 89, 164) which both can lead to an increase in pulmonary vascular 
resistance and subsequent structural vascular remodelling, and right-sided failure. In our 
study, RVSP was independently correlated with LA size, severity of MR, and RV systolic 
function as assessed using TAPSE. It is likely that chronic elevation of LV filling pressures due 
to LV dysfunction in these patients translated into left atrial enlargement, which then led to 
an increase in RVSP. Our findings are similar to previous studies in which specific cardiac 
structural abnormalities correlated with PH-LHD (67, 164). These findings suggest that despite 
their relative young age, our patients presented at advanced disease when severe PH had 
already caused RV dysfunction; this can therefore explain the more severe symptoms and 
reduced exercise capacity. Similarly, Stewart et al (110) reported that up to 28% of de novo 
cases of heart failure in the Heart of Soweto study presented with right heart failure. Except 
NT-PROBNP, none of the clinical or biological characteristics were associated with increased 
RVSP, similar to findings in research conducted by Damy et al (67). Nevertheless, because it 
has been well established that RVSP increases with age (85, 166), we cannot rule that the 
absence of correlation between age and RVSP in our study could simply be due to the younger 
age our population. That NT-proBNP was higher in patients with severe compared with mild 
PH-LHD may suggest a relationship worth exploring between RV structure and function (167) 
in PH. This requires confirmation on a larger sample. 
5.4.3. Short term mortality and hospital admission in PH-LHD 
In the systematic review presented in the background Chapter (119), we found PH to be 
almost invariably associated with increased mortality, but information on readmission for 
heart failure was limited. Short term admissions were frequent in our sample, and correlated 
with PH severity. Considering the younger age of our population and relatively better systolic 
function, our admission rate looks high, and could be due to late presentation or health 
system factors. Indeed, using similar diagnostic criteria, Mutlak et al (168) reported a lower 
12-month rehospitalisation rate (9.2%) in patients with PH due to HF following acute 
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myocardial infarction. In the ESCAPE trial of patients with severe HFrEF, the 6-month re-
hospitalization rate was 50% in patients with PH, but PH failed to predict admissions (81). 
Other studies of PH-LHD with longer follow-up (63, 75, 76, 168, 169) have reported similar 
results.    
PH has been almost invariably shown to inversely affect mortality in patients with left heart 
disease (119) and RV dysfunction is a marker of poor prognosis in HF (133). Some possible 
explanations of the absence of lack of effects in our cohort include: 1) the small sample size, 
especially given the heterogeneity of the affected population; 2) with up to 70.2% of patients 
having a poor RV function, the discriminatory power markers of RV function for mortality risk 
will drop. It remains possible however that a difference could be observed in a longer follow 
up of a larger sample.  
5.4.4. Strengths and limitations 
Most limitations discussed in chapter 2 and 3 of this thesis apply. This includes our diagnostic 
methods for PH (echocardiogram without confirmation by RHC), the small sample size and 
the short term follow up. It is of note that Doppler echocardiography is the most commonly 
employed diagnostic tool in clinical practice for diagnosis and follow up of the majority of 
LHD. Second, as discussed in Chapter 3, the classification of PH in limited resource settings 
with high prevalence of major risk factors remains an enormous global health challenge. We 
cannot rule out that some women exposed to indoor smoke might have a lesser degree of 
obstructive pulmonary disease which could overlap with left heart disease and aggravate PH. 
Third, we did not record enough detailed measures of diastolic function; Doppler tissue 
imaging indices would have contributed in better characterization of HFpEF(78). Finally, the 
small number of patients who consented for blood sample extraction limited investigation of 
the role of NT-PROBNP in diagnosis and prognosis of PH.  
5.5. Conclusion 
In this study, we have shown that a simple and quick estimation of RVSP by echocardiography 
in low-resource settings is feasible within a prospective cohort design, and can give reliable 
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information both on baseline status and future outcomes. Pulmonary hypertension due to 
left heart disease affected people of relatively young age; LA size, TAPSE and severity of MR 
were strong correlates, and PH was an independent predictor of subsequent HF admissions. 
This indicates that an increase in RVSP in our setting identifies a group of patients prone to 
develop clinical congestive heart failure. A long term follow-up of a larger sample is necessary 
to confirm these observations. 
157 
Chapter 6. Prevalence and predictive utility of 
specific ECG criteria of right ventricular 
hypertrophy and right atrial enlargement in 
pulmonary hypertension: Evidence from the 
Pan African Pulmonary hypertension Cohort 
(PAPUCO) study. 
6.1. Introduction 
Despite the improvements in understanding PH and developing novel therapies, the condition 
is still diagnosed at the advanced stage in a significant proportion of patients, due to the 
paucity of symptoms in early stage of the disease. This has negative impacts on subsequent 
quality of life and survival (141). The American College of Cardiology/American Heart 
Association (31) and the European Society of Cardiology/European Respiratory Society (141) 
guidelines recommend ECG as an initial tool in exploring patients with suspected PH based on 
studies conducted predominantly in patients with PAH. However, these guidelines consider 
ECG to be an inadequate tool for screening, and emphasize on the advantage of Doppler 
echocardiography.  
In SSA where chronic and endemic precursors of PH including chronic infectious diseases, 
hypertensive heart disease, cardiomyopathy and rheumatic heart disease are highly 
prevalent, early diagnosis of PH is of particular importance. The high cost, low availability, and 
the need of expertise for echocardiography limits its utility in this part of the world and 
justifies the interest in alternative tests like ECG. ECG abnormalities in patients with PH have 
been predominantly described from western registries of PH (170-174). In this chapter, we 
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aimed to assess the predictive value of an affordable, widely available, objective and 
reproducible test like ECG to diagnose PH in resources-limited settings.  
6.2. Methods 
6.2.1. Study design, patients and clinical settings  
The purpose and methods of the PAPUCO study has been described in Chapter 2. 
6.2.2. Electrocardiogram selections and interpretation in patients and control 
subjects 
We searched ECGs from the PAPUCO registry to identify all patients who had both Doppler 
Echocardiography and 12-lead ECG performed within a forty eight hour interval of their 
baseline inclusion. We excluded all patients with pacemakers (due to inapplicability of 
standard ECG criteria), poor quality ECG and those without measurable RVSP. Control subjects 
were patients with normal Doppler echocardiography and RVSP less than 35 mm Hg who 
underwent ECG recording during their baseline inclusion in the Heart of Soweto Study (28). 
All ECGs were reviewed and interpreted by two independent board certified cardiologists who 
were blinded to clinical and echocardiography results. Disagreements were resolved by 
consensus and if could not be reached, a third opinion was requested. We electively studied 
pre-specified ECG patterns classified into minor or major abnormalities (Table 27) as 
previously described in a large African cohort of heart disease-free Africans (175). The 
following ECG patterns suggestive of right heart strain (Table 27) were particularly studied: 1) 
QRS axis ≥ 100°; 2) R/S ratio >1 or RV1 >7 mm; 3) right ventricular hypertrophy (RVH) defined 
as a QRS axis ≥ +100°; and R/S ratio ≥1 or R in V1 >7mm, right bundle branch block associated 
with QRS right axis deviation (≥ 100°), and P-pulmonale. 
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6.2.3. Statistical analysis 
All statistical analyses were performed with SPSS 20.0, Chicago, Illinois. Prevalence, sensitivity 
(Se), specificity (Sp), and positive (or negative) predictive values (PPV or NPV) of ECG patterns 
suggestive of right heart strain were calculated by the following formulas (19, 90): 
 Prevalence of an ECG abnormality = Total with the abnormality of interest/total
number of patients in the group of interest.
 Se = True positive/(True positive +False negative) x 100
 Sp = True negative/ (True negative + False positive) x 100
 PPV = [𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑥 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒] ÷ [𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑥 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 + (1 −
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦) ∗ (1 − 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒)] 
 NPV = [𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 𝑥 (1 −  𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒)] ÷ [𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 𝑥 (1 − 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒) +
(1 − 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦) ∗ 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒]
Prevalence, Se, Sp, PPV, NPV are presented as percentages, while continuous variables are 
presented as means and standard deviation (SD), or median (25th to 75th percentiles). We 
used ² to compare proportions of categorical variables and student t test to compare mean 
for continuous variables. A p-value <0.05 was considered statistically significant. 
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Table 27: Classification of electrocardiographic abnormalities (176) 
Minor abnormalities  
Sinus tachycardia (>100 bpm) 
Minor T-wave changes (T-wave 
flattening) or early repolarization 
Definitive right ventricular 
hypertrophy 
 QRS axis ≥ +100o
 R/S ratio ≥1, or R V1 >7mm
RBBB + QRS axis ≥ +100o 
Major abnormalities 
Major T-wave abnormalities (T-wave inversion) 
Left ventricular hypertrophy  
Cornell voltage criteria for LVH 
 S in V3 + R in aVL >24mm (men)
 S in V3 + R in aVL >20mm (women)
Pathological Q waves 
Prolonged QTc (>470ms as calculated by Bazett’s formula) 
LBBB or other conduction delay 
P-pulmonale: P wave in lead II > 2 mm, or >1.5mm in lead
V1/V2, unchanged duration
RBBB: right bundle branch block, LVH: left ventricular hypertrophy, LBBB: left bundle branch 
block 
6.3. Results 
6.3.1. Clinical characteristics 
Table 28 depicts the clinical characteristics of the 65 patients with PH. Patients were young 
(mean age = 47±14 years), 21 (32%) were men, and all except four were of Black African origin. 
The control subjects were younger with a mean age of 36 ±10 years and 48 (16%) were males. 
All demographic, clinical and echocardiographic profile were similar between men and 
women in the patient group except for significant sex differences seen with higher prevalence 
of male smokers (47.6% vs. 6,8%; p<0.001) and in distances reached in the 6-minute walking 
test (352m ± 97m vs. 254m ± 142m, p=0.017). According to the WHO classification, group 2 
PH was predominant (46%), followed by group 1 (31%), group 3 (22%) and group 5 (3%). 55.4% 
of patients presented in WHO functional class III or IV and the mean Karnofsky Performance 
score was 67±17%. 
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Table 28 : Clinical characteristics of the 65 patients with pulmonary hypertension 







Mean age (years) 43±15 47±14 41±15 0.133 










Previous or current pulmonary TB  21 (32.3) 7 (33.3) 13 (29.5) 0.536 
Body mass index (kg/m2) 23.7±5.8 24.1±6.5 23.5±5.5 0.690 
Heart rate (bpm) 93±19 91.6±10.2 94.7±5.8 0.195 
Pulse oximetry at rest (%) 97 (93-98) 97 (93-98) 97 (93-99) 0.156 
Systolic BP (mmHg) 









WHO functional class III or IV  36 (55.4) 13 (61.9) 23 (52.3) 0.323 
Distance walked at 6-minutes 
walking test (m)  
300 (188-360) 350(300-390) 294 (125-345) 0.017* 
Right heart echocardiographic findings 
Right ventricular systolic pressure 
(mmHg) 
61.4 ± 19.8 60.5±24.6 61.8±17.2 0.797 
Tricuspid annular plane systolic 
excursion (mm) 
14.9±5 14.7±5.8 15±4.5 0.844 
Right ventricle enlargement 56 (86.2) 18 (85.7) 38(86.4) 0.335 
Right atrial enlargement  57 (87.7) 19 (90.5) 38(86.7) 0.830 
 
Data are n (%) or mean ± SD; BP, Blood pressure; WHO, World Health Organization; * 
statistically significant (p<0.05). 
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6.3.2. Prevalence of ECG abnormalities 
Compared to the control group, all abnormalities were more frequently observed in our PH 
cohort. As shown in Figure 30 (right panel), the most prevalent (cohort vs. control) major 
abnormalities were: pathologic Q wave (47.7% vs. 6.7%) followed by LVH (38.5% vs. 9.8%) and 
P-pulmonale (36.9% vs. 20.7%). None of the patients had a completely normal ECG as 
opposed to 15% in the control group. Of minor ECG abnormalities tachycardia (40% vs. 12.6%) 
and QRS axis ≥ 100° (38.5% vs. 5.3%), were the most prevalent. 58.5% of the PH group vs. 
76.5% were in sinus rhythm. Bradycardia (1.5% vs. 4.9%) and RBBB with QRS right axis 
deviation (1.5% vs. 1.1%) were the least prevalent. ECG minor abnormalities are shown in 
Figure 30 (left panel). Overall, 32.3% (24.6%) of ECGs in PH group had at least 3 to 4 major 





Figure 30: Prevalence of minor (left panel) and major (right panel) ECG abnormalities in 65 patients with PH in the PAPUCO registry 
compared to 285 controls with normal Doppler echocardiography and right ventricular systolic pressure.  
LBBB: left bundle branch block; RBBB: right bundle branch block, QRS right axis deviation = QRS axis > 100°. * p<0.05, ** p<0.01, *** p< 0.001 
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6.3.3. Predictive values of ECG patterns suggestive of right heart strain for 
diagnosis of pulmonary hypertension 
Table 29 below shows the sensitivity, specificity and positive and negative predictive values 
for prevalent PH. Sensitivity ranges between 6.2 and 47.7% while specificity ranges between 
79.3 and 100%. The negative predictive value ranges between 81.5% and 88.9%. Positive 
predictive value was lowest at 25% for RBBB and QRS right axis deviation (≥ 100°) and highest 
at 100% for QRS axis ≥ +100° combined with R/S ratio ≥1 or R in V1 >7mm. 
Table 29: Predictive values of ECG patterns suggestive of right heart strain (Right 
Ventricular Hypertrophy or Right Atrial Enlargement) for diagnosis of PH in the 
PAPUCO registry 






QRS axis ≥ 100° 38.46% 94.74% 62.50% 87.10% 
R/S ratio >1 or RV1 >7 mm 47.69% 95.79% 72.09% 88.93% 
Definite RVH: QRS axis ≥ +100o; 
and R/S ratio ≥1 or R in V1 >7mm 
30.77% 100.00% 100.00% 86.36% 
Right bundle branch block and 
QRS right axis deviation (≥ 100°) 
1.54% 98.95% 25.00% 81.50% 
P > 2,.mm in lead II or >1.5mm in 
lead V1/V2, unchanged duration 
36.92% 79.30% 28.92% 84.64% 
RVH, Right ventricular hypertrophy
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6.3.4. Predictive values of ECG patterns of right heart strain for diagnosis of 
indirect signs of PH (echocardiographic right ventricular (atrial) 
enlargement) in patients with PH 
The sensitivity for predicting right ventricular (atrial) enlargement (RV(A)E) were relatively 
similar for all parameters ranging from 2.1 to 56.3 and 2.6 to 57.9 respectively (Table 30). The 
specificity was higher for both RVE and RAE for all parameters (all above 60%). Positive 
predictive value was shown to be higher for RVE than for RAE, where all parameters had higher 
values than 90%. Negative predictive values were higher for RAE than for RVH, but for both it 




Table 30: Predictive values of ECG patterns of right heart strain for diagnosis of 
indirect signs of pulmonary hypertension (Right Ventricular (Atrial) Enlargement) in 
patients with PH from the PAPUCO registry  




RVE RAE RVE RAE RVE RAE RVE RAE 
QRS axis ≥ 100° 45.83% 47.37% 85.71% 73.91% 91.67% 75.00% 31.58% 45.95% 
R/S ratio >1 or RV1>7 
mm 
56.25% 57.89% 78.57% 65.22% 90.00% 73.33% 34.38% 48.39% 
Definite RVH: QRS 
axis ≥ +100o; and R/S 
ratio ≥1 or R in V1 
>7mm 
37.50% 42.11% 92.86% 86.96% 94.74% 84.21% 30.23% 47.62% 
Right bundle branch 
block and QRS right 
axis deviation (≥100°) 
2.08% 2.63% 100.00% 100.00% 100.00% 100.00% 22.95% 38.33% 
P > 2 mm in lead II or 
>1.5 mm in lead 
V1/V2, unchanged 
duration 
45.83% 39.47% 85.71% 60.87% 91.67% 62.50% 31.58% 37.84% 
 




The main findings of the present study are that (i) ECG abnormalities are very common among 
Africans with PH but not specific; ii) ECG abnormalities relating to right heart strain are less 
frequently observed; iii) ECG patterns focusing on the R and S amplitude in V1 and right axis 
deviation with QRS axis deviation > 110° have good predictive values for PH. Previous studies 
in patients with heart failure in SSA have also described high prevalence rates and poor 
specificity of ECG abnormalities (177, 178). In several low-income-countries, 12-leads ECG is 
still not widely available in most rural areas, but remains the only cardiac test affordable for 
rural and poor population (179). The ECG fulfils basic criteria of a good screening test: it is 
rapid, is non-invasive, requires minimal technical expertise to perform, and is inexpensive. 
Even though its performance and reliable interpretation require training, skills can easily be 
acquired and are usually incorporated in basic training of medical students. Performance can 
be incorporated in the training of nurses. Contrariwise, Doppler echocardiography is often 
unavailable in resource-constrained settings, remains very expensive and requires much more 
specialized training competency for performance and interpretation. In this context, the 
validation of ECG as a good clinical tool with acceptable predictive values for significant PH, 
could be a relevant and feasible solution to guide the clinicians in selecting appropriate 
patients for further testing. 
6.4.1. Prevalence of ECG abnormalities in Pulmonary Hypertension 
ECG abnormalities were very common in this cohort, but taken individually, none exceeded 
50%. The fact that all ECGs in this study revealed at least one minor abnormality could be due 
to the following reasons i) the presence of structural cardiac abnormalities since 46% of 
patients had left heart disease and ii) the presence of comorbidities like hypertension (38.5%). 
These findings suggest, as previously reported in SSA populations, that a normal ECG is rare 
in patients with suspected heart disease (177, 178).  In a population of PH predominately due 
to chronic lung disease, Al-Naamani et al (180) reported that ECG patterns suggestive of RVH 
were rare (<7%). In idiopathic PAH, Kopec et al (181) reported that the prevalence of RVH 
varied markedly across the analysed criteria, ranging from 0 to 22. In our study, ECG patterns 
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suggestive of right heart strain range from 13.9 vs. 15.8% for T wave abnormalities to 38.7 vs. 
5.3% for QRS axis deviation in the PH vs. control group respectively. Differences in prevalence 
of ECG abnormalities between studies could be explained by different population 
characteristics but also the late presentation of our patients. This is particularly valid for P-
pulmonale where high prevalence could be because, as suggested in a previous study (180), 
it only occurs with atrial involvement in more advanced disease. Indeed, this is supported by 
the fact that in the overall PAPUCO cohort as described in Chapter 3, 37% of patients 
presented with right heart failure, the only predictor of mortality in our overall cohort of PH. 
In the Heart of Soweto study, up to 28% of 2505 urban Africans presenting with de novo heart 
disease had right heart failure (110). We cannot overemphasize the importance of early 
diagnosis. However, higher prevalence rates of ECG patterns of right heart strain in our 
control group would tend to suggest that the majority of ECG abnormalities are non-specific. 
6.4.2. Predictive value of ECG abnormalities 
Investigating markers of early diagnosis of PH is largely justified by: 1) the current 
unacceptable time interval (27 months) (69) between the onset of symptoms and eventual 
diagnosis; 2) its evolution to right ventricular failure and death when diagnosed late or 
managed inappropriately. Although neglected for years, the role of standard ECG as a marker 
of PH or RV hypertrophy or dilation has received recent attention (170, 173, 174, 180, 181). 
For direct diagnosis of PH, our study showed a poor sensitivity (from 1.5 to 47.7%) and high 
specificity (greater than 80%) for all the studied ECG criteria and good positive and negative 
predictive value for ECG patterns focussing on R or S amplitude. For prediction of indirect 
signs of PH like right ventricular(atrial) enlargement (RV(A)E), criteria focussing on R or S 
amplitude once again showed poor sensitivity, good specificity to RVE and good predictive 
value for both RVE and RAE. Overall, the negative predictive value was poor. QRS axis ≥ 100° 
demonstrated a good positive predictive value as a direct indication of possible PH. The 
classical P-pulmonale had poor performance for predicting both RVE and RAE. That ECG 
criteria focusing on R wave in V1/V2 performed better is not surprising because these leads 
are closer to the right ventricle. In 282 patients with PH (defined as RVSP>30 mmHg), Al-
Naamani et al (180) also reported a best performance to prediction of PH, for ECG patterns 
focusing on the R and S amplitudes and right axis deviation, with very poor prevalence and 
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predictive value of P-pulmonale for PH. Other studies of the predictive value of ECG in PH are 
usually single centre and small sample size studies that have also focused on a specific group 
or subgroup of PH. In 23 patients with scleroderma, Wokhlu et al (182) reported better 
performance for P-wave amplitude in lead II, thus having a 73% sensitivity and 67% specificity 
for the presence or absence of elevated mean pulmonary artery pressure. In 23 patients with 
idiopathic pulmonary arterial hypertension, Kopec et al (181) reported that only a few of 
the recommended ECG criteria proved to be useful in the diagnosis of RV 
hypertrophy or dilation including the ECG voltage criteria based on R wave amplitude in V1 
and ventricular activation time in V1 were useful for differentiating between patients with 
and without RVH. A very high overall sensitivity of the ECG with respect to PH has been 
reported by Bossone et al (183) with only six (9%) out of 64 consecutive patients having a 
normal ECG. Differences with our relatively low sensitivity could again be due to different 
populations of PH groups, but it shall also be noted that the high sensitivity in the study by 
Bossone et al was achieved only if ECG was interpreted by a cardiologist who were aware of 
all other patients’ basic clinic data. Bonderman et al (184) also described a relatively high 
sensitivity of 77% for ECG criteria for suspecting pre-capillary PH. Interestingly, these authors 
tested a unique model of both abnormalities focusing on R or S in V1 and repolarisation 
patterns from V1 to V3. However, it’s only by combining ECG and NT-proBNP in addition to 
Doppler echocardiography that their model could suffice to predict significant pre-capillary 
PH at a level of sensitivity of 100% and specificity of 19.3%. This highlights the need of further 
tests to improve the suspicion index for PH in presence of ECG abnormalities.  
6.4.3. Strengths and limitations 
Among the limitations described in chapter 2, 3 and 4 in this thesis, the absence of 
confirmation of PH diagnosis using right heart catheterization applies here. Second, we did 
not explore the performance of some individual criteria like RV1≥7 mm, RV5≤5 mm, R in lead 
I≤1 mm, S in V1≤2 mm, R/SV1≥1, QRSaxis≥110° but rather their combinations. This is unlikely 
to affect the predictive value of the criteria evaluated in our study, however some of these 
individual indices have been previously shown to have good positive predictive value (181). 
Finally, the heterogeneity of our study population as well as the limited sample size is a 
concern and could limit generalizability of our findings. Beyond these limitations, late 
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presentation of patients with PH worldwide and particularly in the PAPUCO registry and SSA 
at large as described in Chapter 3 is absolutely unacceptable and needs to be addressed with 
simple and available tools.  
6.5. Conclusion 
ECG abnormalities are very frequent in people with PH in SSA, although the value of most of 
these abnormalities is largely limited. When present, some abnormalities like right axis 
deviation and R/S ratio in V1 > 1 or R wave in V1 > 7mm should trigger further investigation 
with echocardiography. Innovative measures in electrocardiography are required for 
improving diagnosis of PH in SSA. This could include studies combining ECG with 
Echocardiography, clinical criteria and cardiac biomarkers to better define criteria to early 
diagnosis of PH without exposing patients to unnecessary and costly right heart 
catheterization in limited resources settings. 
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Chapter 7. Prognostic Significance of ECG 
Abnormalities for Mortality Risk in Acute Heart 
Failure: Insight from the Sub-Saharan Africa 
Survey of Heart Failure (THESUS-HF) 
7.1. Introduction 
As previously described in the background section of this thesis, our knowledge of the 
contribution of ECG in the management of pulmonary hypertension (PH) is limited and derives 
much from western studies either on heart failure (HF) or on pulmonary arterial hypertension 
(PAH). Yet, it is recommended by several international guidelines that ECG should be included 
in the initial diagnostic process of all patients with HF (54, 185). HF is the main etiology of PH 
worldwide. ECG is a simple, relatively cheap and available test that can be used in exploring 
all patients with suspected HF regardless of the presence of PH. Considering the rising burden 
of HF in SSA (115, 186), we investigated the predictive utility of 12-lead ECG abnormalities 
among Africans with acute heart failure (HF) using data from the sub-Saharan Africa Survey 
of Heart Failure. The PAPUCO data were not enough to investigate this question, and due to 
different inclusion criteria and temporal difference in recruitments, we used only the THESUS-
HF data.  
Our result showed that a normal ECG is very rare among Africans with acute HF. Also, some 
ECG findings had prognostic value for mortality risk, although most of them were nonspecific 
and added little to the risk stratification of these patients.  
We concluded that ECG may add to the immediate diagnosis of patients presenting with 
dyspnea in the emergency room in SSA settings and can therefore be used to screen patients 
needing a more expensive, more specialized and less available test like echocardiography. 
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and Ibadan, Abuja, and Kano, Nigeria 
ABSTRACT 
 
Objective:  The aim of this study was to assess the predictive utility of 12-lead electrocardiogram (ECG) 
abnormalities among Africans with acute heart failure (HF). 
Methods and Results:  We used the Sub-Saharan Africa Survey of Heart Failure, a multicenter prospec- 
tive cohort study of 1,006 acute HF patients, and regression models to relate baseline ECG findings to all- 
cause mortality and readmission during a 6-month follow-up period. Of 814 ECGs available, 523 (49.0% 
male) were obtained within 15 days of admission, among which 97.7% showed abnormalities. Mean age 
was 52.0 years and median follow-up was 180 days, with 77 deaths (Kaplan-Meier 17.5%) through day 
180 and 63 patients with death or readmission to day 60. QRS width, QT duration, bundle branch block, 
and ischemic changes were not associated with outcomes. Increasing ventricular rate was associated with 
increasing risk of both outcomes (hazard ratio [HR] 1.07 per 5 beats/min increase for 60-day death or re- 
admission, 95% confidence interval [CI] 1.02e1.12; P 5 .0047), and the presence of sinus rhythm was 
associated with lower risk (HR 0.58, 95% CI 0.34e0.97; P 5 .0385). There was a strong association be- 
tween survival and heart rate in patients in sinus rhythm, with heart rate O119 beats/min conveying the 
worst mortality risk. 
Conclusions:  ECG abnormalities are almost universal among Africans with acute HF, which may add to 
the immediate diagnosis of patients presenting with dyspnea. Although some ECG findings have prog- 
nostic value for risk of adverse outcomes, most of them are nonspecific and add little to the risk stratifi- 
cation of these patients. (J Cardiac Fail 2014;20:45e52) 
Key Words:  Africa, heart failure, electrocardiogram, outcome, prognosis. 
test in patients with heart failure (HF).1,2  Indeed, most pa- 
tients with HF due to systolic dysfunction have a significant 
abnormality on ECG.3 
However, the grade and spectrum of ECG abnormalities 
may differ by HF etiology and possibly other factors, such 
The   12-lead   electrocardiogram   (ECG)   represents  a 
widely available test, relatively inexpensive, simple to 
perform, and yields an instant result. It is objective and 
reproducible. ECG is recommended by the American Heart 
Association and European Society of Cardiology as initial 
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as ethnicity.4  The current knowledge on 12-lead ECG ab- 
normalities in HF is largely derived from North American 
and European cohorts (predominantly white men).4  Sliwa 
et al recently reported findings from a large study of elec- 
trocardiographic findings among heart diseaseefree Afri- 
cans,
5  
showing that some of the suggested ECG criteria 
may be less applicable in this population; eg, up to 13% 
of  the  studied  population  presented  with  significant  Q 
waves in the absence of myocardial ischemia. 
To our knowledge, the diagnostic and prognostic utility 
of the ECG in Africans with acute HF was not been re- 
ported. The Sub-Saharan Africa Survey of Heart Failure 
(THESUS-HF)6  prospectively collected clinical data in an 
African cohort of patients with HF during admission and af- 
ter follow-up, and thus gives the first unique opportunity to 
study the utility of ECG in patients admitted with HF in this 
part of the world. 
assessed at the same time points. Changes in dyspnea and well- 
being relative to admission were assessed on days 1, 2, and 7 
(or at discharge if earlier). Investigators provided the final diag- 
nosis of HF and its cause. Cardiomyopathy was classified accord- 
ing to the position statement from the European Society of 
Cardiology.  Hypertensive HF, right-sided HF, and ischemic HF 
were defined by standard criteria.9 
Study Outcome 
Subjects who were discharged after admission were evaluated at 
1 and 6 months. At these time points, patients were evaluated for 
signs and symptoms of HF, laboratory evaluations were per- 
formed, and oral medications were recorded. Readmissions and 
death, with reasons and cause, respectively, through 6 months of 
follow-up were collected. 
8 
ECG Data  Acquisition and Interpretation 
A 12-lead ECG was performed within 15 days of admission. 
All ECGs were read centrally by Momentum Research by one 
cardiologist  (O.M.)  and  reviewed  another  (G.C.).  ECGs were 
analyzed for conduction or rhythm disturbances, evidence of 
myocardial ischemia/infarction, or  hypertrophy. The following 
parameters were entered in the database registry together with 
other clinical data: heart rate; length of QRS, QT, and QTc inter- 
vals; type of rhythm (sinus rhythm, atrial fibrillation/flutter, other 
supraventricular tachycardia, ventricular tachycardia, junctional 
rhythm, ventricular pacing, 1st-, 2nd-, or 3rd-degree atrioventric- 
ular block); Q wave compatible with myocardial infarction as 
well as all other forms of Q waves; and ST-T segment changes. 
ST-T segment changes were noted as ST-segment elevation at 
the J point in 2 contiguous leads of 0.2 mV in men or 0.15 mV 
in women in leads V2eV3 or 0.1 mV in other leads, as ST- 
segment depression of horizontal or down-sloping depression of 
0.05 mV in 2 contiguous leads, as nonspecific ST-T abnormality 
where changes did not meet the above criteria for ST-segment 
elevation or depression, or as changes due to bundle branch block. 
Left ventricular hypertrophy (LVH) was determined with the use 
of the Sokolow-Lyon index (SV1 þ RV5/6 O 35 mm), and all of 
other described ECG parameters were defined and analyzed ac- 
cording to the standard international criteria and definitions.10,11
All  ECG  abnormalities  were  classified into  major  and  minor 
with the use of the Minnesota code classification system which 
allows a systematic approach and facilitate an easy appreciation 
of the prognostic value of ECG findings for total cardiovascular 
disease.12
Statistical Analyses 
All data were processed at the central coordinating center at 
Momentum Research, Durham, North Carolina, USA. Data were 
analyzed with the use of SAS version 9.2 (SAS Institute, Cary, 
North  Carolina).  Summary  statistics  (mean,  SD,  median,  and 
25the75th  percentiles)  are  provided  for  continuous  variables 
and frequencies for categoric variables. Some parameters could 
not be estimated or interpreted by the central reader from the 
ECG provided. These were treated as missing in the analyses. 
The associations of ECG findings with the composite end point 
of all-cause death or readmission to 60 days and all-cause death to 
day 180 were evaluated in those subjects with ECGs administered 
within 15 days of the admission. Univariable and multivariable 
Cox  regression models  were  constructed considering the  time 
from admission to the first event; times for patients without the 
Methods 
Study Design and Clinical Setting 
THESUS-HF  was  a  prospective,  multicenter, international 
observational survey conducted in 12 cardiology centers from 9 
countries in the southern, eastern, central, and western regions 
of sub-Saharan Africa, as described in detail elsewhere.6  Ethical 
approval was obtained from the Ethical Review Boards of the 
participating institutions, and the study conformed to the princi- 
ples of the Declaration of Helsinki. 
Inclusion and Exclusion Criteria 
Patients admitted with dyspnea as the main complaint to each of 
the participating centers from July 2007 to June 2010 were 
screened for inclusion in the study. Patients $12  years of age 
with clinical signs and symptoms consistent with congestive heart 
failure (ie, pedal edema, elevated jugular venous pressure, pulmo- 
nary congestion, and tender hepatomegaly) and patients that were 
prepared to continue follow-up, including visits over 6 months, 
were included. Exclusion criteria included acute ST-segment 
elevation myocardial infarction (but not chronic ischemic cardio- 
myopathy), severe known renal failure (patients on dialysis or 
creatinine O4 mg/dL), nephrotic syndrome, and chronic liver dis- 
ease or other cause of hypoalbuminemia. Written informed con- 
sent was obtained from each subject. 
Data  Collection 
A comprehensive range of clinical data were collected on a 
standardized case report form. This included demographic data 
and detailed medical history. A detailed echocardiographic assess- 
ment of ventricular contractility, valvular structure and function, 
and regional wall abnormalities was performed. All echocardio- 
graphic procedures were undertaken by trained physicians and 
measurements made according to the American Society of Echo- 
cardiography guidelines.7 
Laboratory evaluations provided by the local institutions and 
intravenous  and  oral  medications  were  recorded  at  admission 
and days 1, 2, and 7 (or at discharge if earlier). Vital signs (blood 
pressure, heart rate, respiratory rate, and temperature) and signs 
and symptoms of HF (including oxygen saturation, intensity of 
edema  and rales, body weight, and levels of orthopnea) were 
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event of interest were censored at the earlier of the last date the 
patient was known to be alive or the period of interest. Unadjusted 
Kaplan-Meier survival estimates are presented in the figures. 
Multivariable models were constructed from ECG parameters 
with values available for sufficient subjects. None of the associa- 
tions between continuous ECG predictors and each outcome was 
found to  be  significantly nonlinear,  as  assessed by  examining 
the significance of the nonlinear terms of restricted cubic splines 
(RCSs) with 4 ‘‘knots.’’ Multivariable models were adjusted for 
clinical covariates included in multivariable prognostic models 
in the overall THESUS-HF registry.6  For the outcome all-cause 
death or readmission to 60 days, these included history of hyper- 
lipidemia, malignancy, or cor pulmonale, systolic BP, left ventric- 
ular  ejection  fraction,   oxygen  saturation,   rales,  blood  urea 
nitrogen, and  region.  For  the  outcome  all-cause  death  to  day 
180, clinical covariates included sex, history of malignancy, cor 
pulmonale, smoking, or human immunodeficiency virus, systolic 
blood  pressure  (BP),  heart  rate,  oxygen saturation,  orthopnea, 
rales, edema, creatinine, and hemoglobin. The ECG parameters 
QRS  duration, QT,  QTc,  ventricular  rate,  sinus  rhythm, atrial 
fibrillation/flutter, bundle branch block, left ventricular hypertro- 
phy, T-wave inversion in $2 contiguous leads, ST-segment 
depression $1  mm, ST-segment elevation $1  mm, nonspecific 
ST-T changes, isolated pathologic Q waves and Q waves compat- 
ible with myocardial infarction (MI) were then added to the multi- 
variable models to see if any had a significant association after 
adjusting for the clinical covariates. 
Approximately 40% of subjects were missing $1 of the predic- 
tors. Multiple imputations with the use of 7 imputed datasets and 
assumption of multivariate normality were used to handle missing 
values. The Rubin algorithm was used for averaging parameter es- 
timates across the imputed datasets. Backward selection of the 
ECG parameters was performed for each imputed dataset, with 
predictors with P ! .1 kept in the model. ECG parameters that 
remained in a majority ($4)  of the models were then included 
in the final model. c-Statistics are reported for the models with 
and without the ECG parameters to examine the change in model 
discrimination with the addition of ECG information. 
Table 1. Baseline Characteristics for Subjects With an 
Electrocardiogram Within 15 Days of Admission (n 5 523) 
Age, y 
Gender, male 
Systolic blood pressure, mm Hg 
Heart rate, beats/min 
O2  saturation, % 
Ejection fraction, % 
Rales (2/3 vs 0/1) 
Orthopnea (2/3 vs 0/1) 









Etiology of heart failure 
Hypertensive CMP 
Idiopathic dilated CMP 
Rheumatic heart disease 









   1  
1.73 m




QRS duration, ms 
QT duration, ms 
QTc, ms 
Ventricular rate, beats/min 
Sinus rhythm 
Atrial fibrillation/flutter Left 
bundle branch block Right 
bundle branch block Left 
ventricular hypertrophy 
Other electrocardiographic abnormalities 
T-wave inversion in $2 contiguous leads 
ST-segment depression $1 mm 
ST-segment elevation $1 mm 
Nonspecific ST-T changes 
Isolated pathologic Q waves 
Q-waves compatible with MI 
52.0 6 18.4 
256 (49.0%) 
132.9 6 34.3 
105.1 6 21.9 
93.6 6 7.4 



















1.43 6 1.09 
12.4 6 2.4 
81.7 6 49.1 
33.3 6 33.5 
73.9 6 26.7 
348.3 6 52.3 
274.4 6 71.3 













Of the 1,006 patients enrolled in the THESUS-HF study, 
813 patients had an available 12-lead ECG, 523 of which 
were obtained within 15 days of admission and were included 
in the analyses.6 Characteristics of these patients were similar 
to the overall study population (Supplementary Table 1). The 
majority of included patients were enrolled in Nigeria 
(32.1%),  Uganda  (21.0%),  and   South  Africa   (18.9%). 
Table 1 depicts the baseline characteristics of the 523 subjects 
(49% male, overall mean age 52 6 18.4 years) included in the 
analysis. The etiologies of HF were dominated by hyperten- 
sion  (43.2%),  idiopathic  dilated  cardiomyopathy (21.0%), 




Values are presented as mean 6 SD for continuous variables and n (%) 
presented for categoric data (percentages of nonmissing values). CMP, car- 
diomyopathy;  HIV,  human  immunodeficiency virus;  eGFR,  estimated 
glomerular  filtration rate;  BUN,  blood  urea  nitrogen;  MI,  myocardial 
infarction. 
alterations similar in men and women. The distribution of 
subtypes of minor abnormalities in men and women is de- 
picted in Figure 2. 
ECG Abnormalities and Morbidity and Mortality Risks 
 
Patients  included  in  the  analyses  were  followed  for 
a median of 180 days. There were 77 deaths to day 180, 
with  a  Kaplan-Meier  event  rate  of  17.5%.  There  were 
63 patients with a death or readmission to day 60, for 
a  rate  of  13.5%.  Eighty  subjects (15.3%) died  without 
completing a 6-month assessment, 261 (49.9%) had a 6- 
month  assessment, and  156  (29.8%)  had  a  last  known 
The  mean ventricular  rate  was 104  beats/min,  with  a 
ranged of 40e200 (Supplemental Table 1). Abnormal ECG 
was detected in 511 out of 523 patients (97.7%). Figure 1 
shows the ECG abnormalities in these patients, with major 
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Increasing  ventricular  rate  was  associated  with  incr- 
easing risk of both outcomes, whereas the presence of sinus 
rhythm was associated with lower risk (Fig. 3). Heart rate 
analysis when patients were divided into quartiles based 
on the heart rate showed an association with survival prob- 
ability. Further analysis based on the heart rate and sinus 
rhythm/atrial fibrillation showed strong association be- 
tween survival and heart rate specifically in patients in sinus 
rhythm. Patients in sinus rhythm with heart rate of O119 
beats/min fared the worst (Fig. 3). 
After multivariable adjustment, lack of sinus rhythm and 
Q waves associated with MI were the only ECG variables 
associated (P ! .10) with the risk of death or readmission 
within 60 days (Table 2) or death within 180 days (Table 3). 
The addition of these ECG parameters did not improve the 
multivariable   models’   discrimination   (the   ability   to 
correctly classify patients with versus without an event) 
over a model including clinical and laboratory characteris- 
tics for either 60-day readmission or death (c-statistic 0.74, 
95% CI 0.67e0.80,  versus 0.70, 95% CI 0.65e0.75)  or 
180-day mortality (c-statistic 0.77, 95% CI 0.72e0.82, 
versus 0.72, 95 CI 0.68e0.75).13
Fig. 1. Major electrocardiographic abnormalities in male and fe- 
male patients. LVH, left ventricular hypertrophy; AF, atrial fibril- 
lation/flutter;   QMI,   Q   wave   compatible   with   myocardial 
infarction; PB, premature beats; BBB, bundle branch block. 
date alive. The remaining 26 patients (5.0%) were consid- 
ered to be lost to follow-up. 
Without adjustment, QRS width and QT duration were 
not associated with either the composite outcome of death 
or readmission through 60 days or death through 180 days 
(Tables 2 and 3). Bundle branch block and ischemic changes 
were not independently significantly associated with either 
outcome. 
Corrected QT intervals were calculated for all patients, 
and after dividing patients into male and female cohorts 
only 7 out of 254 male patients (2.8%) had a borderline to 
abnormal QTc (O430 ms) and only 6 out of 267 female pa- 
tients (2.2%) had a borderline to abnormal QTc (O450 ms). 
Discussion 
In this large cohort study of acute HF in 9 sub-Saharan Af- 
rican countries, we found a high prevalence (97.7%) of ECG 
abnormalities.  Also,  our  analysis  indicated  that  some  of 
these abnormalities are associated with a higher risk for 
adverse outcome in these patients. The predominant abnor- 
malities include increased heart rate, lack of sinus rhythm, 
and Q waves, all of which were associated with a higher 
risk of adverse outcomes. This study confirms the previously 
reported high prevalence rates of abnormal ECG3  and the 
fact that some of these findings are associated with more 
adverse outcome.14  However, when adjusted for additional 
baseline characteristics, ECG findings did not improve the 
ability of the model to predict adverse outcome and therefore 
added little to the risk stratification of patients with AHF. 
The high prevalence of ECG abnormalities is probably 
because  a  significant number  of  these  patients  suffered 
from structural cardiac abnormalities such as reduced EF 
and valvular diseases as well as comorbidities such as hy- 
pertension (56%) and diabetes mellitus (DM) (11%). This 
finding would tend to suggest, as reported elsewhere, that 
a normal ECG is rare in patients with suspected HF and 
is clinically useful in confirming the presence of heart dis- 
ease without a need to resort to other tests, such as B-type 
natriuretic peptide. The almost universal presence of ECG 
abnormality implies that a patient with signs and symptoms 
of acute HF and a normal ECG has a noncardiac cause of 
the presentation until proven otherwise. Interestingly, and 
consistent with the main results of the THESUS-HF study, 
only  90  patients  (17.2%) were  found to  have  Q  waves 
compatible with MI, which, again, is in line with earlier 
studies showing that ischemic heart disease is an uncom- Fig. 2. Minor electrocardiographic abnormalities in male and fe- 
male patients. RVH, right ventricular hypertrophy. Africa.
6,15e18mon  cause  of  acute  HF  in  sub-Saharan 
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Table 2. Univariable and Multivariable Models of All-Cause Death or Readmission Through Day 60 
Univariable Models Full Model Multivariable Model 
HR for 






Value Baseline Characteristic HR (95% CI) HR (95% CI) HR (95% CI) 
History of hyperlipidemia 
History of malignancy 
History of cor pulmonale 
Systolic blood pressure 
Ejection fraction 
O2  saturation 
Rales 
Laboratory tests 







Ventricular rate, beats/min 
Sinus rhythm 
Atrial fibrillation/flutter Left 
bundle branch block Right 






50 vs 28 
5 









































































































Other electrocardiographic abnormalities 




ST-segment elevation $1 mm 
Nonspecific ST-T changes 
Isolated pathologic Q waves 
Q waves compatible with MI 
Yes/No 0.71 (0.40e1.26) .2399 1.18 (0.58e2.38) .6453 




















.1297 1.86 (0.97e3.54) .0608 
c-Statistic 0.7448 (0.6782e0.8113) 0.7387 (0.6749e0.8024) 
MI, myocardial infarction. 
*Regions: East: Ethiopia, Kenya, Sudan, and Uganda; South: Mozambique and South Africa; West: Cameroon, Nigeria, and Senegal. 
Most other ECG findings were nonspecific. These observa- 
tions are in agreement with the recent study that was con- 
ducted  by  Khan  et  al3ddrawing  from  the  Euro  Heart 
Failure survey of 11,327 patients admitted for acute HFd 
suggesting that most ECG findings in these patients are 
nonspecific and that ECG criteria alone were not accurate 
for the diagnosis or exclusion of specific cardiac abnormal- 
ities in patients with acute HF. 
Similarly, the results of the present study suggest that 
although some ECG variables (especially rate and rhythm 
and the presence Q waves) are associated with worse 
outcomes,  these  factors  do  not  increase  the  predictive 
value of the models for readmission or mortality. Untreated 
patients  with  HF  usually  exhibit  a  high  heart  rate  that 
results from hyperadrenergia; however, we  can  not  rule 
out that the association of higher heart rate with morta- 
lity may indeed be due to more severe neurohormonal acti- 
vation in these patients.19   The rate of left bundle branch 
block (LBBB) in our study was low (8%), compared with 
16%e22% in other populations admitted for HF in Euro- 
pean countries.
20,21   
Moreover, LBBB was not associated 
with increased mortality, in contrast to associations re- 
ported  in  the  European  population;  differences  between 
populations with different age and etiology of HF (ie, less 
ischemic cardiomyopathy, more hypertensive and rheu- 
matic heart disease) might account for these findings. 
Similar results were reported by Hebert et al, in Hispanics 
with systolic HF.22  Even though they found higher preva- 
lence of paced rhythm, LBBB, and abnormal QT intervals, 
in univariate and multivariate analysis corrected for other 
characteristics (age, sex, coronary artery disease, hyperten- 
sion, ejection fraction, medications) ECG findings added 
little prognostic information. Therefore, it seems that 
although ECG is an important assessment that should be 
performed routinely in patients with acute HF, its value 
lies mostly in excluding some specific causes of acute HF 
such as MI or life-threatening arrhythmias. Other electro- 
cardiographic  findings  do  not  substantially  help  in  the 
risk stratification of patients with acute HF. 
Although found previously to be independently associ- 
ated with adverse outcomes in 2 recent studiesdin 872 
patients  with preserved systolic function23   and in  4,133 
patients enrolled in EVEREST trial24  which included acute 
HF patients with ejection fraction #40%dQRS duration 
was  nonsignificantly  associated  with  adverse  outcome 
in the present study. Regarding QTc abnormalities, Kolo 
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Table 3. Univariable and Multivariable Models of All-Cause Death Through Day 180 
Univariable Models Full Model Multivariable Model 
HR for 






Value Baseline Characteristic HR (95% CI) HR (95% CI) HR (95% CI) 
Male sex 
History of malignancy 
History of cor pulmonale 
History of smoking 
HIV positive 
Systolic blood pressure 
Heart rate 











Ventricular rate, beats/min 
Sinus Rhythm 
Atrial fibrillation/flutter 
Left bundle branch block 
Right bundle branch block 







118 vs 90 
5 
(2/3 vs 0/1) 
(2/3 vs 0/1) 

























































































































Other electrocardiographic abnormalities 
T-wave inversion in $2 
contiguous leads 
ST-segment depression$1 mm 
ST-segment elevation $1 mm 
Nonspecific ST-T changes 
Isolated pathologic Q waves 
Q waves compatible with MI 


























1.57 (0.91e2.72) .1057 
2.45 (1.39e4.32) .0020 
c-Statistic 0.7729 (0.7198e0.8260) 0.7683 (0.7163e0.8204) 
MI, myocardial infarction. 
et  al,25   in  a  study  including 90  Nigerian patients  with ECGs had characteristics similar to the rest of the cohort. 
The second issue is the lack of standardization of the 
manner  in  which the  ECGs were  acquired.  Inconsistent 
placement of ECG electrodes is known to have an effect 
on ECG voltages which are important in the assessment 
of cardiac hypertrophy.27 Third, missing data for other vari- 
ables may have diluted the associations that were sought in 
this study. Fourth, owing to no access to cardiac catheteri- 
zation in a number of centers, we might have missed some 
cases of HF due to ischemic origin. And finally, we can not 
rule out the possibility that by recording ECGs at 615 days 
and not absolutely on admission, our study missed some 
transient ECG abnormalities. These limitations, however, 
have to be considered in the context of the study setting, 
where major constraints to high-quality clinical research 
are still commonplace. The study was conducted in selected 
specialized centers, and only patients who consented to the 
study were enrolled; thus, not all patients admitted with 
AHF are  represented  and  the  study’s generalizability  is 
somewhat limited. However, we have increased our under- 
standing of the growing importance of chronic cardiovascu- 
lar disease in this population, who are often thought to 
suffer much from infectious diseases. 
chronic HF, found QTc to be prolonged in 63% of patients. 
However, in the present study of patients with acute HF, we 
found that few patients had QTc prolongation: 7 out of 254 
male patients (2.8%) had a borderline to abnormal QTc 
(O430  ms) and 6 out of 267 female patients (2.2%) had 
a borderline to abnormal QTc (O450 ms). 
Taking into consideration that a significant proportion of 
the patients in our study were hypertensive, we expected to 
find a substantial prevalence of ECG signs of LVH. Howev- 
er, only 158 patients (30.6%) met the criteria for LVH. 
Moreover, in disagreement with earlier subanalysis of the 
CHARM program,26  where ECG LVH was reported as an 
independent  predictor  of  worse outcome,  in  the  present 
study patients with LVH tended to be at decreased risk 
for both all-cause mortality and readmission through day 
60 as well as all-cause mortality through day 180. This 
finding is unexpected and requires confirmation in further 
studies; however, it is possible that hypertensive HF has a 
relatively benign prognosis in Africa. 
There are several weaknesses of the present study. First, 
ECGs were available in only 523 of the 1,006 patients in 
the THESUS-HF cohort. However, patients with available 
 
 
   
 
179 Dzudie  et al 
51
ECG,  Acute HF, and  Mortality Risk in Sub  Saharan Africa 
Fig. 3. Kaplan-Meier estimates of 180-day survival according to various electrocardiographic findings within 15 days of admission. Afib/ 
Aflut, atrial fibrillation/flutter. 
Siem Abebe and Leslie Quinn for trial coordination and 
data management and Sylvia Dennis for assistance with 
manuscript preparation. 
Conclusion 
In African patients admitted for acute HF, ECG abnor- 
malities are present in 98% of cases, and some of these ab- 
normalities   (eg,   higher   heart   rate,   nonsinus   rhythm, 
presence of Q waves) are associated with higher risk for 
adverse outcomes. Although ECG should be routinely ob- 
tained in patients admitted for acute HF to confirm presence 
of heart disease and rule out acute ischemia and severe 
rhythm disorders, for the most part ECG abnormalities in 
African patients with acute HF are nonspecific and add lit- 
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Chapter 8. Conclusions and ways forward 
 
Pulmonary hypertension (PH) has progressively moved from an orphan disease to a major 
public health problem as attested by data from registries in high income countries. However, 
the condition has yet to be fully characterized around the world. Comparative data on the 
prevalence of different groups of PH is lacking. Due to the high prevalence of predisposing 
conditions to PH in sub-Saharan Africa (SSA), knowledge of the profile of patients and 
distribution of PH aetiologies in this part of the world is a public health priority. 
A well designed and managed clinical registry has several advantages. Firstly, it can provide 
reliable data about cohorts of patients who are likely to be a subset of a larger population 
with similar disease patterns. Secondly, it provides an opportunity for physicians and 
scientists at large to generate knowledge about the current epidemiology, actual course and 
therapies of diseases in the context of their local health system. This information is crucial for 
an objective estimation of the future health care needs and expenditures.  Thirdly, a clinical 
registry is a basis of hypothesis formulation for further investigation by clinical trials. For all 
these reasons, a clinical registry of PH across Africa was urgently needed. 
In this doctoral research endeavour, using two prospective clinical registries, we have 
attempted to address several gaps in the knowledge about PH. In the paragraphs below, we 
summarize our main findings from investigation of specific questions and we suggest main 
future research directions. 
8.1. The clinical profile and distribution of etiologies of pulmonary 
hypertension in Sub-Saharan Africa.  
The analysis of data from the PAPUCO registry, the first multicentric and multinational cohort 
study of PH in Africa demonstrated that all groups of PH are represented in SSA, with left 
heart disease (LHD) being the leading cause of PH, followed by HIV and post-tuberculosis lung 
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disease. PH tend to affect predominantly poorly or uneducated women who are 
disproportionately exposed to indoor fume, and present late to the hospital. PH-LHD in SSA 
affects people in their young and active age, and is predominantly due to a number of causes 
such as heart failure and its different aetiologies, and rheumatic valvular heart disease. Our 
experience from the PAPUCO registry highlights the potential of generating accurate and 
reliable data on PH and its aetiologies in SSA. Our findings are likely applicable to other low-
income countries at large, and such data are needed to assist health care and policies planning 
in the region.  
Future directions in terms of research on the epidemiology of PH in SSA should include the 
study of a large sample of PH sub-groups that are almost specific to the LIC including 
rheumatic valvular heart disease, sickle cell disease and HIV/AIDS. This will help filling the 
following knowledge gaps: 
i. Rheumatic valvular heart disease: the updated guidelines by the European 
Society of Cardiology and the European Association for Cardio-Thoracic Surgery (1) 
suggest PH as an indication for surgery in asymptomatic people with mitral 
regurgitation (MR) if the systolic pulmonary pressure exceeds 50 mmHg at rest or 
60 mmHg at effort. However, these guidelines are based on studies in patients 
with degenerative MR and do not provide enough support for PH in patients with 
multivalvular lesions as it is usually the case for rheumatic valvular heart disease 
(150). A study with a large number of patients with rheumatic heart valve disease 
will facilitate the refinement of knowledge on the added value, if any, of PH to 
outcome risk stratification in this specific population, and will also improve the 
understanding of the mechanisms underlying the risk of developing PH. Indeed, 
there is still very vague understanding of who among patients with valve disease 
is likely to develop PH, and why in a proportion of these patients with PH due to 
valve disease, the post capillary and reversible PH will be superimposed by a pre 
capillary pulmonary vasoconstriction and vascular remodelling leading in some 
cases to persistent PH event after corrective surgery (86, 187). Also, little 
information is available on the predictors of persistent PH as well as on the 
indications for PH specific therapies following corrective surgery for VHD. The 
pathogenesis of rheumatic heart disease is not fully understood, but suggested to 
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involve molecular mimicry and genetic predisposition that lead to autoimmune 
reactions. It would be interesting to investigate whether a subset of this 
population, due to their genetic background is more likely to develop post capillary 
PH and subsequent evolution to a pre-capillary component that deserves special 
attention.  
ii. Sickle cell disease (SCD): SCD is the most common monogenic disease in humans
and a global public health issue, affecting up to 300,000 new-borns each year, with
more than 70% of them found in Sub Saharan Africa. As discussed in Chapter one
of this thesis, 30% of SCD patients develop PH with increase mortality risk. Current
guidelines (32) suggest that these patients should be screened using
echocardiogram yearly and undergo right heart catheterization (RHC) if tricuspid
velocity by echocardiogram ≥2.5 m/s. A recent study (188) showed that
echocardiography alone likely has a low positive predictive value for PH people
with SCD, which means the decision on when to either proceed with RHC or further
non-invasive monitoring of a patient with SCD remains a clinical challenge. It would
be relevant to explore the combined diagnostic utility of all non-invasive tests
including ECG, NT-proBNP and echocardiography to correctly identify or exclude
PH in SCD patients referred for clinical suspicion of PH. This also applies to the HIV-
infected patient’s subgroup who have a 2500-fold increased risk of developing
PAH.
8.2. The early diagnosis of PH and heart failure in resources-poor 
settings 
Early diagnosis and treatment of PH and its etiological factors is important considering that at 
the advanced stage, the disease is less amenable to treatment and is associated with poor 
outcomes. Although RHC is expensive, less available and an invasive test with non-negligible 
complications, it remains the gold standard for diagnosis of PH. Cost-effective strategies that 
can assist early diagnosis and distinction between pre and post-capillary PH and therefore 
avoid unnecessary RHC are warranted. In SSA, 12-lead electrocardiogram (ECG) represents 
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the more widely available test, relatively inexpensive, simple to perform, objective and 
reproducible. We assessed in a large sample of ECGs from the THESUS-HF the predictive utility 
of ECG abnormalities among Africans with acute HF. This study illustrated that ECG 
abnormalities are almost universal among Africans with acute HF, but most of the 
abnormalities are non-specific, although some have prognostic value for mortality risk. In a 
sub-study of the PAPUCO-registry, we similarly found that a normal ECG is rare in patients 
with PH, but most of these abnormalities were non-specific and ECG criteria of right 
ventricular strain were rare and also non-specific among patients with PH. It will be important 
in the future to investigate whether a combination of non-invasive criteria like the six minute 
walk test, ECG, and NT-proBNP on top of echocardiography helps rule out false positive case 
of PH among patients referred with dyspnea and suspicion of PH, while not missing true pre-
capillary PH. Further research in this area from low income countries should also be directed 
towards improving diagnosis of HF or PH by an early identification using innovative 
technologies. For instance, with the wide availability of smartphones in Africa and the low 
doctor-to-patient ratio (189), it is timely to explore in a larger sample of patients with PH and 
assess whether mobile ECG (incorporated in smartphones) can be a viable alternative to 
traditional ECG (which needs medical training for recording) for detecting patients with PH or 
predisposing conditions. Secondly, the diagnostic capability of recently available and less 
expensive hand-held echocardiography versus conventional transthoracic DE used as a gold 
standard in diagnosis of PH will be a key step towards improvement of diagnostic strategies 
for PH and predisposing conditions in limited resources’ settings. Thirdly, novel biomarkers 
like NT-proBNP have been well shown to predict adverse outcomes in patients with HF and 
to also serve as a guide to therapy (176). Exploring if NT-pro BNP assay is a good marker for 
diagnosis and assessment of severity of RV remodeling and PH is another important critical 
area where further research is needed.  
8.3. The outcomes of PH-LHD in Low income countries 
In a systematic review, we found that PH-LHD, the main cause of PH, is almost invariably 
associated with increased mortality risk in patients with LHD. However, evidence originated 
essentially from studies in high income countries and above all, the effects of PH on 
185 
 
hospitalization risk have been less investigated. What are the effects of PH-LHD on 
hospitalizations and mortality in Low Income Countries (LIC)? To examine this question, we 
investigated the clinical profile and short term outcomes of patients with PH-LHD from the 
multicentre PAPUCO study. We found that left atrium size and tricuspid annular plan 
excursion (TAPSE) were predictors of RVSP in this cohort. RVSP (but not TAPSE) predicted 
short term hospitalization but not mortality. In spite of the short term follow-up, these 
findings raised two important questions: 1) is the absence of an adverse effect of PH-LHD on 
mortality in this thesis a result of our younger population with a different etiological profile 
or would an extended follow-up of a larger sample have revealed different results? 2) Can 
hospitalization risk be reduced in patients with PH-LHD and how can this be achieved? A 
longer follow-up of a larger population sample with various causes of PH-LHD will help refine 
the mortality risk and stratification of the management of these patients. Also, the 
importance of the right ventricular dysfunction in the context of PH-LHD needs further 
exploration. In the attempt to target PH to reduce outcomes, as described in Chapter one of 
this thesis, the lack of evidence based advanced therapy in PH-LHD is of great concern. To 
date, clinical trials have been characterized by limited sample size, single centre, lack of 
uniform stratification of patients based on PH and finally, unsatisfactory, if not detrimental, 
results on the outcome of interest.  New trials that specifically address PH in left heart disease 
patients are warranted. In a thesis conducted at the University of Cape Town, G. J. Maarman 
(190) demonstrated that treatment with melatonin confers cardioprotection in a rat model 
of PH. As melatonin is inexpensive, safe and already available in several low income countries, 
a multicentre randomized control trial to evaluate the efficacy and safety of this drug in 
patients with PH-LHD is a key future step for SSA settings. 
 
In conclusion, several gaps exist in the knowledge of contemporary PH worldwide and 
specifically in low income countries where the prevalence and burden of PH is estimated to 
be high due to prevalent predisposing conditions. This thesis has provided greater insight into 
clinical profile of PH and its aetiologies, PH-LHD predictors and outcome, the diagnostic utility 
of ECG in PH and finally its prognostic significance in heart failure. It has also raised future 
research questions for which relevant agendas are delineated.  
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Baseline 
Patient’s Initials: Patient Number:               –                  
day month year 00:00 to 23:59 
day month year 
day month year 
9 3 3 
■ /mm3 or /cumm or /µL or /mcL
■ ■ nkat/L      % 
pg/mL OR BNP  pg/mL 
natriuretic peptide) 
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Demographics 
1   Date of admission:      /   /200   Time:  :   
2   Date of birth:      /   /  
3   Sex: ■1  Male ■1  Female
4   Race: ■1  Black    ■2  Asian    ■3  Caucasian
5   Height:  cm 
6   Weight:  kg 
Pre-Admission 
1   Number of acute heart failure (AHF)  admissions in the last 12 months: 
2   Date of last acute heart  failure (AHF) admission:  /  /200  OR  ■96  NA
3  NYHA (New York Heart Association) classification 1 month prior to admission:   ■ I       ■ II       ■ III       ■ IV     ■ NA
ECG (Electrocardiogram) 
Please  attach  copy of admission  ECG in the CRF divider pocket. 
Baseline Labs  First obtained at Admission 
Lab  Value        Units 
1   Creatinine ■ mg/dL    ■ µmol/L
2   BUN (blood urea nitrogen)/urea ■ mg/dL     ■ mmol/L
3   Sodium ■ mmol/L   ■ mEq/L
4   Glucose ■ mg/dL    ■ mmol/L
5   Hemoglobin ■ g/L    ■ mmol/L    ■ g/dL
6   Total WBC (white blood count) ■ x10 /L or 10 /mm
7   Lymphocytes % % 
8   Cholesterol ■ mg/dL    ■ mmol/L
9   Triglycerides ■ mg/dL    ■ mmol/L
10 Peak CK (creatine kinase)  ■ IU/L    ■ µkat/L      ■ nkat/L
11 Peak CK-MB (creatinine kinase myocardial band) ■ IU/L     ■ µg/L    ■ µkat/L     ■ ng/mL
12 Peak Troponin  ng/mL 
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Baseline Characteristics  at Time of Admission 
1   Diabetes    ................................   ■0 No  ■1 Yes ➞   If Yes: Check all that apply:   ■ Diet    ■ Oral     ■ Insulin
2   Ischemic heart  disease   ......  ■0 No  ■1 Yes ➞   If Yes: Check all that apply:
■ History  of CABG (coronary artery bypass graft) 
■ History  of PCI (percutaneous  coronary intervention)
■ Stable angina ➞ If Yes: Canadian Cardiovascular Society
Class. of angina:   ■ I       ■ II       ■ III       ■ IV
3   Valvular disease   .................. ■0 No  ■1 Yes ➞   If Yes: Check all that apply:
■ Mitral regurgitation
■ Aortic  regurgitation
■ Other (specify):
4   HIV test positive  ■99  Unknown ■0 No  ■1 Yes ➞   If Yes: Antiretroviral therapy?  ■0 No     ■1 Yes
5   Hypertension  ........................   ■0 No  ■1 Yes
6   Hyperlipidemia  .................... ■0 No  ■1 Yes
7   Stroke    ....................................   ■0 No  ■1 Yes
8   PVD (peripheral vascular disease)   ....  ■0 No  ■1 Yes
9   Smoking   ................................   ■0 No  ■1 Yes
10 Malignancy    ..........................   ■0 No  ■1 Yes
11 Depression    ............................   ■0 No  ■1 Yes
12 Dementia    ..............................   ■0 No  ■1 Yes
13 Atrial fibrillation   .................. ■0 No  ■1 Yes
14 Pacemaker   ............................   ■0 No  ■1 Yes
15 Pericardial  disease  .............. ■0 No  ■1 Yes
16 Cardiomyopathy  .................. ■0 No  ■1 Yes
17 Cor pulmonale     .................... ■0 No  ■1 Yes
18 Ejection fraction:  % 
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day month year 
■ µmol/L 
■ mmol/L 











































































Hospital  Data  See opposite  page for instructions 
Date ➞ 
 
           /                /200    
day           month              year 
 
          /                /200    
day           month              year 
 
          /                /200    
day           month              year 
 
          /                /200    
day           month              year 
 
          /                /200    
day           month              year 
 
          /                /200    
1  Symptom Scale 1 Month Pre Admission Day 1 Day 2 Discharge or Day 7 Follow Up 
Dyspnea +3 to –3 NA NA 
    
Well-being +3 to –3 NA NA 
    
Orthopnea 0 to 3       
Dyspnea  on 
exertion 
0 to 3  OR NA 
(not evaluable) ■ NA                   ■ NA                   ■ NA                   ■ NA                   ■ NA                   ■ NA 






               /             
 
               /             
 
               /             
 
               /             
 
               /             
 






   
     
Respiration breaths/minute         
O2  saturation %            .               .               .               .               .               .    
Temperature °C            .               .                .               .               .               .    
Peripheral  edema 0 to 3+ 
      
Rales 0 to 3       
JVP (Jugular 
venous pressure) 
1 to 3  OR NA 





      
3  Labs Unit 1 Month Pre Admission* Day 1 Day 2 Discharge or Day 7 Follow Up 
 




    
 




    
 




    
BNP pg/mL  
 
NA* 
    
NT Pro BNP pg/mL  
 
NA* 
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■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
■1   Yes 
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Hospital  Data  See opposite  page for instructions (continued) 
 
4  IV Drugs 
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■1   Yes 
■0   No 
■1   Yes 
■0   No 
■1   Yes 
■0   No 
■1   Yes 
■0   No 
■1   Yes 
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■0   No 
■1   Yes 
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■1   Yes 
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■1   Yes 
■0   No 
■1   Yes 
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■1   Yes 
■0   No 
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Outcome 
 
Hospital discharge date:            /                  /200    
 










Rehospitalization  #1 
 
 
          /                  /200    
day              month                 year 
 
 
Rehospitalization  #2 
 
 
            /                  /200    
day              month                 year 
 
 
Rehospitalization  #3 
 
 









■0  No     ■1  Yes 
 
■0  No     ■1  Yes 
 





■0  No     ■1  Yes 
 
■0  No     ■1  Yes 
 





■0  No     ■1  Yes 
 
■0  No     ■1  Yes 
 





■0  No 
■1  Yes ➞ Specify: 
 
■0  No 
■1  Yes ➞ Specify: 
 






■0  No 
■1  Yes ➞ Specify: 
 
■0  No 
■1  Yes ➞ Specify: 
 




1   Date of death:            /                  /200    
2   In hospital at time of death? ..................................................  ■0  No     ■1  Yes 
3   Sudden  death?   ........................................................................  ■0  No     ■1  Yes 
4   During acute heart  failure?   ..................................................  ■0  No     ■1  Yes 
5   During acute ischemia?   ..........................................................  ■0  No     ■1  Yes 
6   Associated with arrhythmia?  ................................................  ■0  No     ■1  Yes 
7   Other cardiac?  ..........................................................................  ■0  No     ■1  Yes  ➞ Specify:     
8   Non-cardiac?   ............................................................................  ■0  No     ■1  Yes  ➞ Specify:     
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day month year 
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Echocardiographic Evaluation 
 
Date of echocardiogram                                                /                  /200    
 
 
1   Heart rate                                                                           bpm 
Dimensions and LV Function              Value 
2   Left ventricular size systole                                                         mm 
3   Left ventricular size diastole                                                        mm 
4   Ejection fraction                                                                            % 
5   Intra ventricular septum (diastole)                                                 mm 
6   Posterior wall (diastole)                                                                   mm 
Diastolic Function                       Value 
 
7   Left atrial size, antero-posterior                                              mm 
8   Left atrial size, planimetry                                                           mm2 
9   Mitral E-wave                                                                                mm/sec 
10 E-wave deceleration time                                                            msec 
11 Mitral A-wave                                                                               mm/sec 
12 Mitral A-wave (duration)                                                            msec 
Valvular Severity Rheumatic? 
13 Aortic stenosis ■0  None    ■1  Mild   ■2  Moderate    ■3  Severe ■0  No    ■1  Yes   ■ NA 
14 Aortic regurgitation ■0  None    ■1  Mild   ■2  Moderate    ■3  Severe ■0  No    ■1  Yes   ■ NA 
15 Mitral stenosis ■0  None    ■1  Mild   ■2  Moderate    ■3  Severe ■0  No    ■1  Yes   ■ NA 
16 Mitral regurgitation ■0  None    ■1  Mild   ■2  Moderate    ■3  Severe ■0  No    ■1  Yes   ■ NA 
17 Tricuspid regurgitation ■0  None    ■1  Mild   ■2  Moderate    ■3  Severe ■0  No    ■1  Yes   ■ NA 
 
19 Other ■0  None    ■1  Mild   ■2  Moderate    ■3  Severe ■0  No    ■1  Yes   ■ NA 
Pericardial Effusion Severity Tuberculosis? 
 
20 Pericardial  effusion ■0  None    ■1  Mild   ■2  Moderate    ■3  Severe ■0  No    ■1  Yes   ■ NA 
 
21 Other conditions ■0  No     ■1  Yes ➞ If Yes: Specify: 
22 Other conditions ■0  No     ■1  Yes ➞ If Yes: Specify: 
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Diagnosis 
Type of Heart Failure (HF) (please answer all questions): 
1   Diastolic dysfunction ■0  No ■1  Yes
2   Systolic dysfunction ■0  No ■1  Yes
3  Dilated—idiopathic cardiomyopathy (CM)     ■0  No     ■1  Yes
4   Peripartum  cardiomyopathy  ■0  No ■1  Yes
5   Ischemic heart  disease ■0  No ■1  Yes
6   HIV cardiomyopathy  ■0  No ■1  Yes
7   Rheumatic heart  disease ■0  No ■1  Yes
8   Hypertensive cardiomyopathy (HTN CM) ■0  No ■1  Yes
9   Endomyocardial fibroelastosis ■0  No ■1  Yes
10 Pericardial  effusion/tamponade ■0  No ■1  Yes
11 Other factors  ■0  No  ■1  Yes ➞ If Yes: Specify:
12 Other factors  ■0  No  ■1  Yes ➞ If Yes: Specify:
  
THESUS-HF 
Contact Information Log 
Retain at Site 
2007 DCRI  — Confidential Thesus-HF_V1.0_21 MAR 2007 Contact Information Log 
Patient Number Full Name Phone Number Address ID Number 
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PAPUCO : CASE REPORT FORM 
 
Pan  African Pulmonary Hypertension Cohort Study 
 
www.papuco.org 
A research collaboration for  Africa 
CASE REPORT FORM 
Baseline 
(On database: Master 
record) 
Patient initials 
1. ELIGIBILITY CRITERIA 
2. PATIE N T INFORMATION  
Folder number 
Enter the  patient hospital or clinic folder  number. 
 
ID or Passport number 
 
 
Patient sur name 
 
 







Date of birth: 
 
 




Enter  the  language of the  patient's mother 














Enter the  patient's 
race. (single answer) 
 
African or black 
Coloured or mixed race 
Indian or Asian 
Arab 
Caucasian or white 
Other 
Clinical and echocardiography criteria for the  diagnosis of pulmonary 
hypertension 
Does the patient has clinical and echoc ardiography evidence of pulmonary 
arterial hypertension (RVSP>=35 mmHg) 
Yes 
 
Patient fulfilling inclusion criteria 
Does the patient fulfil inclusion criteria (new diagnosis  and  previously  not 












Date of informed consent/enrolment 
Enter the  date when  the patient or next of kin consented to the  PAPUCO study. 
 
 
PAPUCO - Pan African Pulmonary Hypertension Cohort Study Patient initials 
Other 
300 to 499 USD 
3. LOCATION
4. MEDICAL HISTORY
designed by integerafrica Baseline CRF 2/14 
Family history of CVD 
Does the patient have a positive family history of cardiovascular diseases 











Education level  completed  
Enter the  highest education the patient 
completed. (single  answer). 





Occupation  type 
Enter the  patient's curr ent occ upation 
type. (single answer) 




Employed part  time 
Employed full time 
Self employed 
Homemak er or housewife 
Government grants or pension 
Income 
Enter the  self-reported months income  of the  patient (monthly per  capita 
income). If no personal income, specify  income of household breadwinner. 
(single answer) 
Below 30 USD 
30 to 99 USD 
100 to 299 USD 
500 to 999 USD 
1000  to 1999 USD 
2000  to 4999 USD 
more than  5000  USD 
Type of accommodation 
Enter the  type of accomm odation the patient lives 
in. (single answer) 
House  or permanent building 
Shack on serviced site with sanitation 
Shack without sanitation 
Traditional housing  or hut 
Other 
Referral source 
Enter the  referral source the  patient was referred 
from. (single answer) 
Other  Hospital 
Community clinic 
General pr actitioner 
Medical ward of this hospital 
Outpatient department of this hospital 
Other 
Research sample ID 
Enter the  patient research sample ID that will be written on the labor atory 
tubes. Enter  your own  sample ID number or if the field is left blank, a sample ID 
will be  generated for the patient research sample. Please  label all samples using 
Patient mobile phone  number 
Other (partner, friend, parents)  phone number 1 
Other phone  number 2 
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Lung cancer 
5. ENVIRONMENT
designed by integerafrica Baseline CRF 3/14 
Living at high altitude 
Does  or did the patient live at high altitude (>1500  meter  above sea  level)? 
YES 
NO 
Years at high altitude 
Working in mine 
Does  or did the patient work in a mine? 
YES 
NO 
Indoor cooking or heating without chimney 
Does  or did the patient cook indoor  using  burnable (e.g. w ood, charcoal, 
kerosene, paraffin,  dung  etc.) without chimney? 
YES 
NO 
Smoking  habit 
Does  or did the patient 
smoke? (single answer) 
Current smoker 
Ex-sm oker 
Never  smoked 
 Number of pack-years 
Date of discontinuation: 
Enter the  date the  patient stopped smoking 
Alcohol abuse 
Does  or did the patient abuse  alc ohol? 
YES 
NO 
Recreational  drug use 




















Has the patient been diagnosed with rheum atic disease (E.g. Rheum atoid arthritis)? 
YES 
NO 
Type of rheumatic disease 
Select the  type of rheumatic 
disease. (multiple answers) 
Scleroderma (systemic sclerosis) 
Mixed connective tissue  disease (MCTD) 
Systemic lupus  erythematosus (SLE) 
Rheum atoid arthritis (RA) 
Systemic necrotizing vasculitis 
Idiopathic inflamm atory myositis 
Other 
Deep vein  thrombosis: 




Has the patient been diagnosed with pulm onary em bolism (PE)? 
YES 
NO 
Chronic lung disease 
Has the patient been diagnosed with chronic  lung disease? 
YES 
NO 
Type of chronic lung disease 
Select the  type of chronic lung disease. COPD includes  pul monary emphysema. 
Destructive lung disease in HIV due to TB, PCP or other pul monary infection should 
be classified  bronchiectasis. 
(multiple answers) 
Asthm a 
COPD / emphysema 
Bronchiectasis 
Other 
Specify chronic lung disease 
Specify the chronic lung disease of the 
patient. Please  be specific. 
Chronic liver disease 
Has the patient been diagnosed with chronic  liver disease? 
YES 
NO 
Type of chronic liver disease 









PAPUCO - Pan African Pulmonary Hypertension Cohort Study Patient initials 
6. INFECTIOUS DISEASES 
How many TB episodes: 
How many  times was the patient diagnosed for TB in his life? 
episode? 
if patient is still on TB treatment. 
YES 
NO 
Concurrent TB treatment 
Is the patient still on TB treatment? 
designed by integerafrica Baseline CRF 4/14 
HIV testing 
Has the patient been test ed  for HIV? If not, council and  test  the  patient for HIV 
according to your national HIV testing guidelines. If patient refuses to get 





Enter the  HIV status of the patient. 
Positive 
Negative 
Date of HIV diagnosis 
Enter the  date of HIV testing. If the exact date is unknow n, calculated 
the approximate date  according  to patient inform ation. 
 
CD4 nadir 
CD4 nadir is the  lowest CD4 count  of the patient ever  measured. If it is identical 
with the field ‘Latest CD4 count’, fill in both fields with the  same CD4 count. 
cells per  10^6/L 
 
Latest  CD4 count 
Enter the  latest CD4 count  of the patient. 
cells per  10^6/L 
 
Date of latest CD4 count 
Enter the  date of the latest CD4 count. 
 
Latest HIV viral load 
Enter the  latest HIV viral load  in plasma. If HIV viral load is suppresse d in plasm a 
according to the lowest level of detection of your laboratory enter ‘0’. 
copies/mol 
 
Date of latest viral load 
Enter the  date of the latest HIV viral load in plasm a. 
 
 
Antiretroviral  therapy 
Is the  patient currently receiving ART? 
YES 
NO 
 Date of ART initiation   
Enter the  date when  patient was started on ART. 
 
Previous TB 
Has the patient ever been diagnosed or treated for TB? 
YES 
NO 
    
 
 
Date of last  episode: 
 
 
Enter the date of the latest TB episode. 
 
Site of TB 




Format:  Y YY Y-MM-DD 
Pulmonary and/or pleural TB 
Abdominal TB 
Lymph node  TB 
CNS TB 
Pericardial  TB 
   Disseminated TB 
Other  site of TB  
 Treated for TB  YES 
NO 
YES 
Has   the  patient   received   TB  treatm ent   for    his/her   latest   TB 
 
Completed  TB treatment 
 Has the patient complete d treatment for his/her latest TB episode? Select 'Yes' 
NO 
 
if TB treatm ent  was com pleted; sel ect ‘No’ if TB treatm ent  was not  completed or 
 
Type of recreational drug use 
Select the  type of recreational drug 
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Other 
Was abdominal ultrasound performed to screen for schistosomiasis. NO 
Hydr onephrosis 
schistosomiasis? Example: single  oral dose of the drug 
Specify  treatment: 
designed by integerafrica Baseline CRF 5/14 
Exposure to schistosomiasis  
Has the patient ever lived or does he/she live in an endemic region 
YES 
NO 
 for schistosomiasis  ? 
years Years of exposure 
Enter the  years  (cumulative years)  of exposure to an endemic  region 
 for schistosomiasis. 
YES Haematuria at presentation: 
 Does  or did the patient experien ce haem aturia? NO 
YES Microscopy  for schistosomiasis: 
Was microscopy  performed to diagnose schistosomiasis? 
Specimen for microscopy 
Enter the  type of specimen that was used to diagnose 





Schist soma  eggs present 
Select the  type of schistosoma that was 






YES Abdominal  ultrasound 
 
Ultrasound findings suggestive for schistosomiasis Select 




Normal  abdominal ultrasound 
Liver left lobe  enlargement 
Periportal fibrosis 
Liver left lobe  enlargement AND Periportal fibrosis 
Thickening or calcification  of bladder wall 
Thickening or calcification  of bladder wall AND Hydronephrosis 
Other  abdominal pathology 
YES 
NO 
Previous treatment for schistosomiasis 
Did the patient ever  receive treat ment for 
praziquantel. 
ART regimen 
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(On database: Baseline visit data) 
1. PATIE N T INFORMATION Date 
2. CLINICAL PRESENTATION 
Shortness of breath 
Bluish lips or skin 
Non-productive  cough 
Does the patient suffer  non-productive couch? NO 
Does the patient suffer  fatigue? NO 
Does the patient suffer  dizziness? 
Does the patient suffer  episodes of syncope or near 
Palpita 
carefully. (single  answer) NYHA IV 
NYHA   I: No sym ptoms and  no limitation in ordinary  physical ac tivity. 
NYHA  II: Mild symptoms (mild shortness of breath and/or angina) and  slight limitation during  ordinary  ac tivity. 
NYHA  III: Marked limitation in activity due to symptoms, even  during less-than-ordinary activity. Comfortable only at rest. 
NYHA  IV: Severe limitations. Experiences sym ptoms even while at rest. Mostly bedbound patients. 
3. CLINICAL INVESTIGATIONS 
Karnofsky Scale 
The Karnofsky Performance Scale is an assessment tool  used to assist clinicians and  caretakers in measuring a patient's ability to 




most of his personal needs. 
medical care. 
death not  imminent. 
treat ment necessary. 
designed by integerafrica Baseline CRF 6/14 
 
 
Able to carry on normal activity and to work; no special 
care needed. 
 
100 Normal  no com plaints; no evidence of disease. 
 
90 
Able to carry on normal activity; minor  signs  or symptoms of 
 
80 
Normal  activity with effort; some  signs  or symptoms of 
 
 
Unable to work; able to live at home and care for most 




Cares for self; unable to carry on normal activity or to do 
 
60 








Unable to care for self; requires equivalent  of 
institutional or hospital care; disease may be 
progressing  rapidly. 
 
40 Disabled; requires special care and  assist ance. 
 
30 
Severely disabled; hospital admission  is indicated although 
 
20 
Very sick; hospital admission  necessary; active supportive 
 
10 Moribund; fatal  processes progressing rapidly. 
0 Dead 
   YES 
NO Does the patient suffer  shortness of breath? 




Does the patient experience bluish lips or skin? 
    
YES 
 
    
YES Fatigue 
    
YES Dizziness 
   NO 
YES Syncope 
   NO 
YES syncope? 
 tions NO 
YES Does the patient experience palpitations? 
Angina 
Does the patient suffer  chest  pain  (angina pectoris)? 
NYHA classification 
Please  read  below and select 
NO 
NYH A I 
NYH A II 
NYH A  III 
of visit 
Enter the  date of patient visit (=date  of clinical assessment). 
 
 
Format:  Y YY Y-MM-DD 
 
PAPUCO - Pan African Pulmonary Hypertension Cohort Study Patient initials 
Diastolic blood  pressure at rest 
Enter the  DIASTOLIC value of patient blood  pressure 
Enter  patient pulse at rest. 
Enter  patient pulse  oxymetry reading at rest (SpO2). 
NO 
Peripheral oedema YES 
NO 
Prominence of pul monary arteries 
designed by integerafrica Baseline CRF 7/14 
Body weight 
Enter the  weight of the patient 
kg 
Body height 
Enter the  height of the patient 
cm 
 Systolic blood  pressure at rest mmHG 
Enter the  SYSTOLIC value  of patient blood  pressure 
mmHG 
Pulse at rest bpm 
% Pulse  oxymetry at rest 
breaths per Respiration rate at rest 
Enter  patient respiration rate at rest. 
JVP raised 
Is jugular venous pressure (JVP) raised? 
YES  
minute
Does the patient have clinical 
oedema? 
Heart auscultation: 
Select findings from patient heart 
NO 
Norm al 
Loud P2 heart sound 
auscultation. (multiple answers) Right-sided S3 gallop 
Systolic murmur 
Diastolic murmur 
ECG performed  
Other  murmur 
YES 
Did the patient under go ECG studies at rest?  Of note: An ECG should be 
performed at baseline and  6-month follow-up. 
Date of ECG 
Enter the date of ECG. 
ECG heart rhythm  
Select ECG rhythm of the patient. 
(multiple answers) 
NO 
Format:  Y YY Y-MM-DD 
Normal sinus  rhythm 
AV Block I 
AV Block II Wenckebach 
AV Block II Mobitz 
AV Block III 
AV Dissociation 
Wolff Parkinson White  Preexcitation 
Atrial fibrillation 
Atrial flutter 
Paroxysmal  supr aventricular tachycar dia 
AV Re-entry tachycardia 
Sinus tachycardia 
P Culminate 
Right ventricular hypertrophy 
Left ventricular hypertrophy 
Chest X-ray performed 
Was a chest  X-ray performed? Of note: A chest  X-ray should be performed 
at baseline visit. 
Date of Chest X-ray 
Enter the date of Chest X-ray. 
Chest X-ray findings 
Select chest X-ray findings. 
(single answer) 
YES 
Format:  Y YY Y-MM-DD 
Normal cardio  thor acic ratio 
Suggestive for left heart enlargement 









- Pan African Pulmonary Hypertension Cohort Study Patient initials 






pul monary arteries 
Primary lung disease 
designed by integerafrica Baseline CRF 8/14 
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4. SIX-MINUTE  WALK TEST
designed by integerafrica Baseline CRF 9/14 
Baseline heart rate bpm 
Baseline pulse  oxymetry % 
Baseline dyspnoea 
(single answer) 
0 Nothing at all 
0.5 Very very slight 
1 very slight 
2 Slight (light) 
3 Moderate 
4 Somewhat severe 
5 Severe 
6 





0 Nothing at all 
0.5 Very very slight 
1 very slight 
2 Slight (light) 
3 Moderate 
4 Somewhat severe 
5 Severe 
6 
7 Very severe 
8 
9 
Distance walk in 6 minutes 
Enter the  total distance the patient walked in 6 minutes. 
meters 
Postwalk heart rate bpm 
Postwalk pulse  oxymetry % 
Postwalk dyspnoea 
(single answer) 
0 Nothing at all 
0.5 Very very slight 
1 very slight 
2 Slight (light) 
3 Moderate 
4 Somewhat severe 
5 Severe 
6 





0 Nothing at all 
0.5 Very very slight 
1 very slight 
2 Slight (light) 
3 Moderate 
4 Somewhat severe 
5 Severe 
6 
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5. LABORATORY 
designed by integerafrica Baseline CRF 10/14 
White cell count x 10^9/L 
Red cell count x 10^9/L 
Haemoglobin g/dL 
Haematocrit % 
Platelets x 10^9/L 












HDL Cholesterol mmol/L 
LDL Cholesterol mmol/L 
Glucose mmol/L 
CRP mg/L 
ESR millimetres per  hour 
TSH mix/L 
T4 pmol/L 
Arterial blood gases  pH pH 
Arterial blood gases  PO2  mmHg 













The  presence of  Antinuclear Antibody  (ANA) is indicative of  lupus 
erythematosus,  mixed    connective  tissue  disorder,  and    many 





Anti-extractable nuclear antigen (anti-ENA) is a grouping of antibodies often 
used to screen for mixed connective tissue disease (MCTD), systemic lupus 
erythematosus (SLE), and Sjögren's and  commonly is composed of four tests: 











Other laboratory results 
Enter  any other relevant labor atory result. 
Example:  bet a thalasemia, sickle-cell  anaemia, 
RPR/TPHA for syphilis, etc.). 
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6. ECH OCARDIOGRAPHY
designed by integerafrica Baseline CRF 11/14 
Echocardiographic assessment 
Is an echocardiographic examination performed at this visit? 
YES 
NO 
Date of E chocardiography 
Enter the  date of echocardiographic examination 
Heart rate: beats per  minute 
Aortic root size mm 
Left atrial size mm 
Intraventricular septum diastolic  diameter (IVSD) mm 
Intraventricular septum systolic  diameter (IVSS) mm 
Left  ventricular end  diastolic diameter (LVEDD) mm 
Left  ventricular end  systolic diameter (LVESD) mm 
Posterior wall  diastolic diameter (PWD) mm 
Posterior wall  systolic diameter (PWS) mm 
Fractional shortening  (FS) % 
Ejection fraction calculated  (EF1) % 
Ejection fraction visual  estimations (EF2) % 
 Regional wall motion  abnormality (RWMA) YES 
NO 





Diastolic function assessment 
Are diastolic function tests performed? 
YES 
NO 
Mitral E-wave m per  second 
Mitral A-wave m per  second 
Deceleration time msec 




Moder ately enlarged 
Severely enlarged 




Moder ately enlarged 
Severely enlarged 
Right Ventricular Systolic  Pressure  (RVSP) mmHg 














Mitral stenosis mean gradient mmHg 
Mitral stenosis valve  area (doppler) cm 
Aortic regurgitation 
(single answer) 
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7. RIGHT HEART CATHETE RIZATION
designed by integerafrica Baseline CRF 12/14 
Right heart catheterisation 
Did the patient under go right heart catheterisation? 
YES 
NO 
Date of right heart catheterisation 
Enter the  date of right  heart catheterisation. 
Systolic blood  pressure mmHg 
Diastolic blood pressure mmHg 
Mean right atrial pressure mmHg 
Right ventricular systolic  pressure mmHg 
Right ventricular diastolic  pressure mmHg 
Pulmonary artery wedge pressure mmHg 
Pulmonary artery systolic pressure mmHg 
Pulmonary artery diastolic pressure mmHg 
Mean pulmonary  artery pressure mmHg 
Cardiac output (CO) litre/min 
Cardiac index liter/min/sqm 
Systemic vascular  resistance Woods  units 
Pulmonary vascular resistance Woods  units 
Right heart catheterization diagnosis 
Enter the  diagnosis of right  heart catheterisation. 
The diagnosis M UST be PULMONARY HYPER TENSION. Also 
describe all other pathological finding. 
Valve repair YES 
NO 
Repaired valve(s) 





Pulmonary  valve 
Reason for valve  repair 
Enter the  clinical reason for valve repair. 
(Example: rheumatic fever,  congenital heart disease, etc.) 
Valve replacement YES 
NO 
Replaced valve(s) 





Pulmonary  valve 
Reason for valve  replacement 
Enter the  clinical reason for valve replacement. 
(Example: rheumatic fever,  congenital heart  disease, etc.) 
ECHO diagnosis 
Enter the  diagnosis of echocardiographic examination. 
The  diagnosis M UST be  PULMONARY HYPERTENSION. Also 
describe all other pathological finding. 
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8. DIAGNOSIS 
Unclassifiable 
designed by integerafrica Baseline CRF 13/14 
Investigation used  to  make  final  diagnosis 
Select the investigations used to make  final 
diagnosis. 
ECHO only 
ECHO and cardiac  catheterization 
Date of final diagnosis 
Enter the  date of final diagnosis. 
 
Final diagnosis 
Select the final diagnosis. 
(single answer) 
 
Pulmonary  Arterial Hypertension (PAH) 
Pulmonary Veno Occlusive  Disease and/or Pulmonary Capillary 
Haem angiomatosis 
PAH due to Left Heart Disease 
PAH due to Lung Disease and/or  Hypoxia 
Chronic Thromboembolic PAH 
PAH due to unclear/multifactorial mechanism 




Heritable (BMPR2, ALK-1, endoglin, unknown) 
Drugs  and toxins induced 
Associated with Connective Tissue Disease (scleroderm a) 
Associated with Connective Tissue Disease (not scleroderm a) 
Associated with HIV infection 
Associated with Portal Hypertension 
Associated with Congenital Heart Disease 
Associated with Schistosomiasis 
Associated with Chronic Haemolytic Anaemia  (including sickel cell anaemia, 
thalassemia) 
Aetiology of PAH due to 
Left Heart Disease (single 
answer) 
Left Ventricular Systolic Dysfunc tion 
Left Ventricular Diastolic Dysfunction 
Valvular disease 
Aetiology of PAH due to 
Lung Disease and/or Hypoxia 
(single answer) 
 
Chronic obstructive pul monary disease 
Interstitial lung disease 
Other  pulmonary diseases with mixed restrictive and  obstructive pattern 
Sleep-disordered breathing 
Alveolar  hypoventila tion disor ders 
Chronic exposure to high altitude 
Developmental abnorm alities 
Aetiology of PAH due to 
unclear/multifactorial mecha nisms 
(single answer) 
 
Haem atological disorders - Myelopr oliferative disor ders 
Haem atological disorders - Splenectomy 
Systemic disorders - Sarcoidosis 
Systemic disorders - Pulmonary  Langerhans cell histiocytosis 
Systemic disorders - Lym phangioleiomyomatosis 
Systemic disorders - Neurofibrom atosis 
Systemic disorders - Vasculitis 
Metabolic disorders - Glycogen  storage disease 
Metabolic disorders - Gaucher ’s  disease 
Metabolic disorders - Thyroid disor ders 
Other  - Tumour obstruction 
Other  - Fibrosing mediastinitis 
Causality classification 
The causality classification rates the  degree 






Substantiate the final diagnosis and notes 
on the  case  
Justify your choice in the text box and  provide 
details of additional examinations the 
patient  under went  for the final diagnosis. 
Elabor ate also on your assum ptions and 
causality classification. 
Please  describe causality and 
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9. TREATMENT
Other 
designed by integerafrica Baseline CRF 14/14 
Antiretroviral  therapy 
This section applies ONLY to patients that are HIV positive and not  yet on antiretroviral therapy (ART) and are starte d on ART during 
the  study  period. 
 ART-naive patients: Initiation of ART YES 
NO Is the  patient initiated on ART during  the study period? 
Start date  of ART 
Enter the  start date ART initiation 
Initiated ART regimen 
Select the initiated ART regimen. 
(single answer) 
TDF 3TC EFV 
TDF 3TC NVP 
TDF 3TC LPVr 
AZT 3TC EFV 
AZT 3TC NVP 
AZT 3TC LPVr 
D4T 3TC EFV 
D4T 3TC NVP 
D4T 3TC LPVr 
Disease-targeted drug therapy 
Disease-targeted drug  ther apy are therapeutics that  are licensed for the  treat ment of pulmonary hypertension. Please  fill out 
this  section at BASELINE and 6-MONTH FOLLOW-UP 
Start date  of diseases-targeted drug therapy 
Enter the  date of final diagnosis. 
Disease-targeted drug therapy 
Select the disease targete d drug  therapy for PAH. 
Example: Sildenafil is a Phosphodiesterase 5 inhibitor 
(multiple answers) 
Endothelin receptor antagonist 
Phosphodiesterase 5 inhibitor 
Prostaglandins 
High dose calcium channel blocker 
Clinical trial therapy 
Heart failure drug therapy 
This section captures inform ation  on heart  failure drug  therapy. The information is a snapshot of the  treat m ent  that  the 
patient receives at this visit including the  drugs that  the  patient is prescribed at this visit. Please  fill out  this section at  BASELINE 
and  6- MONTH FOLLOW-UP. 
















Does the patient receive 




Does  the  patient receive long-term home  oxygen? 
YES 
NO 
Other heart failure treatment 
Drug 1 
Other heart failure treatment 
Drug 2 
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10. Additional notes  of the  case 
Summaries  the case in writing and  comment on specific  findings 
designed by integerafrica Baseline CRF 15/14 
ATTENTION  
 
Upload  ECG and Chest X ray 
Store ECHO on your ECHO machine and  backup the data. 
Anthelmintic  drug therapy 
This section applies ONLY to patients that are diagnosed with pulmonary  hypertension associated with schistosomiasis. 
Treatment  with anthelmintic  drug 
Is the  patient treated with an anthelmintic drug  during  the study period? 
YES 
NO 
Start date of anthelmintic  drug 
Enter the  start date of the anthelmintic 
drug. Example: Praziquantel 
 
Specify anthelmintic  drug therapy 
Specify the anthelmintic drug  therapy the  patient received at 


















Note: Allowable window for 6 -month follow-up clinic visit is 5 to 9 months from baseline. 
In addition, a verbal autopsy should be performed to investigate whether patient is alive on 31 December 2013. 
for lost to  Financial difficulties to pay for transport or clinic visit costs 
 Moderately enlarged 
Version 1.0 _ _ 
Initial and date of person completing the form 
5.      Verbal autopsy 31 December 2013  NOT DONE  
Alive on 31 December 2013                               YES          NO           No telephone contact or unreachable (>15 attempts on 3 different days) 
Date of death:                                                              Format: DD-MMM-YYYY Cause of death: 
3.      Echocardiography at 6 months  NOT DONE  
 
LV-EF calculated __        __ %               LV-EF visual _        _    %                       RVSP           _    mmHg                          TAPSE         _    _ mm 
 
 
Right atrial size 
 
 Normal 
 Mildly enlarged 
 Moderately enlarged 
 Severely enlarged 
 
 
Right ventricle size 
 
 Normal 
 Mildly enlarged 
 
 Severely enlarged 
4.      Hospitalisation  N/A and death  N/A at 6 months 
Hospitalization within 6 months of follow-up?                    YES           NO Total number of days in hospital                                   _        _ days 
Reason for admittance: 
Alive at 6-month follow-up?              YES           NO Date of death:                                                                      Format: DD-MMM-YYYY 
Cause of death: 
Post walk dyspnoea Post walk fatigue 
 0 Nothing at all 
 0.5 Very very slight 
 1 very slight 
 2 Slight (light) 
 3 Moderate 
 4 Somewhat severe 
 5 Severe 
 6 
 7 Very severe 
 8 
 9 
 10 Very very severe 
 0 Nothing at all 
 0.5 Very very slight 
 1 very slight 
 2 Slight (light) 
 3 Moderate 
 4 Somewhat severe 
 5 Severe 
 6 
 7 Very severe 
 8 
 9 
 10 Very very severe 
Baseline dyspnoea Baseline fatigue 
 0 Nothing at all 
 0.5 Very very slight 
 1 very slight 
 2 Slight (light) 
 3 Moderate 
 4 Somewhat severe 
 5 Severe 
 6 
 7 Very severe 
 8 
 9 
 10 Very very severe 
 0 Nothing at all 
 0.5 Very very slight 
 1 very slight 
 2 Slight (light) 
 3 Moderate 
 4 Somewhat severe 
 5 Severe 
 6 
 7 Very severe 
 8 
 9 
 10 Very very severe 
2.      Six minutes walk test at 6 months  NOT DONE  
 
Baseline heart rate 
 




_        _ % 
Distance walked 
in 6 minutes 
_        _ meters 
 
Post walk heart rate 
 
_        _ bpm 
 
Post walk SpO2 
 
_        _ % 
1.      Clinical assessment at 6 months  NOT DONE  
Shortness of breath               YES          NO Fatigue               YES          NO Palpitations                     YES           NO 
Bluish lips or skin                   YES          NO Dizziness           YES          NO Angina                              YES           NO 
Cough                                       YES          NO Syncope            YES          NO Karnofsky Score                      _        _ (between 0 and 100) 
 WHO FC I                    WHO FC II 
WHO functional class              
 WHO FC III                 WHO FC IV 
 
Pulse _         bpm                            Blood pressure     _    /_    __ mmHg 
Date of visit/phone call:                                                       Format: DD-MMM-YYYY 
 6-Month follow-up only through phone contact only 
 
 
Patient lost to 
follow-up?                     
 YES           NO
 
 
 No telephone contact or unreachable (>15 attempts on 3 different days) 
Reason                  Lack of transportation access to the clinic 
 
follow-up              Withdraw of informed consent 
 Other         _        _        _        _ 
Patient number (e.g. FT19750102M)  
   
   




Note: Allowable window for 6 -month follow-up clinic visit is 5 to 9 months from baseline. 
In addition, a verbal autopsy should be performed to investigate whether patient is alive on 31 December 2013. 
Definitions: 
WHO functional class 
Karnofsky Performance Score 
Version 1.0 _ _ 
Initial and date of person completing the form 
Able to carry on normal activity and to work; 
no special care needed. 
100 Normal no complaints; no evidence of disease. 
90 Able to carry on normal activity; minor signs or symptoms of disease. 
80 Normal activity with effort; some signs or symptoms of disease. 
Unable to work; able to live at home and care 
for most personal needs; varying amount of 
assistance needed. 
70 Cares for self; unable to carry on normal activity or to do active work. 
60 Requires occasional assistance, but is able to care for most of his personal needs. 
50 Requires considerable assistance and frequent medical care. 
Unable to care for self; requires equivalent of 
institutional or hospital care; disease may be 
progressing rapidly. 
40 Disabled; requires special care and assistance. 
30 Severely disabled; hospital admission is indicated although death not imminent. 
20 Very sick; hospital admission necessary; active supportive treatment necessary. 
10 Moribund; fatal processes progressing rapidly. 
0 Dead 
WHO FC I Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary 
physical activity does not cause undue dyspnoea of fatigue, chest pain or near syncope.   
WHO FC II Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity causes undue dyspnoea or fatigue, chest pain or near 
syncope.   
WHO FC III Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary activity causes undue dyspnoea or fatigue, chest pain or 
near syncope.   
WHO FC IV Patients with pulmonary hypertension with inability to carry out any physical activity without 
symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even 
be present at rest. Discomfort is increased by any physical activity. 
' 
UNIVERSITY OF CAPE TOWN 
15 June 2011 
HREC REF: 241/2011 
Prof K Sliwa 
Hatter Institute 
Cape heart Centre 
4th Floor, Chris Barnard Building 
Faculty of Health Sciences 
Human Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 406 6626 • Facsimile [021] 406 6411 
e-mail: lamees.emjedi@uct.ac.za
Dear Prof Sliwa 
PROJECT TITLE: THE PAN AFRICAN PULMONARY HYPERTENSION COHORT (PAPUCO) REGISTRY 
Thank you for submitting your study to the Faculty of Health Sciences Human Research Ethics Committee. 
Thank you for your response to the queries raised. 
It is a pleasure to inform you that the FHS HREC has formally approved the above-mentioned study. 
Approval is granted for one year until 28 June 2012. 
Please send us an annual progress report (website form FHS 016) if your research continues beyond the approval 
period. Alternatively, please send us a brief summary of your findings so that we can close the research file. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal investigator. 
Please quote the REC. REF in all your correspondence. 
Yours sincerely 
PROFESSOR M BLOCKMAN f / CHAIRPERSON, HSF HUMAN ETHICS
Federal Wide Assurance Number: FWA00001637. 
lemjedi 
Institutional Review Board (IRB) number: IRB00001938 
This serves to confirm that the University of Cape Town Research Ethics Committee complies to the Ethics 
Standards for Clinical Research with a new drug in patients, based on the Medical Research Council (MRC-SA), 
Food and Drug Administration (FDA-USA), International Convention on Harmonisation Good Clinical Practice (ICH 
GCP) and Declaration of Helsinki guidelines. 
The Research Ethics Committee granting this approval is in compliance with the ICH Harmonised Tripartite 
Guidelines E6: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) and FDA Code Federal Regulation 
Part 50, 56 and 312. 
lemjedi . • ' ' 
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UNIVERSITY Of CAPE TOWN 
FACULTY OF HEALTH SCIENCES 
Human Research Ethics Committee 
Annual Progress Report 
Date 27 November 20 I 3 
HREC REF Number 241/2011 
Protocol number (if The Pan frican Pulmonary Hyperten ion Cohort ( PAPUCO) Regi tr 
applicable) & Protocol 
title 
Principal Investigator Prof. Karen Sliwa 
Department I Office I latter In titute for ardiova cular Re earch in Africa 
Internal Mail Address 
List of documentation 
The information collected via the registry has not changed. No additional approval 
is indicated. 
We have presented preliminary findings of the registry at: 
1. World Congress of Paediatric Cardiology, Cape Town, February 2013
2. Pan African Society of Cardiology meeting, Dakar, Senegal, May 2013
3. NRF Mozambique-South Africa meeting, Maputo 20th November 2013 ( slides
attached).
4. The data will be presented at the World Congress of Cardiology, Melbourne,
Australia, May 2014.
HREC office use only (FWA00001637; IRB00001938) 
CiJ"Approved This serves as notification of annual approval, including all documentation described 
above. 
D Not approved See attached comments. 
Type of review �Expedited D Full committee 
Expiry date 14 
Signature Date 
irJ11;1Chairperson of the HREC 
-� ,c:,9
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Our Ref: ....... ........................... .... ...... . 14th September, 2011 
Your Ref: .................... ...................... . Date: ............ ....... ................... _ 
UNIVERSITY OF UYO TEACHING HOSPITAL, UYO 
HEAL TH REVIEW COMMITTEE. 
APPROVAL. CE.RTIFICATE 
Principal. lnvestigator: Dr. Patience A Udo 
Protocol Title: "The Pan Afrjcan Pulmonary Hypertension Cohort 
(PAPUCO) Regjsiry,r
STATUS 
The University of Uyo Teaching Hospital, Uyo I nsfitut,onal Review 
Committee has reviewed your protocol titled «:The Pan African Pulmonary 
Hypertension �ohort (PAPUCO) Registry'. 
The research Protocol described above has been reviewed by the 
University of Uyo Teaching Hospital, HRC and approval given as 
indicated. 
J� - lnyang 
Secretary, UUTH,
Uyo HRC 
e-mail: info@uu.thuyo.com uuthuyo@gmaU.com 
AMINU KANO TEACHING HOSPITAL
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Director of Administration
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MBBS, FWACS, FICS, Dip. Reprodu6fiv� 
Med & Biology (Geneva) D MAS 
Our Ref: ________ _ 
Chairman Medical Advisory Committee 
�.&f.&ZJ. �-0� 
MB; BS FWACS FMC Opht 
Your Ref: ______________ _ 
NAME OF PRINCIPAL lNVli:STIGATOR: DR. 0. S. OGAH 
c/o Dr. (Mrs.) T. Olunuga 
Director of Admin. & Sec. Board of Mgt. 
� {9. � ((J/Phf/ 
Bsc, MPA, AM NIM, AIPM,Affp,N. ·· 
l2 th December,20 J 1. 
Date: __ �------
TITLE OF STUDY: lmplementation of the pan African pulmonary hypertension corhot (PAPUCO) R.cgist,y 
RESEARCH LOCATION: FEDERAL MEDJCAL CENTRE (FMC), ABEOKUTA
PROTOCOL NUMBER: fMCA/238/10/201 I 
HREC ASSIGNED NUMBER: HREC/10/33/201 l 
NOTIFICATION OF FULL MEMBERS APPROVAL OF RESEARCH PROTOCOL 
This is to infonn you that the Federal Medical Centre, Abeokuta Health Research Ethics Committee (}-lREC) at its 
sitting on 9 th De.cernber,2011 decided tCJ give full member approval to yow· research propoc-aL .ifter necessary 
reviews and corrections, w1dcr the regulations guiding experiments in human subjects. 
This approval is [or a period of one year from 12th of December, 2011 to l I u, December, 20 l 2.. if there is dt:-: .. 1y in 
starting this research, please inform the HREC so that dates of approval can be adjusted accon:lingly. NotC' !'.,at no 
ac!ivit� relr,ted t<,1 this research may be conducted outside these dates. No changes are pennitted in tJ .... , ,esearch 
without pn0r approval by HREC. 
All forms and questionnaires used in this stud.' must catTy the HREC assigned number and 1he dmation or hi?EC 
approval. 
You are to note ft,rther that. the National Code of Health Research Ethics requires you tn comply with ali 
institutional guidelines, rules and regulations, to fol1ow trends of the code. Please ensure lhar ::iny adverse effect 
lrnm your :..tudy i� promptly reported to the HREC Federal Medical Centre, Abeok.uta 
You are e�pected to submit a progress report to this Committee every three (3) months fro 1r, rhe date of approval. 
'fl11.: HR[C rec,erves the right to conduct compliance visits on your research sites without previcrn:; notifi-.:atirn�. 
Dr. (Mrs.) 0. F. Dedeke 
Fm: C!'1airman i-:10spital Research Ethics Commitree 
REPUBLICA DE MOCAMBIQUE 
, ; 
MINISTERIO DA SAUDE 
, , , 




Dr. Albertina Damasceno 
HCM 
Data 20 de Dez�mbro de 2012 
Assunto: Autorizat;ao para iniciar o registo de doentes com hipertensao pulmonar no 
Hospital Central de Maputo . " 
No di.a 20 de Oezernbro de 2012, o Comite Nadonal de Bioetica para a Saude (ONBS) 
analfsou o pedido para l11iciar o registo de doentes com hipertensao pulrnonar no Hospital 
Central de Maputo referentes ao protocalo intitulado: ' Epidemiologia da hiperten'Si/o 
Pulmonar em Maputo (PAPUCO} r; �obre o mesmo, o CNBS chegau a seguinte 
ton�lusao: 
O CNBS nao ve nenhum inconveniente de ordem etica que impec;a a realizac;ao do estudo 
pelo que, da a sua devida autorizac;ao. 
Contudo, recomenda aos investigadores que o mantenham informado do decurso do estudo. 
Faz notar que a aprovac;ao etica nao substitui a autorizac;ao administrativa. 
Sem mais de memento, queiram aceitar as nossas cordiais saudac;oes. 
ENDERE<;:O: 
MINISTERIO DA SAUDE 
C, POSTAL 264 
Av. Eduardo Mo11dlane/Salvador Allende 
MA llTO-MOC'AMR OIIF 
Dr. Joao 
Telefones: 430814/427131(4) 
Telex: 6-239 MISAU MO 
FAX: 258(1)426547 
258 (!) 33320 
